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Applying Next Generation Sequencing to Skeletal Development and Disease 
 
ABSTRACT 
 
Next Generation Sequencing (NGS) technologies have dramatically increased the throughput and 
lowered the cost of DNA sequencing. In this thesis, I apply these technologies to unresolved questions in 
skeletal development and disease. Firstly, I use targeted re-sequencing of genomic DNA to identify the 
genetic cause of the cartilage tumor syndrome, metachondromatosis (MC). I show that the majority of MC 
patients carry heterozygous loss-of-function mutations in the PTPN11 gene, which encodes a 
phosphatase, SHP2, involved in many signaling pathways. Furthermore, I show that cartilage lesions in 
MC patients likely arise following somatic second-hit mutations in PTPN11. Secondly, I use RNA-seq to 
identify gene expression changes that occur following genetic inactivation of Ptpn11 in mouse 
chondrocyte cultures. I show that chondrocytes lacking Ptpn11 fail to properly undergo terminal 
differentiation and instead continue to express genes associated with earlier stages of chondrocyte 
maturation. I validate these findings in vivo by examining markers of specific chondrocyte maturation 
stages in the vertebral growth plates of mice following postnatal mosaic inactivation of Ptpn11. Together, 
my results provide insight into the molecular mechanisms underlying the initiation and growth of cartilage 
tumors. In the third component of my thesis, I develop a method to map and clone zebrafish mutations by 
performing whole genome sequencing on pooled DNA. I apply this method to zebrafish mutants identified 
in a mutagenesis screen for adult phenotypes, including skeletal phenotypes, and determine that a 
nonsense mutation in bmp1a underlies the craniofacial phenotype in the wdd mutant. In summary, I show 
that NGS technologies can be successfully utilized to firstly identify the genetic cause of a human skeletal 
disorder, secondly investigate the molecular mechanisms regulating the maturation of skeletal cells, and 
thirdly expedite the process of mapping and cloning zebrafish mutants with skeletal phenotypes. 
Altogether, my research provides insight into the pathways and processes regulating skeletal 
development and disease.  
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1.1 Skeletal development 
 
The vertebrate skeleton  
The vertebrate skeleton is a complex organ system that provides structural support, allows for 
controlled movements, protects internal organs, stores minerals, and houses hematopoiesis [1]. 
Disrupting the normal process of skeletal development and homeostasis can adversely affect survival and 
quality of life. This is reflected by the large number of inherited disorders of the skeleton [2], as well as 
age related disorders such as osteoarthritis, a degenerative disease of the joints [3], and osteoporosis, a 
weakening of the bones [4].  Two main connective tissues that comprise the vertebrate skeleton are 
cartilage and bone [1]. Cartilage is an avascular tissue that contains chondrocytes embedded in a stiff yet 
flexible extracellular matrix. Bone is a rigid tissue that contains osteoblasts, which lay down a mineralized 
matrix, and osteoclasts, that degrade matrix to facilitate tissue remodeling. In contrast, invertebrates do 
not have an internal skeleton made of bone or cartilage. Instead, invertebrates can have fluid-filled 
hydrostatic skeletons (eg. jelly fish), or endoskeletons or exoskeletons made of the carbohydrate chitin 
(eg. insects), calcium carbonate (eg. mollusks), or silica (eg. sponges) [5].  
Endochondral and intramembranous ossification 
 The development of the vertebrate skeleton is an elaborate and complex task, with over 200 
bones that must each attain their specific size, shape, location and tissue composition [1]. Skeletogenesis 
is initiated when cells from two of the three primary germ layers in the early embryo, the mesoderm and 
ectoderm, become multipotent mesenchymal cells and migrate to sites of skeletogenesis throughout the 
body. These cells are the source of chondrocytes and osteoblasts. Most bones in the skeleton, including 
the long, short and irregular bones, form through a process called endochondral ossification [1]. In this 
process, the primary skeleton forms entirely from cartilage, which is capable of growing rapidly as the 
embryo develops, and is gradually replaced by bone (Figure 1.1) [6]. In contrast, flat bones form by 
intramembranous ossification, whereby mesenchymal cells differentiate directly into osteoblasts, without 
first forming a cartilage template [1]. 
 The growth plate  
 Bones that form through the process of endochondral ossification contain cartilaginous growth 
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plates that allow for longitudinal bone growth. Growth plates consist of chondrocytes arranged in distinct 
zones of maturation (Figure 1.2) [7,8]. The resting zone contains scattered chondrocytes in a quiescent 
state, which serve as a source of cells for the second layer, the proliferative zone. Chondrocytes in the 
proliferative zone divide rapidly and arrange themselves into columns, after which they exit the cell cycle 
to become pre-hypertrophic chondrocytes. A dramatic increase in cell size takes place as pre-
hypertrophic chondrocytes enter the early-hypertrophic zone. The final zone is the terminal or late-
hypertrophic zone in which chondrocytes secrete factors for matrix degradation, calcification and vascular 
recruitment, and ultimately undergo programmed cell death. Invading blood vessels bring in osteoclasts / 
chondroclasts and osteoblasts, which progressively erode and replace the remaining calcified cartilage 
matrix with a new bone matrix. This cycle of chondrocyte proliferation, maturation and replacement by 
bone is what drives longitudinal bone growth.  
The perichondrium 
 The growth plate is surrounded by the perichondrium, which consists of an outer fibroblast layer, 
and an inner layer that contains osteoprogenitor and osteo-chondroprogenitor cells. The osteoprogenitor 
cells give rise to osteoblasts that form the bone collar, and can migrate into the bone cavity to contribute  
                        
Figure 1.1. Formation of bones through endochondral ossification. A: Mesenchymal cells 
condense and differentiate into chondrocytes to form a cartilaginous model of the bone. Chondrocytes in 
the center of the model undergo hypertrophy and calcify the matrix. B: The primary ossification center 
forms in the center of the cartilaginous model when hypertrophic chondrocytes undergo apoptosis and 
promote vascular invasion. Osteoblasts are recruited to lay down the new bone matrix. C: Secondary 
ossification centers form at the ends of the cartilaginous models. The only cartilage that remains 
postnatally is articular cartilage, which covers the ends of bones, and the growth plate cartilage, which 
allows for the longitudinal growth of bones. Figure adapted from Teixeira et al (2008). 
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to the pool of intramedullary osteoblasts [10]. The osteo-chondroprogenitor cells can migrate to the site of 
injury and differentiate into chondrocytes or osteoblasts during fracture repair [11].  
1.2 Signaling pathways regulating the growth plate 
 
The rate of chondrocyte proliferation, maturation and terminal differentiation is tightly regulated by 
a number of paracrine and endocrine hormones and growth factors, to ensure that each skeletal element 
reaches its appropriate size. Several of the key signaling pathways that have been studied in the growth 
plate are outlined here.  
IHH/PTHrP negative feedback loop regulates the length of proliferating columns 
 Indian hedgehog (IHH) is a morphogen secreted by pre-hypertrophic chondrocytes [12,13]. IHH 
induces the production of parathyroid hormone related protein (PTHrP) in periarticular chondrocytes. 
PTHrP signals through its receptor PTHR1 to proliferative and pre-hypertrophic chondrocytes to delay 
their maturation. This well-characterized feedback loop regulates the rate at which chondrocytes exit the 
proliferative zone (Figure 1.3) [12,13]. IHH also acts independently of PTHrP to promote the proliferation 
of chondrocytes by inducing expression of the cell cycle regulator, cyclin D1 [14]. IHH also promotes the 
differentiation of osteoblasts in the perichondrium to form the bone collar [15].  
BMP signaling promotes chondrocyte proliferation and maturation 
Bone morphogenetic proteins (BMPs), acting via type I and type II serine/threonine kinase 
receptors, induce phosphorylation of the receptor-regulated SMADs (R-SMAD1, R-SMAD5 and R-
 
Figure 1.2. Growth plates contain chondrocytes that proliferate, increase in size, and 
subsequently get degraded and replaced by bone. A: Radiograph of a mouse hind limb. The location 
of the proximal tibial growth plate is indicated. B,C: Histological images of the proximal tibial growth plate 
of a 7 week-old mouse. The stages of chondrocyte maturation are indicated. Tissue sections are stained 
with Alcian Blue and Nuclear Fast Red. Scale bars represent 50 microns. 
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SMAD8), which bind SMAD4 and enter the nucleus to regulate gene expression. Inactivation of Bmpr1a 
and Bmpr1b, which encode BMP receptors, indicates that BMP signaling promotes chondrocyte 
proliferation, promotes the onset of hypertrophy, and is required for the columnar organization of 
proliferative chondrocytes [16]. Conflicting reports suggest the BMP signaling either a promotes or inhibits 
the terminal differentiation of late-hypertrophic chondrocytes [16,17]. 
FGF signaling antagonizes IHH and BMP signaling and inhibits chondrocyte 
proliferation and maturation 
There are four fibroblast growth factor (FGF) receptors (FGFR1-4) and 22 FGF ligands in 
mammals. The ligands FGF9 and FGF18 are expressed in the perichondrium, and during early stages of 
chondrogenesis, they activate FGFR3 to promote chondrocyte proliferation, and activate FGFR1 to 
promote the initiation of hypertrophy [18–20]. In contrast, at late embryonic and postnatal stages FGF18 
acts through FGFR3 to inhibit chondrocyte proliferation and maturation, and inhibit Ihh and Bmp4 
expression (Figure 1.4) [21–24].  
IGF1 promotes chondrocyte proliferation and maturation 
Growth Hormone (GH) is produced in the pituitary gland and stimulates the secretion of insulin-
like growth factor 1 (IGF1), both in the liver and in growth plate chondrocytes themselves. IGF1 signals 
                                                
      
Figure 1.3: IHH/PTHrP negative feedback loop regulates the rate of chondrocyte maturation. 
Periarticular chondrocytes secrete the PTHrP ligand, which signals to proliferating chondrocytes to delay 
their maturation (1). Chondrocytes at the lower end of the proliferating zone that are sufficiently far from 
the PTHrP source, start to secrete IHH and undergo maturation. IHH promotes chondrocyte proliferation 
(2), promotes PTHrP production in the peri-articular region (3), and promotes the formation of the bone 
collar (4). Figure adapted from Kronenberg et al (2003). 
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via IGF1R, which is expressed in proliferating and prehypertrophic chondrocytes [25]. Loss of Igf1 or Igf1r 
in mice indicates that IGF1/IGF1R signaling promotes chondrocyte proliferation and maturation [26,27].  
Signaling through EGFR promotes the removal of hypertrophic chondrocytes 
The epidermal growth factor (EGF) receptor, EGFR, is a member of the ErbB family of receptor 
tyrosine kinases, and can be activated by several growth factors, including EGF and TGFalpha. 
Inactivation of Egfr or Tgfalpha, indicates that signaling through TGFalpha and EGFR positively regulates 
the removal of hypertrophic chondrocytes, by regulating matrix degradation and osteoclast recruitment 
[28–30]. While inactivation of Egfr alone does not affect chondrocyte proliferation [31], expression of an 
inhibitor of all ErbB receptors inhibits chondrocyte proliferation [32].   
Canonical Wnt signaling inhibits chondrogenesis but promotes chondrocyte 
proliferation and maturation 
The canonical Wnt pathway inhibits ectopic cartilage formation in the perichondrium, and 
promotes chondrocyte proliferation and maturation. This has been identified by the conditional 
inactivation of beta-catenin, the mediator of canonical Wnt signaling. Inactivation of beta-catenin in 
mesenchymal progenitor cells blocks osteoblast differentiation, and causes osteoblast precusor cells in 
the perichondrium to differentiate into chondrocytes instead of osteoblasts [33,34]. Activation of beta-
catenin in chondrocytes accelerates the onset of hypertrophy while inactivation of beta-catenin in 
                                                           
Figure 1.4: Interactions between BMP, FGF and IHH signaling in the growth plate. A positive 
feedback loop exists between BMP and IHH signaling. In contrast, FGF signaling antagonizes BMP and 
IHH signaling. Figure adapted from Minina et al (2002).  
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chondrocytes delays hypertrophy, and delays the final maturation and removal of hypertrophic 
chondrocytes [35,36]. Inactivation of beta-catenin also leads to decreased chondrocyte proliferation [37].  
1.3 Metachondromatosis and related cartilage tumor syndromes 
 
Benign cartilage tumors: enchondromas and exostoses 
The two most common benign cartilaginous tumors are exostoses/osteochondromas, which form 
on the surface of the bone, and enchondromas, which form within bones (Figure 1.5) [38]. These tumors 
normally arise during childhood near the growth plate of bones formed by endochondral ossification, and, 
although they are benign tumors, malignant transformation to chondrosarcoma can occur [39]. Most often, 
exostoses and enchondromas occur as single sporadic lesions in an individual, but less frequently, 
multiple lesions can occur in an individual as part of a syndrome. Multiple enchondromas are present in 
individuals affected with an enchondromatosis syndrome, the most common of which are Ollier disease 
and Maffucci syndrome [40], while multiple exostoses can occur in patients with the autosomal dominant 
disorder multiple hereditary exostoses (MHE) (also known as multiple osteochondromas (MO)) [41]. A 
third type of cartilage tumor syndrome, metachondromatosis (MC), which is the focus of this thesis, is 
unique in that it is associated with both exostoses and enchondromas. 
 
Figure 1.5. Radiographs of exostoses and/or enchondromas in patients with different cartilage 
tumor syndromes. A: Radiograph showing exostoses on the femurs and tibiae of an individual with 
MHE. Image adapted from Pannier et al (2008). B: Radiograph showing enchondromas in the hand of 
an individual with Ollier disease. Image adapted from Horvai et al (2006). C: Radiograph showing 
exostoses and an enchondroma (arrow) in the hands on an individual with MC. Image adapted from 
Bovee et al (2006).  
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Genetic basis of the enchondromatosis syndromes, Ollier disease and Maffucci 
syndrome 
It has recently been reported that somatic mosaicism for a missense mutation in Isocitrate 
Dehydrogenase 1 (IDH1) or IDH2 underlies Ollier disease and Maffucci syndrome [42–44]. The 
phenotypic differences between Ollier disease and Maffucci syndrome are postulated to be due 
differences in the tissue distribution and/or proportion of cells that carry a somatic IDH1/IDH2 mutation, 
and the lack of genetic transmission of these disorders suggests that heterozygosity for an IDH1/IDH2 
mutation in the germline or embryo is lethal [45]. Missense mutations in IDH1 and IDH2 have also been 
detected in other neoplasms, and lead to neomorphic enzyme activity, resulting in 2-hydroxyglutarate 
production, which induces global DNA hypermethylation [46]. Indeed, an increase in DNA methylation 
was observed in enchondromas carrying IDH1 mutations, but it is not yet known whether or how altered 
methylation contributes to enchondroma formation [44]. Missense mutations in PTHR1 have also been 
found in a small percentage of patients with Ollier disease [47]. One such mutation was shown to 
enhance hedgehog signaling, and mice over-expressing a mutant PTHR1 allele, or the Hedgehog 
transcriptional regulator, Gli2, in chondrocytes, have impaired chondrocyte maturation and develop 
enchondroma-like lesions [47] (Figure 1.6). This supports the hypothesis that enchondromas can arise 
from growth plate chondrocytes that fail to undergo terminal differentiation and be replaced by bone. An 
alternative hypothesis for enchondroma formation is that they arise from mesenchymal precursor cells in 
the bone cavity or perichondrium/periostium that inappropriately differentiate into chondrocytes [48]. 
Further studies will be needed to determine how mutations in IDH1 and IDH2 affect chondrocyte 
differentiation or maturation and lead to enchondroma formation. 
 
Figure 1.6. Disrupting the IHH/PTHrP feedback loop can lead to enchondroma formation in 
mice. Enchondromas arise in mice expressing a mutant PTHR1 transgene (A) or over-expressing the 
Hedgehog-activated transcription factor, Gli2 (B). Images adapted from Hopyan et al (2002).  
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Genetic basis of the exostosis syndrome, MHE 
Inactivating mutations in Exostosin-1 or -2 (EXT1 or EXT2) cause MHE [41]. While patients with 
MHE are heterozygous for a mutation in EXT1 or EXT2, their exostoses are believed to arise from cells in 
which a somatic second hit mutation has inactivated the remaining wild-type EXT1 or EXT2 allele [49]. 
The EXT1/EXT2 protein complex catalyzes the polymerization of sugars to form heparan sulfate 
proteoglycans (HSPGs), which act as receptors or co-receptors in signaling pathways and interact with a 
variety of morphogens, growth factors and extracellular matrix components [50–52].  Studies in mice 
suggest that a deficiency for heparan sulfate in either chondrocytes or perichondrial cells in the growth 
plate results in ectopic BMP signaling in the perichondrium, which induces perichondrial cells to 
inappropriately differentiate into cartilage, resulting in exostosis formation [53–55] (Figure 1.7). 
Unique features of MC: a combined exostosis and enchondroma syndrome  
Patients with the rare (< 50 cases reported in the literature) autosomal dominant genetic disorder, 
metachondromatosis (MC), develop both enchondromas and exostoses [56–60] (Table 1.1). The 
enchondromas associated with MC most frequently occur in the pelvis and long bones of the lower 
extremities, in contrast to the enchondromas associated with Ollier disease or Maffucci syndrome, which 
occur more frequently in the hands and feet [40]. Only one case of malignant transformation has been 
reported for a MC enchondroma [61]. The exostoses associated with MC normally occur on the bones of  
 
 
Figure 1.7. Conditional inactivation of Ext1 in mice leads to exostosis formation and is 
associated with ectopic BMP signaling and chondrogenesis in the perichondrium. A: 3D microCT 
image of exostoses that arise in mice following postnatal mosaic inactivation of Ext1 in chondrocytes. 
Image adapted from Jones et al (2010). B-C: Histological images of mice in which Ext1 was inactivated 
in joint progenitor cells and the perichondrium. Note the formation of ectopic cartilage in the 
perichondrium at P0 (B) and ectopic BMP signaling, as assessed by phospho-smad1/5/8 
immunostaining, in the perichondrium at E15.5 (C). Image adapted from Huegel et al (2013).  
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the hands and feet, point towards the affected joint, and may regress spontaneously, while exostoses 
associated with MHE normally occur on long bones, point away from the affected joint, and only rarely 
regress [62,63]. The phenotypic differences between MC and MHE, Ollier disease and Maffucci 
syndrome suggests that MC is associated with a unique underling genetic defect; indeed, mutations in 
EXT1/EXT2 and IDH1/IDH2 were not detected in MC patients [44,57]. As part of this thesis, I identify 
mutations in the PTPN11 gene in MC patients (Chapter 2). Thus, MC does appear to have a unique 
genetic cause; however, the underlying molecular pathways and developmental processes involved in 
tumor formation in MC patients may be related to those involved in tumor formation in other cartilage 
tumor syndromes. Therefore, the research on PTPN11 presented in this thesis (Chapter 2 and 3) is likely 
to not only further our understanding of MC, but to also further our understanding of the mechanisms 
underlying all types of benign cartilage tumors.   
1.4 Role of PTPN11/SHP2 in cartilage tumor formation 
 
Inactivation of Ptpn11 in mice causes skeletal defects and cartilage tumors 
In this thesis, I show that loss-of-function mutations in PTPN11 underlie the human cartilage  
tumor syndrome, metachondromatosis (Chapter 2). Concurrent with my work, other investigators 
Table 1.1: Comparison of metachondromatosis and related cartilage tumor syndromes 
 MHE MC Ollier disease Maffucci 
syndrome 
Tumor types Exostoses Exostoses & 
enchondromas 
Enchondromas Enchondromas & 
vascular lesions 
Incidence 1/50,000 ~50 case reports 1/100,000 ~200 case reports 
Most common location of tumors:  
   Exostoses Long bones of the 
limbs 
Hands & feet 
 
n/a 
   Enchondromas n/a Pelvis & long bones Hands & feet 
Inheritance Autosomal dominant Autosomal dominant Sporadic 
Affected gene(s) EXT1 or EXT2 PTPN11  IDH1 or IDH2 
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have shown that cartilage tumors can be induced in mice by conditionally inactivating Ptpn11 (Figure 1.8; 
Table 1.2). A requirement for Ptpn11 during mouse skeletal development was first revealed after studying 
mice in which Ptpn11 had been inactivated postnatally in all cell types [64]. These mice developed 
scoliosis, and were found to have an increase in bone mineral content, an increase in trabecular bone, 
disorganized cortical bone, impaired osteoclastogenesis, and disorganized and expanded growth plates. 
Furthermore, these mice formed ectopic cartilage growths on the surface of long bones, resembling 
exostoses, and ectopic cartilage islands in the vertebrae, resembling enchondromas. To determine the 
cell type that contributed to these skeletal defects, Ptpn11 was inactivated postnatally using the Col2a1-
CreER driver, which is expressed in chondrocytes and some perichondrial cells [65,66]. These mice 
developed kyphosis and scoliosis, as well as exostoses on the bones of the hands, feet, wrists and 
ankles, enchondromas in the ribs and vertebrae, and osteophyte-like outgrowths on the vertebrae [65,66].  
 
 
Figure 1.8. Exostoses and enchondromas arise following conditional inactivation of Ptpn11 in 
mice.  A: Histological images of exostoses in the radius and ulna, and enchondromas in the ribs and 
vertebrae, following postnatal inactivation of Ptpn11 using the Col2a1-CreERT2 driver. Images adapted 
from Kim et al (2013) B: Radiographs and microCT images of exostoses arising in the hands following 
inactivation of Ptpn11 using the Ctsk-Cre driver. Images adapted from Yang et al (2013). 
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Table 1.2: Comparison of published mouse models of metachondromatosis 
 Bauler et al. (2011) Kim et al. (2013) Yang et al. (2013) 
Genetic inactivation of Ptpn11    
   Cell type All cell types Chondrocytes & perichondrium 
Osteoclasts & 
perichondrium 
   Time of tamoxifen administration Postnatal Postnatal – 
   Cre or CreERT2 driver Ubc-CreERT2 Col2a1-CreERT2 Ctsk-Cre 
Exostoses*    
   Knee 
   Ankles & wrists 
   Hands & feet 
Y 
n/d 
n/d 
n/d 
Y 
Y 
Y 
Y 
Y 
Enchondromas*    
   Ribs 
   Vertebrae 
   Long bones 
n/d 
Y 
n/d 
Y 
Y 
n/d 
n/d 
n/d 
Y 
Other skeletal phenotypes*    
   Disorganized growth plates 
   Scoliosis & kyphosis 
   Increased bone mineral content 
Y 
Y 
Y 
Y 
Y 
n/d 
n/d 
Y 
Y 
n/d = not determined 
 
   
It was postulated that the exostoses arose from perichondrial cells, while the rib enchondromas were 
remnants of growth plate cartilage [65]. A perichondrial-origin for exostoses was supported by the 
observation that exostoses arose when Ptpn11 was inactivated using the Ctsk-Cre driver, which is 
expressed in perichondrial cells in addition to its expression in osteoclasts [67]. Together, these studies 
suggest that Ptpn11 is essential for normal skeletal development and for suppressing the formation of 
benign cartilage tumors. 
PTPN11/SHP2 regulates many signaling pathways and developmental processes 
PTPN11 is ubiquitously expressed and encodes SHP2, a nonreceptor protein tyrosine 
phosphatase (PTP) [68]. In addition to its role in skeletal development, SHP2 has been shown to play a 
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role in many different tissue types. Complete loss of Ptpn11 in mice leads to peri-implantation lethality 
[69], and tissue specific inactivation of Ptpn11 demonstrates that SHP2 is required for normal 
development of many tissues, including the heart, pancreas, liver, mammary gland, T-cells, CNS, and 
neural-crest derived tissues [68]. SHP2 contains two tandem Src homology 2  (SH2) domains, a PTP 
domain and a C-terminal tail with tyrosyl phosphorylation sites. In response to extracellular stimuli, the 
SH2 domains of SHP2 bind to phosphotyrosine residues on cytokine receptors, receptor tyrosine kinases 
(RTKs) and/or docking proteins that bind to RTKs [68]. Although the physiological substrates of SHP2 are 
not clear, SHP2 has been shown to regulate a variety of signaling pathways [68]. SHP2 is required for full 
activation of the Ras/ERK cascade, although the exact mechanism is not clear [70]. SHP2 has also been 
implicated in regulating signaling through PI3K/Akt [71], Wnt/β-catenin [72], Src family kinases [73], 
JAK/Stat [74], RhoA [75], JNK MAPK [76], p38 MAPK [77], NFAT [78], NF-kB [79], FAK [80]. Studies 
indicate that SHP2 regulates different signaling pathways in different cell types and in response to 
different stimuli [68]. It is not yet known which of these signaling pathways are regulated by SHP2 in 
chondrocytes. Thus, one aim of this thesis was to investigate the molecular consequences of SHP2 
depletion specifically in chondrocytes, and to determine which SHP2-dependent signaling pathways may 
contribute to cartilage tumor formation (Chapter 3).   
Mutations in PTPN11 cause skeletal defects associated with Noonan Syndrome 
and LEOPARD syndrome  
A key role for PTPN11 in human skeletal development first became apparent when mutations in 
PTPN11 were identified in patients with Noonan Syndrome (50%) and LEOPARD syndrome (80%) [81]. 
These syndromes belong to a group called the RASopathies, which are associated with a variety of 
development defects, including skeletal defects such as short stature, osteopenia, osteoporosis, scoliosis, 
kyphosis, hand and anterior chest wall anomalies, and increased fracture rates [82]. The PTPN11 
mutations associated with Noonan syndrome increase the phosphatase activity and alter the binding 
specificity of SHP2 [83], while mutations associated with LEOPARD syndrome impair SHP2 phosphatase 
activity but enhance interactions with some binding partners [84]. Mutations in components of the 
Ras/MAPK pathway (SOS1, RAF1, KRAS, SHOC2) have also been found in patients with Noonan 
Syndrome, and mutations in RAF1 have been found in LEOPARD syndrome patients, suggesting that 
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altered Ras/MAPK signaling underlies these disorders [81]. Indeed, enhanced Ras/ERK signaling has 
been shown to contribute to Noonan Syndrome [84]. On the other hand, enhanced AKT/mTOR signaling 
plays a larger role in LEOPARD Syndrome [84]. Based on the role of SHP2 in many signaling pathways, 
it is likely that the dysregulation of multiple pathways contributes to these disorders. Thus, the research 
on PTPN11 presented in this thesis (Chapter 2 and 3) may also further our understanding of the skeletal 
defects associated with the RASopathies.  
1.6 Next Generation Sequencing Technologies 
 
First generation DNA sequencing: the Sanger sequencing method 
 Following the discovery of the double helix in 1953, the first DNA sequencing methods emerged 
in the late 1960s and 1970s [85]. In 1977, Fred Sanger published his “dideoxy method” for DNA 
sequencing. This method, also referred to as Sanger sequencing, became the gold standard method for 
DNA sequencing, and was the basis for the development of the first automatic sequencing machine by 
Applied Biosystems in 1986. Further enhancements of this technology over the years enabled the 
eventual completion of the first draft of the human genome assembly in 2001. In the Sanger method, a 
DNA synthesis reaction using DNA polymerase is performed using both deoxynucleotide triphosphates 
(dNTPs), which are the building blocks of DNA, and fluorescently labeled dideoxynucleotide triphosphates 
(ddNTPs), which lack a 3’ OH group. When a dNTP is incorporated into the growing DNA strand, DNA 
synthesis can continue; however, when a ddNTP is incorporated, DNA synthesis terminates. The DNA 
sequence can be deduced by separating the resulting DNA fragments using electrophoresis and 
detecting their fluorescent label. Automated sequencing machines using the Sanger method are generally 
capable of running 96 reactions in parallel, with each reaction producing between 500 and 1,000 bases of 
highly accurate sequence. [85]  
Next Generation Sequencing  
 While Sanger sequencing is accurate, it is also low-throughput and labor intensive. Over the past 
decade, new sequencing technologies have emerged that have significantly higher throughput than 
Sanger sequencing. These methods are referred to as massively parallel sequencing or Next Generation 
Sequencing (NGS) [86]. While these methods are currently less accurate and have shorter read lengths 
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than Sanger sequencing, the combined data that is assembled from many individual reads is highly 
accurate due to the high sequence coverage obtainable. The first commercially available NGS platform 
was introduced in 2005 by 454 Life Sciences, which was followed by several additional platforms in 
subsequent years, such as the first Solexa sequencer, the Genome Analyzer, in 2006 [86]. Further 
improvements to these NGS technologies over the years has led to a dramatic reduction in the cost of 
sequencing DNA (Figure 1.9) [87].  
Illumina sequencing method  
 One of the leading NGS platforms is the Illumina/Solexa platform, which was used for the work in 
this thesis. This platform utilizes a sequencing-by-synthesis approach to sequence millions of clusters 
bound to the surface of a glass slide known as a flow cell [85].  To prepare a DNA library for sequencing, 
the DNA is first sheared to fragments that are less than a few hundred bp in size, and adapters are 
ligated to the ends of these DNA fragments. After PCR amplification and purification, the final DNA library 
is then denatured to create single stranded DNA fragments, which are added to the flow cell and allowed 
to bind to primers that are attached to the flow cell surface. Each fragment is amplified through a process 
known as bridge amplification, to obtain millions of dense clusters of single stranded DNA that have 
sequencing primers attached (Figure 1.10) [88]. The sequencing reaction is then performed using 
fluorescently labeled nucleotides that act as reversible chain terminators, and the fluorescence is 
                                        
Figure 1.9. The cost of DNA sequencing has substantially decreased since the introduction of 
NGS. Graph showing the cost per megabase of DNA sequence over time. The sharp drop in 2008 is 
due to the switch from Sanger sequencing to NGS in sequencing centers. Since 2008, the cost of DNA 
sequencing has decreased at a greater rate than predicted by Moore’s Law (grey line). Moore’s Law 
was based on the observation that, in the computer industry, the number of transistors per square inch 
(a measure of computational power) doubles every year. Image adapted from 
http://www.genome.gov/sequencingcosts/ 
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measured after each new base is incorporated, to determine the sequence of each cluster (Figure 1.11) 
[88].  
Applications of Next Generation Sequencing 
 In this thesis, three applications of NGS are explored: whole genome sequencing, targeted re-
sequencing, and RNA-seq [89]. For whole genome sequencing, a library is prepared from genomic DNA 
and is then sequenced by NGS. The resulting DNA fragments are then aligned to a reference genome, 
and variants are identified by comparing the reference genome to the aligned sequence. This allows one 
to obtain sequence information for the entire genome, with the exception of regions that are difficult to 
sequence (such as CG rich regions) or regions that are difficult to align short reads to (such as repetitive 
elements).  
 If one is only interested in variants that lie within the coding regions of the genome, one can 
perform targeted re-sequencing. In this method, only a subset of the genome is sequenced, with the 
advantage being that higher coverage can be obtained for the same cost. One method for targeted re-
sequencing is to perform an array-based target capture (Figure 1.12). DNA libraries are hybridized to an 
array containing DNA probes corresponding to a particular subset of the genome, such as all coding 
exons. This allows one to obtain a library that is enriched for fragments from the region-of-interest.  
                       
Figure 1.10. Generating clusters of DNA on Illumina flow cells. The DNA fragments in a library are 
denatured and allowed to bind to primers that are attached to the surface of the flow cell. Bridge PCR 
amplification enables the generation of millions of clusters on the flow cell surface. Image adapted from 
Metzker et al (2010) 
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 A third application of NGS is RNA-seq. For this method, mRNA is converted to cDNA, which is 
then used to construct a library for NGS. This allows one to identify variants in the transcribed regions of 
the genome, and also allows one to determine the relative abundance of each transcript, based on the 
number of reads that mapped to it. Thus, RNA-seq can be used in place of microarrays to identify 
differentially expressed genes.   
 For all of the applications described here, multiplexing can be used to sequence more than one  
                                 
                                  
Figure 1.11. Illumina sequencing method using reversible chain terminators. A: Fluorescently 
labeled chain terminating nucleotides are added to the flow cell. After one nucleotide is added to each 
growing DNA strand, the excess nucleotides are washed away, and the flow cell is imaged. The 
fluorescent label is then removed to leave an unblocked 3’ end, which is now able to bind to a new 
nucleotide. B: Images are taken after each round of nucleotide incorporation, enabling the sequence 
of each cluster to be determined. Image adapted from Metzker et al (2010). 
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sample on the same sequencing machine. This is achieved by adding a unique index or barcode to each 
library, and then pooling multiple libraries (Figure 1.12). This allows one to obtain sequence for a greater 
number of samples for the same cost, albeit fewer sequencing reads per sample. 
1.6 Studying skeletal development using zebrafish forward genetics 
 
Mutagenesis screens identify zebrafish mutants with skeletal defects 
The zebrafish is a powerful model organism for the study of skeletal development [90]. While 
differences exist between the morphology of the skeleton in fish compared to mammals, many of the 
underlying developmental pathways are conserved. A number of large scale genetic screens have been 
performed in zebrafish to identify mutants with skeletal phenotypes, such as defective patterning of the 
craniofacial skeleton, or impaired cartilage differentiation and morphogenesis [91]. Many of these mutants 
have furthered our understanding of human craniofacial or skeletal disorders. For example, the dak 
mutant, which has defective cartilage morphogenesis and chondrocyte maturation, was found to contain a 
                         
Figure 1.12. Multiplexed targeted re-sequencing by using a capture array to enrich for a subset of 
the genome.  Genomic DNA libraries are prepared for each individual, using a unique barcode for each 
library. Libraries are pooled together and hybridized to an array that contains probes to target a subset 
of the genome, such as all exons, or only the sequence within a linkage interval. The captured DNA is 
then eluted from the array, PCR amplified, and submitted for NGS. Once the sequence data is obtained, 
each sequencing read can be assigned to an individual based on the barcode. In this illustration, the 
barcode sequence corresponds to the first three bases of each read.  
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mutation in the ortholog to the human EXT2 gene, which underlies the MHE cartilage tumor syndrome 
disused above [92].  
Traditional methods for mapping and cloning zebrafish mutants 
The current bottleneck in zebrafish forward genetics is the identification of the causal mutation 
underlying the phenotype of a mutant. Mapping is traditionally performed by analyzing a predefined set of 
markers, such as microsatellite repeats that can be assessed by gel electrophoresis, in DNA pooled from 
multiple mutant fish, to find regions that co-segregate with the mutant phenotype [93,94]. The leads to a 
rough linkage position, which is then further refined by analyzing additional microsatellite repeats or single 
nucleotide polymorphisms (SNPs) in individual fish. Subsequently, candidate genes in the interval are 
sequenced, with the hope of identifying the mutation underlying the phenotype. This method for mapping 
and cloning zebrafish mutations is time consuming and costly [95]. Often, a large number of fish must be 
analyzed to narrow down the linkage interval. Furthermore, the predefined markers are not always 
polymorphic in the particular genetic background used and are therefore uninformative. In addition, 
selecting candidate genes for sequencing is biased, making one more likely to clone a mutation that lies 
in a gene with a known role in development, and less likely to successfully clone mutations in 
uncharacterized genes.  
Using Next Generation Sequencing for mapping in model organisms 
Following the development of NGS technologies, the possibility of identifying causal mutations by 
directly sequencing the genome, without the need for prior mapping data, has become a reality. For 
model organisms such as C. elegans and A. thaliana, it has been demonstrated that WGS can be used to 
simultaneously identify polymorphisms that can be used for mapping, as well as identify variants that are 
potential causative mutations [96–101]. These approaches rely on mapping recessive mutations based 
on homozygosity-by-descent (Figure 1.13). A mapping-cross is first performed to introduce genetic 
diversity. Multiple offspring that have the mutant phenotype are then pooled and sequenced. Regions 
tightly linked to the causative mutation will lack diversity and appear as homogenous sequence. In 
contrast, unlinked regions will contain diversity and appear as heterogeneous sequence. Therefore, by 
scanning the genome for regions of homogeneity, the genomic regions linked to the mutation can be 
identified. Finally, the actual sequence in the linked regions can be analyzed to identify novel variants that 
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may be the phenotype-causing mutation.  
This approach has been successful applied 
to C. elegans and A. thaliana [96–101]. The 
advantage of these organisms is that their genomes 
are relatively small and common polymorphisms are 
well characterized. Importantly, due to their small 
genome size, it is not cost-prohibitive to obtain high 
coverage sequence of the entire genome, thereby 
facilitating accurate variant detection. Only recently 
has it become affordable to obtain low coverage 
sequence of the entire zebrafish genome, which is 
ten-fold larger than that of C. elegans or A. thaliana. 
However, with low coverage sequence data, it is 
difficult to distinguish true polymorphisms from 
sequencing errors, especially when dealing with the 
highly polymorphic zebrafish genome [102,103] for 
which a well-characterized database of all common 
polymorphisms does not exist. Thus, I chose to first 
establish a comprehensive list of zebrafish polymorphisms, by performing WGS on several wild-type 
strains. Secondly, I incorporated this list of polymorphisms into a pipeline I developed to map and clone 
zebrafish mutants based on low coverage WGS data (Chapter 4).   
1.7 Scope of this thesis 
 
 In this thesis, I design and apply massively parallel sequencing strategies to address open 
questions in skeletal biology. In chapter 2, I perform targeted re-sequencing on multiple patients with 
metachondromatosis, and find that loss-of-function mutations in PTPN11 underlie this cartilage tumor 
syndrome. In chapter 3, I further our understanding of the molecular mechanisms involved in cartilage 
tumor initiation and growth by using RNA-seq to identify gene expression changes that occur after the 
loss of Ptpn11 in chondrocytes in vitro. I confirm these findings in vivo by studying mice with a conditional 
 
 
Figure 1.13. Mapping recessive mutants in 
model organisms based on homozygosity-
by-descent. A mapping cross is performed to 
introduce genetic diversity. DNA from multiple 
mutants from the F2 generation is pooled and 
sequenced. Genomic regions tightly linked to 
the causative will appear homogeneous. As 
distance from the causative mutation 
increases, diversity increases due to 
recombination, and the sequence will appear 
heterogeneous.    
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Ptpn11 deletion. Finally, in chapter 4, I develop a whole-genome sequencing data analysis pipeline for 
mapping and cloning mutations in zebrafish, and apply this pipeline to map mutants with skeletal 
phenotypes.  
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2.1 Abstract 
 
Metachondromatosis (MC) is a rare, autosomal dominant, incompletely penetrant combined 
exostosis and enchondromatosis tumor syndrome. MC is clinically distinct from other multiple exostosis or 
multiple enchondromatosis syndromes and is unlinked to EXT1 and EXT2, the genes responsible for 
autosomal dominant multiple hereditary exostoses (MHE). To identify a gene for MC, we performed 
linkage analysis with high-density SNP arrays in a single family, used a targeted array to capture exons 
and promoter sequences from the linked interval in 16 participants from 11 MC families, and sequenced 
the captured DNA using high-throughput parallel sequencing technologies. DNA capture and parallel 
sequencing identified heterozygous putative loss-of-function mutations in PTPN11 in 4 of the 11 families. 
Sanger sequence analysis of PTPN11 coding regions in a total of 17 MC families identified mutations in 
10 of them (5 frameshift, 2 nonsense, and 3 splice-site mutations). Copy number analysis of sequencing 
reads from a second targeted capture that included the entire PTPN11 gene identified an additional family 
with a 15 kb deletion spanning exon 7 of PTPN11. Microdissected MC lesions from two patients with 
PTPN11 mutations demonstrated loss-of-heterozygosity for the wild-type allele. We next sequenced 
PTPN11 in DNA samples from 54 patients with the multiple enchondromatosis disorders Ollier disease or 
Maffucci syndrome, but found no coding sequence PTPN11 mutations. We conclude that heterozygous 
loss-of-function mutations in PTPN11 are a frequent cause of MC, that lesions in patients with MC appear 
to arise following a ‘‘second hit,’’ that MC may be locus heterogeneous since 1 familial and 5 sporadically 
occurring cases lacked obvious disease-causing PTPN11 mutations, and that PTPN11 mutations are not 
a common cause of Ollier disease or Maffucci syndrome. 
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2.4 Introduction 
 
Cartilage tumor syndromes are characterized by multiple cartilaginous bone tumors that develop 
in childhood, often causing significant morbidity and predisposing to chondrosarcoma. Tumors can form 
as exostoses (on the surface of bone), as in the autosomal dominant, multiple hereditary exostoses 
syndrome (MHE; MIM 133700 and 133701), or as endosteal tumors (within bone), as in the sporadically 
occurring multiple enchondromatosis disorders (MIM 166000) Ollier disease and Maffucci syndrome. In 
MHE, mutations in EXT1 or EXT2, which encode heparan sulfate glycosyltransferases, affect 
chondrocyte orientation in the growth plate [1]. A small percentage of patients with Ollier syndrome have 
mutations in PTH1R, which encodes the receptor for parathyroid hormone and parathyroid hormone-
related protein, causing altered chondrocyte differentiation in the growth plate [2]. The cause of Maffucci 
syndrome is unknown [3]. Patients with MHE do not develop endosteal tumors, and patients with Ollier 
disease or Maffucci syndrome do not develop exostotic tumors [1,3,4]. Patients with metachondromatosis 
(MC; MIM 156250) form exostotic and endosteal tumors (Figure 2.1). Fewer than 50 cases of MC have 
been published since Maroteaux’s initial description in 1971 [5]. Exostotic lesions in MC occur frequently 
in the digits, involve metaphyses and epiphyses, and tend to grow toward the joint; in contrast, exostotic 
lesions in MHE occur frequently in the long bones, involve only the metaphyses, and tend to grow away 
from the joint [6–11]. MC exostotic lesions can also spontaneously decrease in size and completely 
regress [6,7,9,12]. Endosteal lesions in MC are common in the metaphyses of long bones and in the 
pelvis [7–11]. Avascular necrosis of the femoral head, due to endosteal tumors, has been a frequent 
complication in patients with MC [7,8,13–15]. Hand deformity due to endosteal tumors is uncommon in 
patients with MC, whereas it is often a significant problem for patients with Ollier disease and Maffucci 
syndrome [3]. Finally, malignant transformation has only been reported in one patient with MC, whereas it 
has been more frequently reported in patients with MHE, Ollier disease, and Maffucci syndrome [3,4,16]. 
The distinct distribution and clinical behavior of lesions in patients with MC, suggest that MC is 
pathophysiologically distinct from these other cartilage tumor syndromes. We therefore sought to better 
characterize MC and to determine its genetic basis. 
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Figure 2.1. Clinical, radiographic, and histologic features of metachondromatosis. (A) Hand 
radiographs of participant B-IV-7, taken when 8-years-old. Exostotic lesions (white arrows) are present 
in the phalanges and metacarpals, and arise from the metaphysis (arrows) or epiphysis  (arrowheads). 
Exostoses tend to point toward the adjacent joint. Endosteal lesions (red arrows) cause metaphyseal 
expansion. (B, C, D) Hand photograph and radiograph, and foot photograph of participant C-III-1 taken 
when 9-years-old, depicting mild shortening and deformity of the digits, a large exostotic lesion arising 
from the second metacarpal bone in the hand, and ankle enlargement superior to the malleoli due to 
exostoses of the tibia and fibula. (E) Ankle radiograph of participant A-IV-8 taken when 19-years-old 
depicting a recurrence of a previously excised exostotic lesion of the distal tibia that spans the physis. 
(F, G) Lateral knee radiographs of participant B-IV-7, taken at 6 years and 16 years, respectively. Note 
that multiple exostotic lesions of the distal femur and proximal fibula (white arrows) seen when 6-years-
old (F) have regressed in the absence of surgical intervention by 16-years of age (G). (H) Ankle 
radiograph of participant B-IV-7, taken when 5-years-old, demonstrating radiolucency associated with 
endosteal lesions (red arrows) in the tibia and fibula, and mild metaphyseal flaring. Despite combined 
metaphyseal and epiphyseal involvement, this individual’s linear growth was not affected. (I) Hip 
radiograph of participant A-IV-8 taken when 22-years-old depicting an endosteal lesion of the femoral 
neck (arrow) that has caused degeneration of the femoral head and spurring of the acetabulum. (J) 
Low power photomicrograph of an hematoxylin and eosin (H&E) stained section through an exostosis 
that had been excised from a patient with hereditary multiple exostoses. Note this exostosis is a typical 
osteochondroma, having a well-developed surface cartilaginous cap (arrow) and endochondral bone 
immediately below (arrowhead). The scale bar represents 0.15 cm (K) Photomicrograph of an H&E 
stained exostotic lesion excised from participant A-IV-5 when 5-years-old. This lesion is predominantly 
covered by a fibrous cap (arrow) and has only a small, eccentric cartilaginous cap  (double arrowhead). 
The majority of cartilage in this, and in 14 other exostoses from patients with MC that have been 
analyzed, is found within a central core (arrow) and has bone formation occurring at the periphery of 
this cartilage core. The scale bar represents 0.5 cm. (L) High-power image of the central cartilage core 
shows chondrocytes with prominent cytoplasm no organization typical of a growth plate. The scale bar 
represents 100 µm 
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2.5 Results 
 
Patient selection 
We diagnosed participants as having MC based upon the presence of both multiple exostotic and 
endosteal cartilaginous lesions as previously described [5–10,15]. We excluded from analysis participants 
with solitary lesions, contiguous endosteal lesions suggestive of Ollier disease, soft tissue lesions 
suggestive of Maffucci syndrome, or radiographs suggestive of MHE. We included participants who had 
clinical and radiographic features of MC, even if they lacked a positive family history. For each patient, the 
clinical history and radiographs were reviewed by at least 3 authors. MC patients from 17 unrelated 
families from 9 countries were identified (Table 2.1). All participants gave their informed consent following 
the guidelines of each referring institution. In 10 families disease segregation is consistent with autosomal 
dominant inheritance. In 7 families, the disease is suspected to have arisen de novo.  Immediate family 
members of patients with sporadically occurring MC were interviewed and examined, although detailed 
imaging was not performed. For 8 familial cases, blood or DNA was available from additional family 
members.  
Clinical and pathologic features of metachondromatosis  
Figure 2.1 depicts features seen in affected participants with MC. No phenotypic differences 
could be found between sporadic or familial cases of MC. Radiographs identify exostotic and endosteal 
lesions of the digits (Figure 2.1A–1C) and long bones (Figure 2.1E– 1H), along with degenerative hip 
disease secondary to endosteal lesions in the femoral neck (Figure 2.1I). Spontaneous regression of 
exostotic lesions is seen in radiographs obtained 10 years apart in the same patient (Figure 2.1F,1G). 
Also depicted in Figure 2.1 are histopathologic features that distinguish exostoses in patients with MHE 
from those in patients with MC, based upon a comparison of 30 exostoses excised from children with 
MHE and 15 exostotic lesions excised from 3 affected individuals with MC. Exostoses in children with 
MHE have cartilage caps with endochondral bone growth immediately beneath the cap (Figure 2.1J). In 
contrast, exostoses in children with MC have a predominantly fibrous cap and a core of disorganized 
cartilage.  
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surrounded by trabecular bone (Figure 2.1K, 1L). In all MC cases, the lesions were bilateral and not 
obviously confined to a single body segment as in Ollier or Maffucci patients.  
Linkage analysis.  
 We performed linkage analysis in the largest family (Family A, Figure 2.2A) to identify a genetic 
locus for MC. Raw genotype data were generated using Affymetrix 6.0 SNP arrays and multipoint 
parametric linkage analysis of the autosomal genome was performed using MERLIN [17]. Because non-
penetrance and non-ascertainment are potential confounding factors in the diagnosis of MC, we analyzed 
only founders and affected individuals (Figure 2.2A). Although this limited the maximum attainable LOD 
score to 2.7, which is lower than the genome-wide significance threshold of 3.3, the dense marker set 
ensured a reasonable probability that only one large interval that achieved the maximum LOD score 
would be observed, with the remainder of the genome being excluded. We identified a single interval on 
chromosome 12, from 121.5 to 132.3 cM, that attained the maximum LOD score of 2.7 (Figure 2.2B). No 
other autosomal interval >1 cM yielded a peak LOD score >–1.9. Several intervals <1 cM attained LOD 
scores >0 (Figure 2.3), but we considered these unlikely to be candidate intervals and instead assumed 
they represented either unfiltered genotyping errors or short ancestral population haplotypes, rather than 
familial haplotypes inherited from a common ancestor. 
Multiplexed targeted genomic capture and sequencing of linkage interval 
 We next performed array-based capture, followed by Illumina GAII sequencing, using barcoded 
DNA libraries created from 16 individuals in 11 families. We sequenced 1 affected individual in 8 families, 
2 affected individuals in 1 family, and 2 affected and 1 unaffected individual in 2 families (Table 2.1). We 
prepared barcoded genomic DNA libraries, having an average insert size of 150 bp, using sheared DNA 
from each of the 16 individuals (Figure 2.4). We performed array-based targeted capture by pooling each 
DNA library and hybridizing the pooled sample to an Agilent Technologies 1M SureSelect DNA capture 
array containing 973,952 probes targeting 844,339 bp within the 8.6 Mb candidate interval, including 
88.4% and 98.6% of UCSC exons and CCDS coding sequence, respectively. After hybridization and 
elution, the captured DNA was PCR amplified, purified to remove primer dimers, and sequenced on two 
lanes of an Illumina GA II. We obtained 50 million, 80 bp, single-end reads. Novobarcode software was 
used to sort the reads according to their 3 bp barcode, and Novoalign was used to align the reads to 
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Figure 2.2. Linkage mapping of metachondromatosis to chromosome 12q. (A) Pedigree of the family 
(Family A) used to define the metachondromatosis candidate interval. Affected individuals have filled 
symbols. Individuals who were not examined but who were assumed to be obligate carriers have interior 
dots. An arrow identifies the proband. Participants whose DNA was used for linkage analysis are double 
underlined.  Those participants with a single or double underlines were tested for the PTPN11 mutation, 
after the mutation had been identified in participants AIII-10 and A-IV-5 by targeted array capture and 
Illumina sequencing. (B) LOD score plot of chromosome 12. Only one interval, larger than 1 cM, in the 
entire genome attained the maximum LOD score of 2.7. Several autosomal intervals, each smaller than 1 
cM, also achieved maximum or positive LOD scores (Figure 2.3). These likely represent either genotyping 
errors or short ancestral haplotypes that are coincidental with linkage. The physical coordinates shown 
are derived from GRCh37/hg19.	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Figure 2.3. Linkage mapping of metachondromatosis to chromosome 12q. A whole genome LOD 
score plot is depicted. The chromosomes are color-coded according to the key on the right. Raw 
genotype data were generated using Affymetrix 6.0 SNP arrays and multipoint parametric linkage 
analysis was performed using MERLIN with Affymetrix Caucasian allele frequencies and deCODE 
Genetics genetic map positions. The disease allele frequency was estimated at 1E-7, and phenocopies 
and non-penetrance were not permitted (affectation probability 0/1/1). Error checking identified and 
removed unlikely genotypes during initial analysis, and the cleaned data were then reanalyzed. Because 
non-penetrance and non-ascertainment are potential confounding factors in the diagnosis of MC, we 
analyzed only founders and affected individuals. Our analysis identified one interval on chromosome 12 
(orange above), from 121.5 to 132.3 cM, that attained the maximum LOD score of 2.7. The minimum 
linked interval is bounded by rs1861693 (LOD score 2.1; GRCh37/hg19 coordinate 107603157) and 
rs1520173 (2.3; 116182525), and is flanked proximally by rs12422243 (−5.8; 107595567) and distally by 
rs2460488 (−4.3; 116187660), for a maximum linked interval of 8,592,092 bp. We did not observe any 
other autosomal interval >1 cM with a peak LOD score >−1.9. Several autosomal intervals <1 cM attained 
LOD scores >0, but we considered these unlikely to be candidate intervals and instead assumed they 
represented either unfiltered genotyping errors or short ancestral population haplotypes, rather than 
familial haplotypes inherited from a common ancestor. Although MC is well documented as autosomal 
dominant and many of our own pedigrees show male-to-male inheritance, family A does not; therefore we 
also examined the X chromosome. Four X-linked intervals >1 cM attained LOD scores >−2, but the 
largest was 3.4 cM and the highest LOD score was 0.3; we therefore assumed these intervals also 
represented either unfiltered genotyping errors or short ancestral population haplotypes, rather than 
familial haplotypes inherited from a common ancestor. 
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Figure 2.4. Amplified libraries before and after array capture. (A) Bioanalyzer plot of a representative 
amplified genomic DNA library before targeted array capture. Peaks at 15 bp and 1500 bp represent size 
standards. The broad peak between 100 and 300 bp comprises the barcoded and amplified DNA library. 
(B) Photograph of an Ethidium Bromide stained 4% agarose gel containing the pooled library after 
targeted array capture and amplification, but before E-gel purification. Note the broad band of amplimer 
between 200 bp and 300 bp in size. These sized amplimers were used to obtain Illumina GA II sequence. 
 
 
 
 
 
 
 
 
Table 2.2. Novel coding variants identified in three metachondromatosis families 
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Figure 2.5. Specificity of target capture and read depth of targeted bases. (A) Graph depicting the 
number of filtered Illumina GA II reads per barcoded sample that aligned to the targeted region (dark 
blue), aligned elsewhere in the human genome (medium blue), or failed to align to the reference genome 
(light blue), for both the first (left) and second (right) capture array experiment. Each letter refers to a 
family and if more than one member of the family was sequenced then the specific family member is 
indicated. For each array, of the 50 million reads obtained from two lanes of GA II sequencing, between 1 
and 6 million reads were obtained for each individual. The percentage of each individual's reads that 
mapped to the targeted region was ~60% for the first array and ~40% for the second array. (B) 
Percentage of bases targeted by the array having read depths greater than or equal to a specific fold-
coverage. Graph depicting the mean of the percent of targeted bases captured in each individual at 
greater than or equal to 1, 5, 10, 20, 30, 40, and 50-fold coverage (nX). Values are shown before (dark 
red) and after (light red) removal of PCR duplicates. Error bars indicate 1 SD. 
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the reference genome (hg19). We obtained between 1 and 6 million reads for each individual. Among 
individuals, an average of 61% (±2%) of the aligned reads mapped to regions targeted by the capture 
array (Figure 2.5A). Of the bases targeted by the capture array, 75% (±7%) had a read depth of at least 
5x, which diminished to 55% (±14%) after the removal of PCR duplicates (Figure 2.5B). Twenty percent of 
targeted bases were not captured. In the 3 families for which pairs of affected family members were 
sequenced, total filtered variants in the candidate interval (388–1499 per individual) were analyzed to find 
variants shared by both affected individuals from the same family (Table 2.2). In all 3 families, frameshift 
mutations in exon 4 of PTPN11 were the only novel coding variants present in both affected family 
members and, for Families A and B, absent in the unaffected individual. Family A had a 5 bp deletion, 
Family B had a more complex deletion/insertion, and Family C had a 2 bp deletion (Table 2.1). In the 
remaining 8 families for which only 1 affected individual per family was sequenced, there were 18 novel 
coding variants present in ≥3 reads, one of which was a nonsense mutation in exon 13 of PTPN11  
(p.Q506X) (Figure 2.6). We used Sanger sequence analysis of PCR amplimers to demonstrate that 
affected family members from these 4 families had PTPN11 mutations, and that unaffected family 
members lacked PTPN11 mutations. Sanger sequence analysis of the 15 coding exons of PTPN11 in the 
7 families for whom we had not found mutations by array capture and Illumina-sequencing detected a 1 
bp deletion in exon 11 in 1 of the 7 families (Family D). This deletion was within a 98 bp segment that had 
been targeted but not captured in any of the DNA samples. Another family (F) had a splice-acceptor site 
mutation (AG>CG) in intron 5 in 2 affected siblings, but not in either parent. The siblings’ mother was 
clinically affected with MC, although less severely than her children. The mother was the first in the family 
to have MC and was the only member of the family who was included in the Illumina sequencing. The site 
of the splice-site mutation identified in her children was covered 256 in her DNA sequence and was 
always wild-type, as were her Sanger sequence results. These data suggest the mother is mosaic for a 
PTPN11 mutation and that the family’s mutation would have been found by Illumina sequencing had we 
initially sequenced her children’s DNA  
 We subsequently collected DNA from an additional 6 MC families. Sanger sequence analysis 
revealed a nonsense mutation involving exon 3 (p.K99X) in one family (I), and a splice site mutation in 
intron 9 (c.1093-1G>T) in another family (G). In total, we found PTPN11 mutations in 10 of 17 families.  
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Figure 2.6. Identified coding variants in unrelated individuals from the first capture array. Total 
coding variants identified in the 8 unrelated individuals who were the only members of their families 
included in the first array capture experiment. The graph depicts the number of variants and the number 
of reads containing each variant in an individual. Novel (dark gray) and previously characterized (light 
gray) SNPs are separated into different bars. Note that the ratio between novel and known SNPs 
decreases as the number of reads containing that SNP increases. These data suggest that most novel 
SNPs seen in 3 or fewer reads represent sequence artifacts rather than real variants. Shown above the 
graph are novel variants that were observed in three or more reads in single individuals, with the gene 
names and predicted amino acid changes indicated. Nonsense mutations are indicated in red, 
nonsynonomous mutations are indicated in purple, and synonomous mutations are indicated in green. No 
insertion or deletion variants were seen in more than 2 reads. The family in which the novel variant was 
identified is indicated in parentheses. Two mutations were identified in PTPN11, including a nonsense 
mutation and a synonomous mutation. The nonsense mutation was confirmed by Sanger sequence 
analysis; however, the synonomous mutation could not be confirmed and therefore likely represents a 
false positive result. 
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Figure 2.7. PTPN11 mutations identified in MC participants. (A) Schematic of the exonic structure of 
PTPN11 (above) and the corresponding protein structure of SHP2 (below). The locations of mutations 
that were identified in MC are indicated with black lines. Predicted protein changes are indicated for the 
nonsense (blue) and frameshift (red) mutations, while the cDNA designation is indicated for the splice-site 
mutations (green). (B) Log2 values of the number of Illumina reads obtained per 50 bp window in 
participant S, divided by the average number of reads obtained in other participants whose DNA was 
captured simultaneously using the second capture array. Shown are all 50 bp windows spanning regions 
of PTPN11 targeted by the array, with the corresponding exonic structure of PTPN11 shown below. The 
red bar indicates a region spanning exon 7, in which the average log2 value is approximately −1, 
suggesting a heterozygous deletion. PCR amplification and sequencing of the breakpoint, using primers 
on either end of the deletion, indicate that 14,629 bp of sequence have been deleted and replaced with a 
single CA dinucleotide. 
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Five mutations were frameshift, 2 were nonsense, and 3 disrupted a splice-acceptor site (Figure 2.7A, 
Table 2.1). Each family had a different mutation and mutations were scattered across the gene (Figure 
2.7A). In two families without mutations we had performed aCGH and did not find evidence of PTPN11 
intragenic deletions or duplications (Table 2.1). We did not have other family members’ DNA samples 
from the one familial MC patient who lacked a PTPN11 mutation to be able to test for locus heterogeneity 
by linkage analysis.  
Multiplexed targeted genomic capture and sequencing of PTPN11 and associated genes  
 To test whether the patients without PTPN11 coding mutations had noncoding mutations in 
PTPN11 or had mutations in other genes, we designed a second Agilent 1M capture array. Firstly, we 
included probes to target the entire PTPN11 gene, excluding Alu repeats. Secondly, we included probes 
targeting the exons of 74 genes that function in the same pathways as PTPN11, including the Ras/MAPK 
and PI3K/Akt pathways (Table 2.3). Thirdly, we included probes targeting the exons of the MHE genes 
EXT1 and EXT2, to determine whether any of our patients lacking mutations and classic radiographic 
features of MC had been misdiagnosed. Barcoded genomic libraries for an individual from each of the 7 
MC families without PTPN11 coding mutations and from 2 families originally referred with MC, but whose 
radiographic features were more consistent with MHE, were pooled and hybridized to the capture array. 
The captured DNA was then sequenced using two lanes of Illumina GAII 42 bp single end sequencing. 
For each barcoded sample, 4.3 (±1.2) million reads were obtained, of which 37% (±7%) mapped to 
regions targeted by the array (Figure 2.5A). Of the bases targeted by the array, 85% (±6%) were covered 
by a read depth of at least 10x, which dropped to 83% (±8%) after the removal of PCR duplicate reads 
(Figure 2.5B). Identified variants with a quality score >20 were filtered to remove SNPs listed in the SNP 
Table 2.3. Genes included in second capture array  
Category Gene 
Ras/MAPK pathway KRAS, HRAS, NRAS, ARAF, BRAF, RAF1, MAPK1, MAPK3, MAP2K1, 
MAP2K2, SOS1, SOS2, GRB2, SHOC2, GAB1, GAB2, GAB3, FRS2, 
IRS1, SHC1, SIRPA, PXN, MVP, MPZL1, CRK 
PI3K/AKT pathway AKT1, AKT2, AKT3, PIK3R1, PIK3R2, PIK3R3, PIK3CA, PIK3CB, 
PIK3C2A, PIK3C2B, PIK3C2G, MTOR, RPS6KB1, PDPK1, ILK, PRKCD, 
PRKCZ, PTEN 
Receptor Tyrosine 
Kinases 
FGFR1, FGFR2, FGFR3, EGFR, PDGFRA, PDGFRB, IGF1R, ERBB2, 
ERBB3, ERBB4, ROR1, ROR2, MUSK, AXL, MERTK, DDR1, DDR2 
Other EXT1, EXT2, RHOA, CDC42, RAC1, PTH1R, SRC, PTK2, YES1, FYN, 
LYN, FGR, PLCG1, PLCG2, HSPA4, INPP5D 
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database (version 132) and the 1000 genomes project (Nov. 2010 release). No PTPN11 coding 
mutations were found. We then analyzed the noncoding regions and identified one 3’ UTR mutation, and 
7 intronic mutations, of which 6 were in LINE elements or other repetitive regions (Table 2.4). All intronic 
mutations were at least 300 bp from the nearest exon and, using an online splice prediction tool 
(http://genes.mit.edu/GENSCAN.html), were not predicted to alter splicing. We then analyzed variants 
identified in the exons of the 76 other genes included in the capture array  (Table 2.3). No nonsense, 
frameshift or splice site mutations were identified. Of the missense mutations that were present in more 
than 4 independent sequencing reads, 4 were nonsynonomous (ERBB2 p.S1050L, MTOR p.P1408S, 
MVP p.R49S, SOS2 p.D952N) and 4 were synonomous (PIK3C2B p.D478D, RAF1 p.L351L, MAP2K2 
p.D140D, MVP p.T199T). Further experiments will be needed to determine if any of the novel noncoding 
PTPN11 mutations or novel variants in the other genes are disease causing.  
 We next analyzed the sequencing read depth across the PTPN11 locus to detect deletions or 
duplications. In one individual (Patient S), we identified a ~15 kb region spanning exon 7 that contained 
half as many reads as would be expected based upon the read depths of the other patients included in 
the capture array (Figure 2.7B). As expected, PCR primers that flank this 15 kb region failed to produce 
amplimers when wild-type genomic DNA was used as template. However, PCR amplification using 
genomic DNA from Patient S yielded a 700 bp PCR product and Sanger sequence analysis of this 
product indicated that 14,629 bp of genomic sequence (chr12:112,897,487–112,912,115) had been  
	  
Table 2.4. Mutations identified in second capture array 
Location Patient Mutation  
PTPN11 Chr12 genomic change 
3’ UTR  
 M g.112945402G>A 
Intronic 
 J g.112857243G>T, g.112869736del1, g.112924937C>T 
 M g.112862223C>T, g.112914741C>G, g.112933866A>G, g.112945402G>A 
   
Coding mutations Gene name and predicted protein change 
 J MTOR p.P1408S, MVP p.R49S 
 K ERBB2 p.S1050L, MAP2K2 p.D140D 
 L MVP p.T199T 
 M PIK3C2B p.D478D 
 P SOS2 p.D952N, RAF1 p.L351L 
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Figure 2.8. Heterozygous deletions of EXT1 identified in two participants. (A) Log2 values of the 
number of Illumina reads obtained per 50 bp window in participants N and Q, divided by the average 
number of reads obtained in other participants whose DNA was captured simultaneously using the 
second capture array. Shown are all 50 bp windows spanning the exons of four genes (FGFR1, LYN, 
EXT1, PTK2) located on chromosome 8 that were targeted by the capture array. The red bars indicate a 
region spanning all EXT1 exons in participant N, and exon 1 of EXT1 in participant Q, where consecutive 
windows have log 2 values of approximately −1, suggesting heterozygous deletions of these regions. (B) 
MLPA amplification products separated by electrophoresis. The amplification products of the MLPA 
probes targeting both the middle and the boundary of EXT1 exon 1, and the MLPA probes targeting the 
middle of EXT1 exon 1, have reduced peak heights in participants N and Q respectively (arrowheads). 
(C) Ratio of each EXT1 peak height to the average height of the four control peaks. The ratios were 
normalized based on the ratios obtained in control individuals, such that a ratio of 1.0 indicates a copy 
number of 2, while a ratio less than the threshold of 0.8 suggests a copy number of 1. In both participants 
N and Q, the ratio for the probe corresponding to the middle of EXT1 exon 1 is below 0.8, suggesting a 
heterozygous deletion of this exon. MLPA was performed twice for each participant. Error bars indicate 
standard deviation. 
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replaced with a single CA dinucleotide (Figure 2.7B). In addition, PCR amplification and sequencing of 
PTPN11 in peripheral blood cDNA from this patient, using a forward primer in exon 6 and a reverse 
primer in exon 8, detected a mutant cDNA that lacked exon 7 (data not shown). The loss of exon 7 results 
in a frameshift with introduction of a premature stop codon (T253LfsX54). The read depth of the 
remaining 76 genes targeted by the array was also analyzed to detect deletions or duplications. Two 
patients initially included in the study, but on radiographic review were felt more likely to have MHE than 
MC, were found to have deletions involving EXT1 (Figure 2.8). In one patient (Q), the first exon of EXT1 
contained half as many reads over its 1.8 kb as expected (Figure 2.8A). In a second patient (N), all exons 
of EXT1 had half as many reads as expected (Figure 2.8A). In additional to skeletal lesions, this patient 
has developmental delay, microcephaly and mild dysmorphism, suggesting a possible contiguous gene 
deletion syndrome. EXT1 deletions were confirmed in both patients by multiplex ligation dependent probe 
amplification (MLPA)  (Figure 2.8B,C). 
PTPN11 loss-of-function mutations in metachondromatosis  
Our finding of nonsense, frameshift, and splice-site mutations in multiple exons, as well as a large 
deletion, suggests that MC causing PTPN11 alleles are loss-of-function. We tested this hypothesis by 
performing Western blots on whole protein extracts from white blood cells and from an excised exostotic 
lesion in a patient (B-IV-7) with a PTPN11 frameshift mutation in exon 4. An anti-SHP2 antibody that 
recognizes an epitope amino-terminal of the polypeptide encoded by the frameshifted exon detected only 
full-length, wild-type SHP2 protein (Figure 2.9).  
Loss of PTPN11 wild-type alleles in the cartilage cores of MC exostoses  
We next determined whether MC exostoses arise from a ‘‘second hit’’, similar to what has been 
observed in autosomal dominant MHE [18]. We looked for a second hit in cells of the cartilage core of an 
MC lesion (e.g., Figure 2.1K) by performing microdissection, PCR amplifying the mutation containing 
exon, and Sanger sequencing the amplimers. In tumors from two different patients (A-IV-5, A-IV-8), with a 
5 bp frameshift mutation in exon 4, we observed a clear excess of mutant sequence versus wild-type 
sequence in the tumors’ cartilage cores, as compared to the patients’ peripheral blood and bone/marrow 
from the lesion (Figure 2.10A). We quantified the amount of mutant versus wild-type sequence, by 
extracting DNA from the cartilage core of patient A-IV-8, PCR amplifying exon 4, and subcloning  
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Figure 2.9. Truncated SHP2 protein is not detected. Immunoblots of protein extracted from an 
exostosis from participant B-IV-7 with a truncating frameshift mutation, rib cartilage from an unaffected 
individual (cartilage expression tissue control), and HELA cells (antibody control) that have been 
separated on a 4–12% SDS-PAGE gel and transferred to Immobilon-P. Upper panel: immunodetection 
using mouse-anti-SHP2 that detects an epitope N-terminal of the frameshift mutation. Brackets indicate 
wild-type SHP2 that is differentially phosphorylated. Wild-type protein is present in the exostosis, likely 
from the bone marrow and fibrous elements since the lesional cartilage was not selectively isolated. Note 
absence of a unique band 17 kD in size, that would have been expected if truncated protein was 
produced (arrow). Lower panel: immunodetection of the same blot using a mouse-anti-actin antibody as a 
loading control. 
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Figure 2.10. Loss of the wild-type PTPN11 allele in the cartilage of two exostoses. (A) 
Electropherograms of PCR amplified template DNA that had been extracted from whole blood, a section 
of an exostosis, or the cartilage core of the same exostosis. Exostoses were available from patients A-IV-
5 and A-IV-8. The site of the 5 bp deletion in exon 4 of PTPN11 in both patients is indicated with a box. 
Note that that the heights of the peaks corresponding to the mutant sequence are markedly reduced in 
amplimers from the cartilage-core compared to amplimers from blood or from a section that contains 
cartilage, bone and fibrous tissue. This is consistent with loss-of-heterozygosity in the cartilage 
component of the exostoses. (B) Electropherograms of PCR amplified template DNA extracted from 
blood from participants A-III-9, A-III-10 and A-IV-5, as well as DNA extracted from the cartilage core of the 
exostosis from participant A-IV-5 shown in (A). Blood DNA electropherograms indicate that participants A-
III-9 and A-IV-10 are heterozygous at a position (asterisk) in intron 11 of PTPN11. This is the site of a 
known common polymorphism (rs41279092). Exostosis cartilage DNA electropherograms have a 
reduced adenine peak height at this position. This suggests that the wild-type PTPN11 allele inherited 
from the unaffected parent (A-III-9), which carries an adenine at this position, has been lost in cells that 
contribute to formation of the exostosis' cartilage core. 
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amplimers to determine the percent that contained the mutant allele. Forty-four of 52 individual subclones 
contained the mutant allele, which is significantly higher (p<0.001) than expected for a heterozygous 
mutation. In contrast, 58% of subclones (34/59) from adjacent unaffected bone/bone marrow contained 
the mutant allele, which is not significantly different from the expected value of 50% (p=0.24). These data 
are consistent with an MC exostosis arising from a second hit  (loss of the wild-type allele) within a cell 
that ultimately contributes to the lesion’s cartilage core. Because the mutant allele is 5 bp shorter than 
wild-type PTPN11 in these two patients, we tested for loss of heterozygosity at a second polymorphic site 
in PTPN11 to control for potential PCR bias in amplifying the exon with the deletion. In their peripheral 
blood DNA, patient A-IV-5 and her unaffected mother are heterozygous for a benign polymorphism in 
intron 11 of PTPN11 (rs41279092). The abundance of this SNP, which is in the wild-type PTPN11 allele, 
was markedly reduced in the lesion’s cartilage core, again consistent with LOH occurring in the cell that 
drives formation of the cartilage core (Figure 2.10B).  
PTPN11 mutations are not found in other cartilaginous tumor syndromes  
We finally asked whether mutations in PTPN11 are associated with other cartilaginous tumor 
syndromes. We sequenced the coding exons of PTPN11 in 38 lesions excised from patients with Ollier 
disease, 2 peripheral blood samples from patients with Ollier disease, 15 lesions excised from patients 
with Maffucci syndrome, 4 solitary enchondromas, 9 chondrosarcomas (1 polyostotic), and 3 
osteochondromas without EXT1 or EXT2 mutations. We did not find PTPN11 coding sequence mutations 
in any patient sample. In 24 percent of the samples we observed heterozygosity for noncoding SNPs that 
are known common variants, suggesting that large PTPN11 gene deletions and other causes of LOH are 
not frequently associated with these other cartilaginous tumors.  
2.6 Discussion 
 
We identified 17 unrelated families with MC. Clinical features were similar to previously published 
cases [5–10,15]. The exostoses of MC had been assumed to be identical to the osteochondromas of 
MHE; however, we demonstrate that they are histologically unique lesions with a large cartilaginous core 
(Figure 2.1J–1L). We combined linkage analysis in a single MC family with DNA capture and parallel 
sequencing of bar-coded DNAs from several MC families to identify mutations in PTPN11 as a cause of 
MC. In MC patients without PTPN11 coding sequence and splice site mutations, we generated and 
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pooled barcoded DNAs, and performed a second targeted capture that included the entire PTPN11 gene 
and exons from 76 other genes. This led us to detect a ~15 kb deletion in a patient by analyzing the depth 
of sequencing reads. In total, we found likely disease-causing PTPN11 mutations in 11 of 17 families.  
Concurrent with our studies of MC, Sobreira et al. (2010) reported PTPN11 mutations in 2 MC 
families [11]. They performed whole-genome sequencing (WGS) in a single affected individual who was a 
member of family in which MC was segregating. This approach also required these investigators to 
include linkage data to reduce the number of novel potentially disease-causing heterozygous changes 
that are identified by WGS [19,20]. The investigators next identified an independently arising PTPN11 
mutation in an unrelated patient to strengthen the evidence for causality. However, having only studied 
genomic DNA and finding frameshift mutations in the same exon (exon 4) in their two unrelated patients, 
Sobreira et al. (2010) could not definitively determine the mechanism by which PTPN11 mutations cause 
MC.  
Missense mutations in PTPN11 have previously been identified in patients with Noonan, Noonan-
like, and LEOPARD syndromes, as well as in juvenile myelomonocytic leukemia [21]. In these disorders, 
the mutations are gain-of-function and/or dominant negative for SHP2, which is the PTPN11 protein 
product [22,23]. SHP2 is a protein tyrosine phosphatase and an important intracellular signaling molecule 
linking several growth factor receptors to the Ras/MAPK and other signaling pathways [24]. Therefore, 
frameshift mutations in exon 4 might also create an abnormal protein product by altering PTPN11 mRNA 
splicing. Alternatively, the frameshift mutations might result in loss-of-function because of nonsense 
mediated mRNA decay or rapid degradation of a truncated SHP2 polypeptide. Our finding of nonsense, 
frameshift, and splice-site mutations in multiple exons, as well as a whole-exon deletion, suggests that 
MC-causing PTPN11 alleles are loss-of-function. We tested this hypothesis by performing Western blots 
on whole protein extracts from white blood cells and from an excised lesion containing affected and 
unaffected tissue, and detected only fulllength, wild-type SHP2 protein (Figure 2.9), confirming that the 
mutant alleles are loss-of-function.  
Exostoses in MHE originate from the ‘‘second hit’’ mutations [18]. Mice with conditional alleles at 
the EXT1 locus demonstrate that only a few cells having two mutant alleles are sufficient to cause other 
cells to become misdirected and form an exostosis [25]. By performing microdissection, we found 
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evidence for loss of the wild-type PTPN11 alleles in the majority of cells within the cartilage cores of 
exostoses from two MC patients (Figure 2.10), consistent with a ‘‘second hit.’’ Recently, Bauler et al. used 
a ubiquitously expressed Ert2-Cre driver in 6–8 week-old Ptpn11 floxed mice to generate mice that were 
Ptpn11-null in multiple tissues. Among the consequences of completely deleting SHP2 was the 
appearance of ectopic cartilage islands in the animals’ metaphyseal trabecular bone and growth plates 
[26]. These findings are consistent with the distribution of endosteal tumors and exostoses seen in 
patients with MC. The findings in mice with homozygous deletion of Ptpn11 contrast with the absence of 
skeletal lesions in mice that have heterozygous loss-of-function mutations [27]. We suspect that mice with 
heterozygous mutations have a much lower incidence of noticeable ‘‘second hits’’ compared to humans 
because they have fewer skeletal cells and shorter lifespans. Homozygous inactivation of Ptpn11 solely in 
mouse chondrocytes may be required to enable a detailed understanding of how SHP2 deficiency leads 
to tumorigenesis.  
We did not detect PTPN11 mutations in 6 of 17 patients with MC phenotypes, including 1 patient 
with a family history of MC and 5 patients who are the first affected members in their families. DNA is not 
available from other affected family members of the familial case to determine whether MC exhibits locus 
heterogeneity. Two patients with de novo disease did have DNA variants found in the 3’ UTR and/or in 
introns. None of these variants are in likely regulatory regions or in regions important for mRNA splicing; 
however, we cannot conclude they are benign. Furthermore, we cannot exclude the possibility that 
patients with de novo disease are somatic cell mosaics for PTPN11 mutations that are not present in 
white blood cell DNA, similar to the mildly affected mother in Family F who had two affected children. 
Despite these caveats, MC could be locus heterogeneous, similar to Noonan syndrome, which can be 
caused by mutations in PTPN11 or in other components of the Ras/MAPK pathway [28]; however, our 
targeted capture and sequencing of 74 genes that included most of the Ras/MAPK and PI3K/Akt 
signaling pathways did not find an obvious mutation in another gene in any of the 6 PTPN11 mutation-
negative MC patients.  
We found no evidence of PTPN11 coding mutations in other cartilage tumor syndromes, including 
Ollier disease and Mafucci syndrome. Although sequencing was performed on lesional tissue rather than 
whole blood, it is possible that we may have missed causative mutations that are present in only a subset 
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of cells within the lesion. We may also have missed mutations in the 5’ and 3’ untranslated regions of 
PTPN11 contained within exons 1, 15, and 16, that we did not sequence in these patients. Based on our 
finding heterozygosity for noncoding SNPs in many of these samples, it is unlikely that large PTPN11 
gene deletions or other causes of LOH are common in these syndromes. Despite the aforementioned 
limitations of our mutation detection method, our data are consistent with the separation of MC from the 
other cartilage tumor syndromes based on clinical and pathologic features.  
In conclusion, we combined linkage analysis in a single family with DNA capture and parallel 
sequencing of barcoded DNAs from several families to identify mutations in PTPN11 as a cause of MC. 
The advantages of this approach are its ability to identify a region of interest, then simultaneously 
sequence affected individuals from multiple unrelated families, and then focus on genes for which novel 
SNPs or other mutations are seen in more than one family, all at reasonable cost (<$10,000 in 
consumables). In patients with MC and PTPN11 mutations, we conclude that the mutations are loss-of-
function since the mutant protein is not expressed, and that the loss of the remaining wild-type allele via a 
‘‘second hit’’ is responsible for the formation of the exostoses. Since we did not detect PTPN11 mutations 
in all MC families, MC may be locus heterogeneous, although we have not found evidence after 
sequencing more than 70 genes that function in related pathways. Finally, precisely how mutations in 
PTPN11 give rise to the exostoses and endosteal tumors in patients with MC is not yet known. However, 
this question can now be addressed since mice with alleles of Ptpn11 that can be conditionally inactivated 
in temporal and site-specific manner are available [26,29].  
2.7 Materials and Methods 
 
Ethics 
Informed consent was obtained through a Children’s Hospital Boston IRB approved protocol. 
Specimens and/or DNA received from external institutions were collected under IRB approved protocols 
at host institutions and received coded without identifying information.  
Linkage analysis  
Raw genotype data were generated for multiple members of family A using Affymetrix 6.0 SNP 
arrays, and genotypes were called using Affymetrix Genotyping Console with the Birdseed v2 algorithm 
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and a confidence threshold of 0.02. SNPs with 100% sample call rate or pedigree minor allele frequency 
of 0 were removed, then multipoint parametric linkage analysis of the remaining 421,922 autosomal and 
17,169 X-linked SNPs was performed using MERLIN and its derivative MINX, respectively, with 
Affymetrix Caucasian allele frequencies and deCODE Genetics genetic map positions. The disease allele 
frequency was estimated at 1E-7, and phenocopies and non-penetrance were not permitted (affectation 
probability 0/1/1). Because non-penetrance and non-ascertainment are potential confounding factors in 
MC, we analyzed only founders and affected individuals.  
Barcoded genomic libraries  
 To generate genomic libraries for each individual, 2 µg of genomic DNA were first sheared to 100 
bp–200 bp using Adaptive Focused Acoustics following the manufacturer’s protocol (Covaris, Inc). Blunt-
ended fragments were generated using an End-it DNA End-Repair kit (Epicenter), purified using 
Agencourt AMPure XP magnetic beads (Beckman Coulter), and eluted in 10 mM Tris Acetate, pH 8.0. 
The fragments were A-tailed using the Klenow fragment (NEB), purified, eluted in 1x Quick Ligase Buffer 
(Quick Ligation kit, NEB), and incubated with Quick T4 DNA ligase and 100 µM barcoded-adapters (Table 
2.5) to create a library of adapter-ligated fragments. A different barcoded adapter was used for each 
genomic DNA library. Each library was again purified using Agencourt AMPure XP magnetic beads and 
eluted in 40 µl of 10 mM Tris Acetate, pH 8.0. Libraries used for hybridization to the first capture array 
were amplified according to two strategies: 3 µl amplified for 18 cycles in four 50 ml PCR reactions 
(Phusion High-Fidelity DNA polymerase, Finnzymes), or 2 µl amplified for 11 cycles in one 50 ml PCR 
reaction that was then purified and amplified for 17 cycles in ten 50 µl PCR reactions (FastStart Taq DNA 
polymerase, Roche). For the libraries used for hybridization to the second capture array, 13 µl was 
amplified for 15 cycles in ten 50 µl PCR reactions (Phusion High-Fidelity DNA polymerase, Finnzymes). 
Primers are provided in Table 2.6. Sizes of amplified libraries were confirmed to be between 200–300 bp 
necessary for Illumina GA II sequencing prior to hybridization (Figure 2.4).  
Capture array design  
To enrich regions of interest in the linked interval for sequencing, we used an Agilent 
Technologies 1M SureSelect DNA capture array. Target regions were defined using the UCSC Genome 
Browser and included: the union of exons from multiple GRCh37/hg19 gene, mRNA, and Alt Events  
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Table 2.5. Barcoded library adapters 
AAC     5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAC*T-3’ 
 5’-/5Phos/GTTAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
AGC     5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGC*T-3’ 
 5’-/5Phos/GCTAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
AGG    5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTAGG*T-3’ 
 5’-/5Phos/CCTAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
CAG       5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAG*T-3’ 
 5’-/5Phos/CTGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
CGA       5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGA*T-3’ 
 5’-/5Phos/TCGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
CGT       5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTCGT*T-3’ 
 5’-/5Phos/ACGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
CTC      5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTCTC*T-3’ 
 5’-/5Phos/GAGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
GAC 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGAC*T-3’ 
 5’-/5Phos/GTCAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
GCA 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGCA*T-3’ 
 5’-/5Phos/TGCAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
GGA      5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGA*T-3’ 
 5’-/5Phos/TCCAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
GTC       5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTC*T-3’ 
 5’-/5Phos/GACAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
GTG      5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTGTG*T-3’ 
 5’-/5Phos/CACAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
TCC     5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCC*T-3’ 
 5’-/5Phos/GGAAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
TCG     5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCG*T-3’ 
 5’-/5Phos/CGAAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
TGA    5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGA*T-3’ 
 5’-/5Phos/TCAAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
TGG     5’-ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGG*T-3’ 
 5’-/5Phos/CCAAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’ 
Asterisk (*) indicates a phosphorothioate bond to prevent degradation. Adapter 
sequences are Illumina paired end adapters with a 3bp identifying barcode indicated in 
bold type.  
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tracks; 30 bp of proximal and distal intronic flanking sequence; and 1000 bp of upstream promoter 
sequence. Targets were padded with 60 bp of additional proximal and distal flanking sequence to 
promote uniform capture coverage, for a total size of 1,187,477 bp. Probes were designed against 
NCBI36/hg18 using the Agilent eArray software (https://earray.chem.agilent.com/earray/) and translated 
coordinates, with 60-nt length, 3-nt spacing, and repetitive elements masked. The resulting 243,488 
probes spanned 844,339 bp (GRCh37/hg19), and included 71.1%, 72.2%, 88.4%, and 98.6% of the 
padded target, unpadded target, UCSC exons, and CCDS coding sequence, respectively. The probes 
and their reverse complements were each applied in duplicate to the capture array for a total of 973,952 
probes. For the second 1M SureSelect DNA capture array, Biomart (http://uswest.ensembl.org/biomart/) 
was used to obtain the Ensembl NCBI37/hg19 coordinates for the exons of 76 genes (Table 2.3). Exons 
were padded with 90 bp to define a 718,566 bp target region. eArray was used to design 568,634 probes 
to target the repeat masked sequences of this region (91%). The target region for PTPN11 was defined 
as 93,180 bp spanning 1 kb upstream to 2 kb downstream of the gene. Repeat masker (http:// 
www.repeatmasker.org/) was used to mask only Alu repeats (37% of the region) resulting in a target 
region of 61,365 bp, for which 55,205 probes were designed using eArray. All probes were 60-nt in length 
and spaced every 1-nt. The capture array was designed to include all probes (623,839 total), as well as 
the reverse complement of every 2nd probe and every 17th probe, for a total of 972,455 probes.  
Array hybridization  
For the first capture array, 1.4 µg of each of the 16 amplified libraries was pooled and hybridized 
to the array following Agilent’s SureSelect DNA Capture Array protocol version 1.0. Different blocking 
oligonucleotides (Table 2.6) were added to the hybridization. After elution from the array, half of the 
captured library was amplified in five 50 ml PCR reactions for 18 cycles using Phusion High-Fidelity DNA 
polymerase (Finnzymes) and post-capture primer pair (Table 2.6), purified using an E-Gel CloneWell 
(Invitrogen) to remove primer dimers, and re-amplified using fifteen PCR cycles with the same primer pair. 
The amplified library was again purified to eliminate primer dimers using E-Gel. For the second capture 
array, 2 µg of each of the 12 amplified libraries was pooled and hybridized to the array. After elution, half 
of the captured library was amplified in five 50 ml PCR reactions for 15 cycles and purified using 
Agencourt AMPure XP magnetic beads.  
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Table 2.6. PCR primers for library amplification and blocking oligonucleotides 
 
Pre-capture Primers 
Pre-capture Fw 5’-ACACTCTTTCCCTACACGACGCT-3’ 
Pre-capture Rev 5’-GGTCTCGGCATTCCTGCTGAA-3’ 
  
Post-capture Primers 
Post-capture Fw1 5'- 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC
TTCCGATC*T-3’ 
Post-capture Rev2 5'- 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACC
GCTCTTCCGATC* T-3’ 
Blocking Oligos  
BO_A (Adapter 
sequence 1) 
5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3' 
Rev. comp. BO_A 5'-AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGT-3' 
BO_B (Adapter 
sequence 2) 
5'-GGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-3' 
Rev. comp. BO_B 5'-AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAGACC-3' 
 
1 PCR primer © 2006 Illumina, Inc. All rights reserved.  
2 Bentley et al. (2008) [32]. 
 
Illumina data analysis 
The amplified targeted array captured libraries were sequenced using two lanes of an Illumina GA 
II, using single end 80 bp (first array) or 42 bp (second array) sequencing. Novobarcode software 
(http://novocraft.com/) was used to sort the reads according to their 3 bp barcode. For the first capture 
array, Novoalign was used to align the reads to the reference genome (hg19), using default settings but 
including adapter trimming. For the second capture array, the BWA aligner (http://bio-
bwa.sourceforge.net/) was used. PCR duplicates were removed by the MarkDuplicates command in 
Picard (http://picard.sourceforge.net/index.shtml). Variants were called using SAMtools and low 
confidence variants were removed by the SAMtools varFilter command and by removing all insertions 
and deletions present in only one read. Annovar (http://www.openbioinformatics.org/annovar/) was used 
to identify coding variants, classify SNPs as synonomous or nonsynonomous, and classify SNPs as either 
novel or previously described in dbSNP version 132. For each individual, the percentage of reads that 
overlapped with regions targeted by the capture array was calculated using Galaxy 
(http://main.g2.bx.psu.edu/). The read depth for each base targeted by the array was calculated using the 
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DepthOfCoverage command in the Genome Analysis Toolkit 
(http://www.broadinstitute.org/gsa/wiki/index.php/ The_Genome_Analysis_Toolkit).  
Copy number analysis based on Illumina read depth  
The regions targeted by the capture array were divided into non-overlapping 50 bp windows. For 
each individual, the read depth for each window was normalized based on the total number of reads 
obtained for that individual. For each window in an individual, the normalized read depth was divided by 
the average read depth for that window in all 10 individuals, and the log2 value was calculated. Windows 
with an average read depth of less than 5X were excluded from the analysis. A perl script was written to 
find regions of consecutive windows that had log2 ratios below -0.7 or above 0.5, to identify deletions and 
duplications, respectively. 
Sanger sequencing of PTPN11  
All coding PTPN11 exons were PCR amplified using primers containing an M13 sequencing tag 
(Table 2.7). PCR Primers were located between 26 and 160 bp away from the intron/exon boundary. For 
fragmented DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples, primers closer 
to the intron/exon boundary were used to allow for smaller PCR products (Table 2.7). PCR amplification 
was performed using FastStart Taq DNA Polymerase (Roche) at 95 ºC for 4 min, 35 to 40 cycles of 95 ºC 
for 30 sec, 60 ºC for 30 sec and 72 ºC at 50 sec, followed by 5 min at 72 ºC. PCR products were sent for 
purification and sequencing in both forward and reverse directions, using M13 sequencing primers, at the 
Molecular Genetics Core Facility at Children’s Hospital Boston. 
DNA extraction from exostoses and subcloning of PCR products 
DNA was extracted from several sections of a formalin fixed, paraffin embedded exostosis 
excised from participant A-IV-5, using a QIAamp DNA FFPE Tissue Kit (Qiagen). To isolate DNA from the 
cartilage core of this lesion, Laser Capture Microdissection (LCM) was performed. 7-micron sections were 
placed on PEN membrane glass slides (MDS Analytical Technologies). Sections were stained using 
Toluidine Blue. The cartilage cores of several sections were isolated using LCM, pooled, and DNA was 
extracted using a PicoPure DNA Extraction Kit (Applied Biosystems) with an overnight incubation at 65 ºC. 
A second exostosis, that had been removed from participant A-IV-8, was frozen and embedded in several 
blocks of OCT. Hematoxylin & Eosin staining of sections of this exostosis was used to identify a block  
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Table 2.7. Primers used for amplification of PTPN11 coding exons 
 
Exon Forward primer Reverse primer PCR 
product 
size (bp) 
 Sequence1 Position2 Sequence3 Position2  
1 GGGCAGCTGCACA
GTCTC 
-178 to     -
160 
GGGGACGAGGAG
GGAAC 
+143 to 
+127 
334 
1S4 CGGAGCCTGAGCA
AGGAG 
-54 to -35 CTTCCGGACGGGG
CTAAC 
+71 to 
+56 
139 
2 AAGGGACAGGGAA
GGTCTTG 
-137 to     -
118 
AACCCTGAAGGCA
GCCC 
+133 to 
+117 
393 
2S4 AGTGCTGACAGTGT
CTTGTTTTT 
-52 to -30 CTCTCAGGATCCTC
TCTTTTCA 
+33 to 
+12 
208 
3 TGTGGTTATTTCAC
CCATCG 
-163 to     -
144 
AAAGGTACTCTGAA
AATAATTTGATGC 
+100 to 
+121 
539 
3S4 AACTCTTTATTTGTC
CCCTTGC 
-47 to -26 AGGGAGCAGCAGA
CTTTGTG 
+40 to 
+21 
284 
4 TGATCAATCCCTTG
GAGGAA 
-134 to     -
115 
GAAAAATCACCCAA
AGGTAACA 
+56 to 
+35 
383 
 
4B TGAAAGAACAACAT
GAACCCATA 
-61 to -38 GTGCGCACAGAAA
GAACAAA 
-68 to -87 187 
4S14 TGAAAGAACAACAT
GAACCCATA 
-61 to -39 GTGCGCACAGAAA
GAACAAA 
c.451 to 
c.471 
187 
4S24 CTTGTACGAGAGAG
CCAGAGC 
c.406 to 
c.427 
TCTTGCCAGACCC
ATTTTTC 
+35 to 
+15 
154 
5 CTGCAGTGAACATG
AGAGTGC 
-83 to -63 TTCTGTCTACCTCT
GTATGTTTGC 
+89 to 
+66 
289 
5S4 TGAGAGTGCTTGAA
AACACTAATGTAA 
-71 to -45 TTTAAGTTTTTAAG
GAGAAAGCTTGAG 
+44 to 
+18 
232 
6 TTTGCATTAACACC
GTTTTCTG 
-64 to -43 CAAGAGCAACTTCT
CCTCCA 
+71 to 
+52 
249 
6S4 CATCAACTGCTGTA
CTCGATCA 
-23 to -6 CAGGTCCAATTCCA
AACACA 
+89 to 
+70 
226 
7 CCCAGATGAACATT
CTTGTAGC 
-145 to     -
126 
CAATTAAAGAAGCT
AAGGCCTCC 
+124 to 
+102 
366 
7S4 TTTTTCTGTGACTC
TTTGACACG 
-52 to -30 GGTGCTAGGAATC
AAAATCTCC 
+38 to 
+59 
208 
 
8&9 TGGACTAGGCTGG
GGAGTAA 
-87 to -68 TTCCTAAACATGGC
CAATCTG 
+55 to 
+76 
527 
8S4 TGGACTAGGCTGG
GGAGTAA 
-68 to -87 TTTCAGGACATGAG
GAAGGA 
+83 to 
+64 
250 
9S4 TCCTTCCTCATGTC
CTGAAAG 
-63 to -43 TTCCTAAACATGGC
CAATCTG 
+75 to 
+55 
297 
10 CTAACAGATGCGAA
ACAGGC 
-133 to     -
114 
GGAAGCTAATAAAT
GGCTACTGAATC 
+137 to 
+112 
402 
10S4 CAGAGTTCACAGAA
TTAACTTTCTTTT 
-44 to -18 TCCCAAAGTCTCTA
GAATACGACA 
+34 to 
+11 
210 
11 GGACCTTTCAGTGG
AACCTG 
-128 to     -
109 
CAATGCAGTTGCTC
TATGCC 
+139 to 
+120 
423 
11S4 CGGGTGATTCCTCA
ACCTCT 
-64 to -45 CGCTAGGAGACAG
GGACAGG 
+52 to 
+33 
271 
12 CTGACTCCAAAGCC
CTATGC 
-173 to     -
154 
TCTGTTCTCAGGCA
GACACAC 
+154 to 
+134 
395 
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(Table 2.7 continued) 
 
 
 
Exon Forward primer Reverse primer PCR 
product 
size (bp) 
 Sequence1 Position2 Sequence3 Position2  
12S4 GAGTCTGAAACCCC
CATGAA 
-59 to -40 CCAGACTGTTTTCG
TGAGCA 
+79 to 
+59 
205 
13 CTGTAGCCATTGCA
ACATGC 
-140 to      -
121 
TGGGAGTTTGTTTC
CCATTC 
+130 to 
+111 
422 
13S4 CCTGGCTCTGCAGT
TTCTCT 
-47 to -28 AGAGGCCTAGCAA
GAGAATGA 
+51 to 
+31 
250 
14 TTTTTGCTTTTTATC
CCCTTAAA 
-64 to -43 AAACCACCATGAC
CAGGTAAA 
+46 to 
+26 
223 
15 CAGGAACTGTGTCT
GTACCATATC 
-121 to      -
102 
CCTGGTTTGTAAAA
CTCAATTATGG 
+120 to 
+96 
347 
15S4 GCTTAAACAGCGTG
GTCTACA 
-57 to -37 TGCCAATTATATAA
ACAATTAACCAA 
+48 to 
+23 
207 
 
 
1 The forward M13 sequencing tag (5’-GTAAAACGACGGCCAGT-3’) was added on the 5’ end of all 
forward primers. 
2 Number of nucleotides upstream of the 5’ end of the exon (-) or downstream of the 3’ end of the exon 
(+). For exons 1 and 15, the end of the UTR was used rather than the end of the exon.  
3 The reverse M13 sequencing tag (5’- AACAGCTATGACCATG-3’) was added on the 5’ end of all 
reverse primers.  
4 Primers closer to the intron/exon boundary were used on some formalin-fixed paraffin-embedded tumor 
samples for which the amplification of PCR products greater than ~300bp failed, which suggested 
fragmentation of DNA.  
 
 
consisting of >90% cartilage cells, and similarly to identify a block consisting of a majority of bone and 
fibrous tissue. For both blocks, several sections were pooled and DNA was extracted using the PicoPure 
DNA Extraction Kit (Arcturus) with a 3 hr incubation at 65 ºC. PCR amplification of DNA from both 
participant’s exostoses was performed using 2 to 6 µl of extracted DNA, in a 20 µl PCR reaction, using 
PCR conditions described above, and primer pair 4S1 (Table 2.7), or, to amplify the SNP in intron 11 of 
PTPN11, the primers 5’-GACCCTACAGCACTGCCATT-3’ and 5’-CCCCACCACCTCAATACCTA-3’.  
For the exostosis from participant A-IV-8, PCR amplimers from the cartilage or the bone and fibrous 
tissue sections were subcloned into a PCR-4-TOPO Vector using a TOPO TA cloning kit (Invitrogen). 
Individual colonies were selected and resuspended in a PCR mix, and amplified using primer pair 4S1 
(Table 2.7). To distinguish between mutant and wild-type subclones, the PCR amplimers were restriction 
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digested by combining 0.2 µl of DdeI, 1.0 µl of Buffer 3 (New England Biolabs), and 9 µl of each PCR 
reaction and then incubating at 37 °C for 2 hours.  Digested products were separated by electrophoresis 
on a 4% agarose gel.  The 5 bp deletion creates a novel DdeI restriction site.  
Multipex Ligation-Dependent Probe Amplification  
 MLPA was performed using the SALSA MLPA EK1 Kit (MRC-Holland). A custom probemix was 
used, including two probes targeting exon 1 of EXT1 [30,31]  and four control probes (Table 2.8). The 
resulting labeled PCR products were separated according to size (Applied Biosystems 3730 DNA 
Analyzer) and the height of each peak was calculated. For each EXT1 peak, a ratio was calculated by 
dividing the height of the EXT1 peak by the average height of the non-EXT1 peaks. For each participant, 
this ratio was divided by the average ratio obtained in the control samples, to obtain a corrected ratio, 
such that a value of 1.0 represents a copy number of 2, and a value below the threshold of 0.80 
represents a deletion. 
 
Table 2.8. Probes used for MLPA 
 
Gene Chr Amplicon 
size (bp) 
Upstream hybridizing 
sequence 
Downstream hybridizing 
sequence 
EXT1 
exon1 
middle 
8 116 5’_GGACACATGCAGGCCA
AAAAACGCTA_3’ 
5’_TTTCATCCTGCTCTCAGC
TGGCTCTTGTCTCGCCCTTT
TGTTTTCATG_3’ 
EXT1 
exon1-
intron1 
8 112 5’_GCATGGCAAAGACTGG
CAAAAGCACAAGGAT_3’ 
5’_TCTCGCTGTGACAGAGA
CAACACCGAGTATGAGAAG
TAA_3’ 
 
RGAG1 X 102 5’_TGACTGTGAATTCTACA
ACATATGGAGCGC_3’ 
5’_CTACCTTGTGCAAGGCA
TTGTGGGTAAGTC_3’ 
 
AMMEC
R1 
X 106 5’_GCTCCCGGAAGATGGT
GGTGTCAGCAGAGATG_3’ 
5’_TGCTGCTTTTGCTTCGAT
GTGCTCTACTGTCA_3’ 
 
SERPIN
B2 
18 122 5’_CATGACTCCAGAGAACT
TTACCAGCTGTGGGTTCAT
GCA_3’ 
5’_GCAGATCCAGAAGGGTA
GTTATCCTGATGCGATTTTG
CAGG_3’ 
 
CHRDL
1 
X 126 5’_CCAATGGAAAGACCTAT
TCTCATGGCGAGTCCTGG
CACCCAA_3’ 
5’_ACCTCCGGGCATTTGGC
ATTGTGGAGTGTGTGCTAT
GTACTT_3’ 
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Microarray-based comparative genomic hybridization analysis  
 To determine if some patients with MC had deletions or duplications within the candidate interval on 
chromosome 12, we performed microarray-based Comparative Genomic Hybridization (aCGH) on 8 
affected individuals from 7 families (Table 2.1). We designed an 8x60K Agilent SurePrint G3 array using 
eArray to include probes spanning the linkage interval, with an average probe spacing of 160 bp. We 
found 7 potential small duplications or deletions, all of which were less than < 1.5 kb in size. One of the 
duplications spanned a coding region in IFT81, but we could not verify this duplication using a PCR-
based assay. 
Immunodetection of SHP2 
An excised exostotic lesion from participant B-IV-7 and rib cartilage from an unaffected individual 
were homogenized in RIPA buffer (25 mM Tris pH7.4, 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS, 
0.5% sodium deoxycholic acid). HELA cells were lysed directly in NuPAGE LDS sample buffer 
(Invitrogen). Protein extracts were separated on a NuPAGE 4-12% Bis-Tris Gel (Invitrogen) and 
transferred to an Invitrolon PVDF membrane (Invitrogen). Immunodetection of SHP2 was performed 
using a WesternBreeze Chemiluminescent Immunodetection Kit (Invitrogen) and a 1:1000 dilution of 
mouse-anti-SHP2 (610621, BD Biosciences). As a loading control, immunodetection using mouse-anti-
actin antibody (ab3280, Abcam, 1:600 dilution), was performed on the same blot. 
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3.1 Abstract 
 
Loss of SHP2 in mice or in human metachondromatosis (MC) patients causes benign cartilage 
tumors on the bone surface (exostoses) and within bones (enchondromas). To further our understanding 
of the mechanisms underlying cartilage tumor formation, we investigated the role of SHP2 in chondrocyte 
maturation in vitro and in vivo. We performed massively parallel mRNA sequencing (RNA-seq) to define 
the transcriptional consequences of SHP2 depletion during the maturation of chondrocytes in primary 
pellet cultures. We found that SHP2 depletion delays terminal differentiation to the late-hypertrophic stage 
and maintains gene expression associated with earlier maturation stages (proliferative, pre-hypertrophic 
and early-hypertrophic stage). We observed similar transcriptional changes in pellets treated with a 
MEK1/2 inhibitor, suggesting that SHP2 signals via the ERK1/2 pathway to delay terminal differentiation. 
We next analyzed chondrocyte maturation in vivo following postnatal mosaic inactivation of Ptpn11, which 
encodes SHP2.  We observed that Ptpn11-cKO vertebral growth plates are highly disorganized and have 
an expanded domain of hypertrophic chondrocytes that have not yet terminally differentiated to the late-
hypertrophic stage. Furthermore, we found that enchondroma-like lesions in Ptpn11 cKO vertebrae arise 
from chondrocytes displaced from the growth plate due to non-uniform rates of maturation and 
ossification, and that they contain both SHP2 deficient and wild-type chondrocytes. These data suggest 
that mosaic loss of Ptpn11 alters paracrine signaling within growth plates, consistent with our 
observations that maturation zones are similarly disorganized in the cartilage core of exostoses from 
human MC patients. In summary, these data suggest that in patients with MC, who are heterozygous for 
inherited PTPN11 loss-of-function mutations, second-hit mutations in PTPN11 produce enchondromas by 
causing disorganized growth, delayed terminal differentiation, and abnormal paracrine signaling from 
SHP2-deficient chondrocytes.  
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3.4 Introduction 
 
 Enchondromas in bone cavities and exostoses on bone surfaces are the two most common types 
of benign cartilage tumors [1].  Both tumors occur in patients with the autosomal dominant heritable 
disorder metachondromatosis (MC) [2].  Families with MC segregate heterozygous loss-of-function 
mutations in PTPN11, and their cartilage tumors are thought to arise from cells that have second-hit 
somatic PTPN11 mutations [2,3].  PTPN11 encodes the tyrosine phosphatase, SHP2, which has cell 
type-dependent and context-dependent roles in many signaling pathways [4].  MC is unique in that it is 
associated with both enchondromas and exostoses.  Other genetic conditions cause enchondromas or 
exostoses, but not both. Patients with Ollier disease and Maffucci syndrome, due to somatic gain-of-
function mutations in IDH1 or IDH2, have enchondromas [5–7]. Patients with heterozygous loss-of-
function mutations in EXT1 or EXT2 segregate multiple hereditary exostoses (MHE) [8].  The mechanism 
by which cartilage tumors arise in patients with MC is incompletely understood.  Also unknown is whether 
tumor formation in patients with MC results from perturbation of the same biologic pathway(s) that are 
affected in patients with Ollier disease, Maffucci syndrome, and MHE.  
 Mice have been used to model tumor formation caused by SHP2 deficiency. Unlike humans, 
cartilage tumors have not been observed in mice that are heterozygous for Ptpn11 loss-of-function 
mutations, and complete absence of Ptpn11 in mice causes embryonic lethality [9].  However, cartilage 
tumors can be induced by a conditional biallelic inactivation of Ptpn11 [10–12].  Mosaic inactivation of 
Ptpn11 in chondrocytes and/or perichondrial cells produces enchondromas in the vertebrae and ribs, and 
exostoses in the limbs [11–13].  These data suggest that exostoses arise from Ptpn11-null perichondrial 
cells that inappropriately differentiate into chondrocytes [11,12], and that enchondromas arise from 
Ptpn11-null growth plate chondrocytes that fail to be replaced by bone [12]. Thus SHP2 appears to 
participate in the specification, proliferation, and maturation of chondrocytes. 
 One downstream signaling pathway likely altered in SHP2 deficient chondrocytes is the ERK1/2 
pathway.  Exostoses in Ptpn11-mutant mice have reduced levels of phospho-ERK1/2 [11,12].  While in 
vivo studies have not directly demonstrated that inactivation of the ERK1/2 pathway is sufficient to 
produce cartilage tumors, studies have shown that inactivation of Erk1 and Erk2 in mesenchymal cells 
leads to ectopic cartilage clusters in the perichondrium of mouse embryos [14]. Therefore, it is possible 
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that these ectopic clusters could develop into exostoses had the mice survived into adulthood.  
Furthermore, inactivation of Erk1 and Erk2 in chondrocytes disrupts the growth plate’s columnar-
organization, causes chondrocytes to hypertrophy prematurely, and delays the replacement of cartilage 
with bone [14,15].  Thus reduced ERK1/2 signaling following SHP2 depletion may mediate some of the 
phenotypic features in patients with MC 
 Because the molecular consequences of SHP2 depletion or ERK1/2 inactivation in chondrocytes 
are incompletely understood, we investigated the transcriptional response to either SHP2 depletion or 
MEK1/2 inhibition in chondrocyte pellet cultures by performing massively parallel mRNA sequencing 
(RNA-seq).  We also conditionally inactivated Ptpn11 in vivo and examined the effect of SHP2 depletion 
on chondrocyte maturation, and we examined chondrocyte maturation in exostosis lesions from MC 
patients. Herein, we report that SHP2 and the ERK1/2 pathway have overlapping effects on gene 
expression during chondrocyte maturation in pellet culture, and we suggest a mechanism by which 
enchondromas arise in MC patients that involves disrupted growth plate architecture and inclusion of 
normal cells within enchondromatous lesions.  Lastly, in addition to providing insights into the roles of 
SHP2 and ERK1/2 during chondrocyte maturation, the RNA-seq method and transcriptome database we 
developed should be useful to other scientists who are interested in growth plate biology and chondrocyte 
maturation.  
3.5 Results 
 
RNA-seq analysis of pellet cultures identifies both previously known and novel 
transcriptional changes that occur as chondrocytes mature from the proliferative 
through to the late-hypertrophic stage 
To establish a system in which the molecular consequences of SHP2 depletion in chondrocytes 
could be studied, we utilize mouse primary chondrocyte pellet cultures [16,17]. In the growth plate, 
chondrocytes proceed through distinct zones of maturation before their cartilage is degraded and 
replaced by bone (Figure 3.1A). The proliferative zone (PZ) contains small, rapidly dividing chondrocytes 
that form columns, while the hypertrophic zone (HZ) contains chondrocytes that have exited the cell cycle 
and dramatically increased in size (Figure 3.1A) [18]. In chondrocyte pellet cultures, the transition from 
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the proliferative to hypertrophic state can be modeled (Figure 3.1B). We evaluated the process of 
chondrocyte maturation at the transcriptional level by performing RNA-seq on pellet cultures.  
To verify that RNA-seq is a reproducible method for measuring transcript abundance in 
chondrocytes undergoing maturation in pellet cultures, we first performed RNA-seq on wild-type 
chondrocytes after 4 days, or 1, 2 or 3 weeks in culture. We sequenced 3 libraries per time point, and 
obtained, on average, 13 million 50-bp paired-end reads per library, of which >95% could be mapped to 
 
 
Figure 3.1. Identifying transcripts associated with the maturation of wild-type chondrocytes in 
pellet cultures. A: Schematic representation of the zones of maturation in the growth plate. Examples of 
four transcripts that are associated with specific maturation states are indicated. PZ: proliferative zone. 
HZ: hypertrophic zone. B: Photomicrographs of Alcian Blue and Nuclear Fast Red stained sections 
through chondrocyte pellets after 1 week (w1) and 3 weeks (w3) in culture (scale bar = 50 µm). Note the 
overall increase in chondrocyte size between w1 and w3, consistent with chondrocytes undergoing 
hypertrophy. C: Graphs showing the abundance (RPKM) of selected transcripts in wild-type chondrocytes 
after 4 days, or 1, 2 or 3 weeks in pellet culture. Above each graph, the growth plate zones in which 
transcripts have previously been shown to be most abundant are indicated. RNA-seq was performed on 3 
pellets per time point, and the average RPKM at each time point is indicated (± 1 SD). Transcripts that 
significantly (p<0.05) increase or decrease in abundance over time are indicated with an asterisk. D: Flow 
Chart showing the method used to define a set of transcripts that consistently decreased or increased in 
abundance over time in three independent experiments.  
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the mouse genome (Table 3.1). To determine the relative abundance of transcripts at each time point, we 
counted the number of reads mapping to each transcript, and normalized this based on the length of the 
transcript and the number of reads per library, to obtain an RPKM value [19] (Supp Data File 1). We 
found that the abundance of transcripts was similar across libraries from the same time-point (R2 > 0.99) 
(Figure 3.2), and that the most abundant transcripts corresponded to genes known to be highly expressed 
in chondrocytes (e.g., Col2a1, Col9a1, Sparc) [20]. Furthermore, while transcripts associated with 
intermediate stages of chondrocyte maturation (pre-hypertrophic and early-hypertrophic) did not 
consistently change in abundance over time, many transcripts known to be associated with proliferative 
chondrocytes decreased in abundance and transcripts associated with late-hypertrophic/terminally 
differentiated chondrocytes increased in abundance (Figure 3.1C; Table 3.2). This indicates that as pellet 
cultures mature, the proportion of proliferative chondrocytes decreases, while the proportion of terminally-
differentiated chondrocytes increases. Thus, our data suggest that RNA-seq is a reliable method for 
detecting changes in transcript abundance that occur as chondrocytes mature from the proliferative 
through to the late-hypertrophic stage.  
 To further define transcriptional changes associated with chondrocyte maturation, we sought to 
identify a reproducible set of transcripts that change in abundance over time. First, we selected all 
transcripts that significantly increased or decreased in abundance over time in our wild-type pellet 
cultures. Only transcripts with an RPKM > 3 that showed at least a 2-fold change and a p value < 0.05 
were selected. Second, to reduce false positives, we incorporated data from 2 additional independent 
RNA-seq data sets. These were from pellets that were used as vehicle controls in our experiments 
described in further detail below. We justified incorporating data from vehicle-treated pellets by showing 
that vehicle-treatment alone did not affect known chondrocyte maturation transcripts (Figure 3.3) and that 
the correlation coefficient between untreated and vehicle-treated libraries at the same time point was high 
(R2 > 0.98) (Figure 3.2). We found that 81% of all transcripts that increased or decreased in abundance 
over time in untreated pellets also increased or decreased in abundance by at least 1.5 fold in both sets 
of vehicle-treated pellets.  By focusing only on the transcripts that reached statistical significance and 
exhibited at least a 2-fold change in all three experiments, we identified a high-confidence set of 176 
transcripts that consistently decreased in abundance over time (“upper zones” transcript set) and a set of  
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Table 3.1: Number of reads and mapping statistics for each library 
 
Mouse 
litter Genotype & time point Replicate 
Total # reads (50bp 
paired end) % mapped 
A 1  24,958,041  96% 
 2  10,908,661  97% 
 
Day 4 
Wild-type 
3  13,805,624  97% 
 1  13,367,197  95% 
 2  13,300,200  98% 
 
Week 1 
Wild-type  
3  9,673,123  97% 
 1  13,234,707  96% 
 2  9,378,957  96% 
 
Week 2 
Wild-type  
3  10,341,598  98% 
 1  11,077,264  96% 
 2  10,969,002  97% 
 
Week 3 
Wild-type  
3  13,946,829  97% 
B Week 1, 4-OHT 1  16,566,070  96% 
 Wild-type  2  17,246,647  96% 
  3  16,205,375  96% 
 Week 1, untreated 1  17,057,605  97% 
 Wild-type 2  23,336,815  97% 
  3  25,856,434  97% 
 1  20,776,870  95% 
 2  16,113,528  96% 
 
Week 3, 4-OHT 
Wild-type 
3  14,954,606  85% 
 1  15,769,721  97% 
 2  14,294,479  95% 
 
Week 3, untreated 
Wild-type 
3  20,438,780  97% 
C 1  12,110,000  93% 
 2  9,657,059  94% 
 
Week 1, 4-OHT 
Ptpn11 –/fl; CMV-CreERT2 
3  9,507,599  96% 
 1  25,954,789  95% 
 2  12,766,566  97% 
 
Week 1, untreated 
Ptpn11 –/fl; CMV-CreERT2  
3  7,648,448  86% 
 1  31,478,241  97% 
 2  40,187,879  96% 
 
Week 3, 4-OHT 
Ptpn11 –/fl; CMV-CreERT2 
3  31,181,967  96% 
 1  26,929,091  96% 
 2  18,316,729  93% 
 
Week 3, untreated 
Ptpn11 –/fl; CMV-CreERT2  
3  21,570,699  94% 
D 1  14,138,829  97% 
 2  12,634,668  96% 
 
Week 1 
U0126 
3  13,823,998  96% 
 1  12,165,140  97% 
 2  11,748,157  96% 
 
Week 1 
DMSO control 
3  12,558,375  97% 
 1  12,765,004  93% 
 2  11,862,249  97% 
 
Week 3 
U0126 
3  13,849,488  95% 
 1  13,018,137  94% 
 2  12,150,097  93% 
 
Week 3 
DMSO control 
3  12,601,300  96% 
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Table 3.2: Previous studies identifying transcripts that are associated with a specific chondrocyte 
maturation stage.  
 
Growth plate 
zone Transcript Reference 
Col2a1 [21] 
Col9a1 [21] 
Col9a2 [21] 
Col9a3 [21] 
Col11a1 [21] 
Col11a2 [21] 
Sox9 [22] 
PZ 
 
Fgfr3 [23] 
Pth1r [24] 
Ihh [24] 
Panx3 [25] 
Pre-HZ 
Sp7 [26] 
Col10a1 [22] 
Phospho1 [27] 
Bmp6 [28] 
Early-HZ 
Alpl [29] 
Spp1 [22] 
Mmp13 [22] 
Hpse [30] 
Adamts5 [31] 
Adamts1 [32] 
Tnfsf11 [33] 
Late-HZ 
Ibsp [34] 
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Figure 3.2: Correlation between libraries from the same time point. Scatterplots comparing the 
number of reads mapping to each gene in RNA-seq libraries prepared from pellets harvested after 1 week 
in culture. Each circle represents an individual gene. A: Comparison of two representative RNA-seq 
libraries prepared from pellets that were established at the same time from the same litter of mice. B: 
Comparison of two representative RNA-seq libraries prepared on different days from pellets that were 
independently established from different mouse litters. Pellets in set A were untreated. Pellets in set B 
were treated with 0.1% DMSO and were used as vehicle control pellets in our MEK1/2-ihnibition 
experiment. The Pearson correlation coefficient (R2), calculated using the trimmed-mean method, is 
indicated on each plot.  
 
 
                                               
 
Figure 3.3: Vehicle treatment alone does not significantly alter chondrocyte maturation in pellet 
cultures. Heatmap showing the fold change in transcript abundance over time (from w1 to w3) in three 
independent pellet culture experiments, for a set of transcripts associated with the proliferative zone (PZ) 
or late-hypertrophic zone (late-HZ). A = untreated pellets. B = pellets treated with 0.1% DMSO as a vehicle 
control in our MEK1/2-inhibition experiments. C = pellets treated with 0.1% EtOH as a vehicle control in 
our 4-OHT-treatment experiments.   
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479 transcripts that consistently increased in abundance (“lower zones” transcript set) (Figure 3.1D, Supp 
Data File 1). Known markers of proliferative or hypertrophic chondrocytes were identified in these 
transcript sets, respectively, thus validating our approach (Figure 3.1D). Conversely, many of the 
transcripts in these data sets have not yet been studied in the growth plate and likely represent novel 
factors involved in chondrocyte maturation.  
SHP2 depletion increases the abundance of transcripts associated with early 
maturation stages, and decreases the abundance of transcripts associated with 
terminal differentiation   
 We performed RNA-seq on pellets carrying a conditional Ptpn11 allele and a tamoxifen-
dependent Cre recombinase, that were treated daily with 4-hydroxytamoxifen (4-OHT), to inactivate 
Ptpn11 (Ptpn11 cKO), or with vehicle control (0.1% v/v EtOH).  One week of 4-OHT treatment induced 
recombination in >90% of chondrocytes (Figure 3.4) and reduced SHP2 levels (Figure 3.5A).  Two weeks 
of 4-OHT treatment, followed by an additional week in culture, almost completely depleted SHP2 (Figure 
3.5A). Since it was not yet known whether long-term 4-OHT treatment itself would affect gene expression, 
we also performed RNA-seq on similarly treated wild-type pellets (Figure 3.5B, Supp Data File 1). Of all 
transcripts that changed in abundance in Ptpn11 cKO pellets, 18 (5%) at w1 and 59 (15%) at w3 also 
changed in wild-type pellets treated with 4-OHT.  We therefore excluded these 77 transcripts from 
subsequent analyses (Figure 3.5B, Figure 3.6). There was significant (p < 0.001) overlap between  
 
 
 
Figure 3.4: Using the mTmG reporter to monitor CreER mediated recombination in pellet cultures. 
Merged images of GFP, RFP and DAPI channels after daily 4-OHT treatment of chondrocytes pellet 
cultures established from mice carrying the mTmG reporter allele. The mTmG reporter initially drives 
expression of Tomato Fluorescent Protein (TFP), but after CreER-mediated recombination, it drives the 
expression of Green Fluorescent Protein (GFP). The number of green cells (recombined) and red cells 
(un-recombined) were counted in multiple tissue sections from pellets cultured for 3, 4, 5 or 7 days. The 
average percentage of recombined cells at each time point is indicated. Based on the half-life of the TFP 
protein, some TFP will still be present in cells with a relatively recent recombination event, and these cells 
will appear yellow.  
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Figure 3.5: Identifying transcripts that change in abundance following SHP2-depletion or 
MEK1/2-inhibition in pellet cultures.  A: Immunodetection of SHP2, phospho-ERK1/2, total ERK1/2, 
and phospho-AKT in chondrocyte pellet cultures. Top: pellets from Tg(CMV-CreERT2); Ptpn11fl/– mice 
were treated daily with 4-OHT or vehicle control (EtOH) an harvested after 1 and 3 weeks. Bottom: 
pellets from wild-type mice were treated daily with a MEK1/2 inhibitor (U0126), or vehicle control 
(DMSO), and harvested after 1 and 3 weeks. B: Number of transcripts that had significantly lower (blue) 
or higher (red) abundance in treated pellets compared to vehicle treated pellets, either at w1 or w3. 
Transcripts that changed in abundance in Ptpn11 cKO pellets were excluded if they exhibited similar 
changes in wild-type pellets treated with 4-OHT.  
 
      
Figure 3.6: Overlap between transcripts that change in abundance after SHP2-depletion, 4-OHT 
treatment, or U0126-treatment.  A: Heat map of all transcripts that changed in abundance after SHP2-
depletion, 4-OHT-treatment or U0126-treatment, at either w1 or w3. B: Venn diagrams showing the 
overlap of transcripts that decrease (blue) or increase (red) in abundance, at w1 or w3, in U0126-treated 
(left circle), Ptpn11-cKO (right circle) and 4-OHT-treated (lower circle) pellets.  
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transcripts whose abundance changed in Ptpn11 cKO pellets at w1 and w3 (Figure 3.7).  However, there 
were also differences between the w1 and w3 data sets.  For example, transcripts encoding protein 
translation components were decreased in w1 but not w3 in Ptpn11 cKO pellets (Figure 3.8). Thus, during 
chondrocyte maturation the transcriptional response to short term versus sustained SHP2 depletion is 
similar but not identical 
To assess the effect of SHP2 depletion on chondrocyte maturation, we compared transcript 
abundance in Ptpn11 cKO pellets to that of vehicle pellets at w3.  Transcripts expressed by proliferative 
through early hypertrophic chondrocytes were increased and transcripts expressed by late stage 
hypertrophic chondrocytes were decreased in Ptpn11 cKO pellets (Table 3.3; Figure 3.9A).  The greatest 
change in transcript abundance following SHP2 depletion was in the pre-hypertrophic chondrocyte  
 
 
 
Figure 3.7: Overlap between transcripts that changed in abundance at w1 and w3. Venn diagrams 
showing the overlap between transcripts that increased (red) or decreased (blue) in abundance after 
SHP2-depletion (A) or U1026 treatment (B) at w1 and w3.  
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Figure 3.8: Gene Process Networks enriched in differentially expressed genes. List of enriched 
Gene Process Networks, identified using the MetaCore software suite from GeneGo Inc, in the list of 
transcripts that increased (red) or decreased (blue) in abundance after U0126-treatment, SHP2 
depletion, or 4-OHT treatment, at w1 or w3. The list of transcripts included in each network is indicated. 
Only networks with a MetaCore p value less than 1x10-6 are shown.   
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Table 3.3: Effect of SHP2 depletion or MEK1/2 inhibition on markers of chondrocyte maturation 
zones 
 
  MEK1/2 inhibition SHP2 depletion 4-OHT treatment 
GP zone Gene FC* P value FC* P value FC* P value 
Sox9 2.81 2.4E-03 1.55 7.7E-01 1.19 1.0E+00 
Col9a1 2.26 3.3E-02 1.73 5.2E-01 0.98 1.0E+00 
Fgfr3 4.29 1.4E-05 3.44 7.7E-03 0.75 1.0E+00 
PZ 
Acan 3.60 1.4E-04 1.49 7.7E-01 1.09 1.0E+00 
Pth1r 2.88 5.0E-03 4.00 1.5E-03 0.75 1.0E+00 
Ihh 7.18 3.1E-09 14.13 7.6E-11 0.61 4.5E-01 
Panx3 5.90 1.6E-08 10.35 5.5E-09 0.68 7.0E-01 
Pre-HZ 
Sp7 2.80 4.4E-03 2.06 2.5E-01 0.88 1.0E+00 
Col10a1 2.14 5.3E-02 2.07 2.5E-01 0.56 1.3E-01 
Phospho1 4.52 8.3E-06 3.44 8.5E-03 0.90 1.0E+00 
Bmp6 3.56 2.4E-04 2.83 4.1E-02 0.71 1.0E+00 
Early-HZ 
Alpl 2.49 1.9E-02 4.60 3.2E-04 0.81 1.0E+00 
Adamts1 0.61 3.5E-01 0.30 1.6E-02 1.42 8.8E-01 
Adamts5 0.18 1.1E-07 0.34 2.9E-02 1.14 1.0E+00 
Spp1 0.05 1.5E-22 0.83 1.0E+00 0.62 3.4E-01 
Late-HZ 
Hpse 0.21 1.8E-06 0.26 4.5E-03 0.30 2.9E-06 
* FC = Fold change when comparing treated pellets to control pellets at w3 
 
 
 
expressed protein IHH (14-fold increase).  However, not all well-characterized stage-specific transcripts 
were altered by SHP2 depletion.  Therefore, we took a non-biased approach by examining the effect of 
SHP2 depletion on the “upper zones” and “lower zones” transcript sets we had previously defined in wild-
type pellet cultures (Figure 3.1D). Compared to control pellets at w3, Ptpn11 cKO pellets had 44% of the 
“upper zones” transcripts increase in abundance by > 1.5 fold, and 34% of the “lower zones” transcripts 
decrease in abundance by > 1.5 fold.  When considering Ptpn11 cKO transcripts whose change in 
abundance satisfied our significance criteria (2-fold change, p < 0.05) 20 “upper zones” transcripts were 
increased and 54 “lower zones” transcripts were decreased (Figure 3.9B; Figure 3.10).  These data are 
consistent with SHP2 depletion delaying terminal differentiation while maintaining chondrocytes in the 
proliferative, pre-hypertrophic, or early-hypertrophic stage.  
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Figure 3.9: SHP2 depletion or MEK1/2 inhibition increases the abundance of PZ, pre-HZ and 
early-HZ transcripts, and decreases the abundance of late-HZ transcripts. A: Heat map showing 
the fold change in abundance (treated vs. control pellets at w3) of selected transcripts that are 
associated with a specific stage of chondrocyte maturation. B: Heat maps showing the fold change in 
abundance (treated vs. control pellets at w3) for all transcripts that we included in the “upper zones” 
and “lower zones” transcript sets. The graph below the heat map indicates the percentage of 
transcripts for which the increase (red) or decrease (blue) in abundance was significant (p<0.05). The 
number of “upper zones” transcripts that increased in abundance in treated pellets (red), and the 
number of “lower zones” transcripts that decreased in abundance in treated pellets (blue), is indicated 
below. For Ptpn11 cKO pellets, of the 108 “lower zones” transcripts that significantly decreased in 
abundance, 54 did not significantly change in wild-type pellets treated with 4-OHT.  
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Figure 3.10: Identification of transcripts associated with chondrocyte maturation that changed in 
abundance after MEK1/2-inhibition or SHP2-depleiton. Heatmaps for a subset of transcripts identified 
in our “upper zones” (A) or “lower zones” (B) transcript sets that significantly changed in abundance at w3 
after either MEK1/2-inhibition or SHP2-depletion. Transcripts were selected based on their known roles in 
processes that are relevant to proliferative chondrocytes (eg. matrix synthesis) or late-hypertrophic 
chondrocytes (eg. matrix degradation). Some, but not all, of the “lower zones” transcripts that decreased in 
abundance after SHP2-depletion also decreased in abundance after 4-OHT treatment of wild-type pellets. 
The increase in the abundance of transcripts encoded by the mitochondrial genome may be a result of the 
increase in the number of mitochondria per cell due to the increase in chondrocyte cell size following 
SHP2 depletion or MEK1/2 inhibition.   
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MEK1/2 inhibition perturbs chondrocyte maturation in a similar manner to SHP2 
depletion 
SHP2 has been proposed to positively regulate the ERK1/2 pathway in chondrocytes [11,12]. Indeed, we 
observed reduced phospho-ERK1/2 levels after SHP2 depletion in pellet cultures (Figure 3.5A). To 
determine whether this reduction in ERK1/2 pathway activity mediates the transcriptional changes that 
occur following SHP2 depletion, we performed RNA-seq on pellets cultured for 1 or 3 weeks in the 
presence of either a vehicle control (0.1% v/v DMSO) or a MEK1/2 inhibitor (U0126) (Figure 3.5A, B). 
When considering the transcripts that changed in abundance after SHP2 depletion (excluding transcripts 
that changed after 4-OHT treatment alone), we found that 177 (53%) and 116 (35%) had similar changes 
after U0126-treatment at w1 and w3, respectively (Figure 3.5B, Figure 3.11). The observed overlap is 
significantly greater than expected by chance alone (p<0.001). As with SHP2 depletion, we found that 
U0126-treatment increased the abundance of transcripts associated with the PZ, pre-HZ and early-HZ, 
with the most substantial changes involving the pre-HZ transcripts, Ihh and Panx3 (> 6-fold increase) 
(Table 3.3; Figure 3.9A,B). Furthermore, we found that U0126-treatment decreased the abundance of 
late-HZ transcripts associated with matrix degradation, apoptosis, angiogenesis and osteoclastogenesis 
(Figure 3.9A,B; Figure 3.10). In particular, a gene ontology analysis revealed that transcripts with reduced 
abundance in U0126-treated pellets were significantly enriched for proteins involved in matrix degradation 
and remodeling (Figure 3.8). We used quantitative reverse transcription PCR (qRT-PCR) to confirm that 3 
weeks of U0126-treatment increased the abundance of pre-HZ and early-HZ markers (Ihh, Phospho1) 
and decreased the abundance of a late-HZ marker (Spp1) (Figure 3.12). Altogether, these data indicate 
there is substantial overlap between the genes regulated by SHP2 and MEK1/2 in chondrocytes, and that 
MEK1/2 inhibition and SHP2 depletion have similar effects on chondrocyte maturation.   
 
Chapter 3 
83 
 
 
 
Figure 3.11: Overlap between transcripts that changed in abundance following SHP2 depletion and 
MEK1/2 inhibition. Venn diagrams showing the overlap between transcripts that increased (red) or 
decreased (blue) in abundance after SHP2-depletion or U1026 treatment at w1 (A) and w3 (B).  
 
 
  
 
Figure 3.12: pRT-PCR validation of transcripts that changed in abundance following MEK1/2 
inhibition at w3. Graph showing expression, relative to beta-actin, of selected genes in vehicle treated 
pellets (black) and U0126-treated pellets (grey). For each gene, the expression levels were normalized 
such that the expression level in vehicle treated pellets equals 1. Error bars indicate standard deviation. 
Asterisk indicates a significant (p<0.05) difference between Ctrl and U0126-treated pellets.  
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RNA-seq identifies transcription factors with known roles in chondrocyte 
maturation, and suggests novel transcription factors that may be involved in this 
process 
To identify the transcription factors that may mediate the perturbation of chondrocyte maturation observed 
in U0126-treated and SHP2-depleted pellets, we selected the 57 transcription factors that had increased 
or decreased abundance in U0126-treated or SHP2-depleted pellets at w3, and were unaffected in wild-
type pellets treated with 4-OHT (Figure 3.13). We identified several transcription factors that may be 
responsible for maintaining the expression of genes associated with the pre-hypertrophic and early-
hypertrophic stages, and for repressing the expression of genes associated with the late-hypertrophic 
stage, in U1026-treated or SHP2-depleted pellets. In particular, we observed increased expression of 
transcription factors known to promote hypertrophy and/or inhibit terminal differentiation (Mef2c, Tcf7, 
Dlx5, Msx2, Hey1, Sox9), and decreased expression of transcription factors known to inhibit hypertrophy 
and/or promote terminal differentiation (Foxp1, Rbpj) (Figure 3.14A, Table 3.4). In addition, we identified 
several transcription factors whose known target genes were also affected by MEK1/2 inhibition or SHP2 
depletion, such as Egr1 and its target genes Spp1 and Hpse, which all decreased in abundance following 
MEK1/2 inhibition (Figure 3.14B, Table 3.5).   We selected 3 transcription factors for qRT-PCR validation 
(Hmga2, Fols1, Egr1) and verified that they were less abundant following U0126-treatment (Figure 3.12). 
Thus, we have identified multiple transcription factors with known roles in the growth plate that may act 
downstream of SHP2 and ERK1/2 during the maturation and terminal differentiation of chondrocytes. This 
suggests that other transcription factors identified by RNA-seq (Figure 3.13) also have roles in 
chondrocyte maturation or terminal differentiation.  
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Figure 3.13: MEK1/2- and SHP2-dependent transcription factors. Heatmap showing all 57 
transcription factors that were differentially expressed at w3 in Ptpn11 cKO or U0126-treated pellets. 
For comparison purposes, the fold change at w1 is also shown, and the fold change in 4-OHT treated 
pellets is shown.  
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Table 3.4: Previous studies identifying transcription factors involved in chondrocyte maturation 
and/or terminal differentiation.  
 
Transcription 
factor Role in the growth plate Reference 
Mef2c [35] 
Tcf7 [36] 
Dlx5 [37] 
Msx2 
Promotes hypertrophy 
[38] 
Foxp1 Inhibits hypertrophy [39] 
Hey1 [40] 
Sox9 [22] 
Dlx5 [37] 
Msx2 
Inhibits terminal differentiation or 
cartilage resorption 
[38] 
Rbpj Promotes terminal differentiation or cartilage resorption [41] 
 
 
 
 
 
Figure 3.14: MEK1/2 inhibition or SHP2 depletion alters the expression of transcription factors with 
known roles in chondrocyte maturation. Schematic diagrams of genes encoding transcription factors 
(solid boxes) or their known target genes (empty boxes) that significantly decreased in abundance (blue) 
or increased in abundance (red) in U0126-treated pellets at w3. All transcription factors showed similar 
increases or decreases in Ptpn11 cKO pellets at w3, but not all reached statistical significance. A: 
Transcription factors with known roles in promoting chondrocyte hypertrophy (upper green arrow), or in 
promoting the terminal differentiation of chondrocytes and/or their replacement by bone (lower green 
arrow). B: Transcription factors whose known target genes also significantly changed in abundance in 
U0126-treated pellets. Arrows indicate transcriptional activation while bar-headed lines indicate 
transcriptional repression.   
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Table 3.5: Genes regulated by MEK1/2-dependent transcription factors 
 
 
Transcription 
factor 
Effect on gene 
expression 
Target 
gene Reference 
Ihh 
Alpl Msx2 
positive 
Col10a1 
[38] 
Mef2c positive Col10a1 [35] 
Hey1 positive Col10a1 [40] 
positive Col10a1 [42] 
negative Spp1 Sox9 
 Mmp13 [22] 
positive Hpse [43] 
 Spp1 [44] Egr1 
negative Acan [45] 
positive Mmp13 Mafb negative Acan [46] 
positive Mmp13 [47] 
 Mmp12 [48] AP-1 complex 
 Spp1 [49] 
Rbpj positive Mmp13 [41] 
 
 
Mosaic inactivation of Ptpn11 in vivo alters chondrocyte maturation, disrupts the 
normal organization of growth plates, and leads to enchondroma-like lesions that 
contain mixtures of Ptpn11 mutant and non-mutant chondrocytes  
Since SHP2 depletion perturbed chondrocyte maturation in pellet cultures, we inactivated Ptpn11 
in vivo and determined the effect on chondrocyte maturation. It has recently been reported that postnatal 
inactivation of Ptpn11 in chondrocytes alters the thickness and organization of vertebral growth plates 
[13], but it was not shown on a molecular level whether the process of chondrocyte maturation was 
altered. We used a tamoxifen-inducible chondrocyte Cre driver (Col2a1-CreER) to inactivate Ptpn11 
postnatally. Mice were treated with tamoxifen for 5 days, starting at week 1, and analyzed at weeks 3, 7 
and 10. A clear expansion of the vertebral growth plates, osteophyte-like lateral cartilaginous outgrowths, 
enchondroma-like cartilage islands below the growth plate, and an increase in chondrocyte cell size were 
observed by weeks 7 and 10 (Figure 3.15A-E). The severity of the phenotype was variable between mice 
(Figure 3.16). Areas of ectopic ossification in upper regions of some growth plates were observed (Figure  
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Figure 3.15: Lineage tracing of SHP2-depleted chondrocytes in mouse vertebral growth plates 
following mosaic postnatal Ptpn11 inactivation. Tissue sections of lumbar vertebral growth plates 
(GP) and intervertebral disks (IVD) from Tg(Col2a1-CreER); Rosa26mTmG ;Ptpn11fl/+ or Ptpn11fl/fl mice 
that had been administered tamoxifen for 5 days, starting at w1, and sacrificed at w7. A-C: Tissue 
sections stained with Alcian Blue and Nuclear Fast Red. In Ptpn11 cKO mice, the vertebral growth 
plates are enlarged and disorganized, with ectopic areas of ossification inside the growth plate (red 
arrow in B) and enchondroma-like lesions below the growth plate (C). D-G: Merged fluorescent 
images showing cells in which the mTmG reporter allele has (green fluorescence) or has not (red 
fluorescence) been recombined by Cre recombinanse. Note that approximately 50% of growth plate 
chondrocytes fluoresce green, and in Ptpn11 cKO mice, the expanded regions of the growth palate 
(E), lateral outgrowths (F) and enchondroma-like lesions (G) contain both green and red fluorescing 
cells. Dashed-white lines outline the cartilage. Scale bars = 100 µm.  
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Figure 3.16: Phenotypic range observed in Ptpn11-cKO vertebral growth plates. Tissue sections 
of lumbar vertebral growth plates from Col2a1-CreER; mTmG mice that were heterozygous (Ctrl mice) 
or homozygous (Ptpn11 cKO mice) for a conditional Ptpn11 allele and had been administered 
tamoxifen for 5 days, starting at w1, and sacrificed at week 3, 7 or 10. Tissue sections were stained 
with Alcian Blue and Nuclear Fast Red. In Ptpn11 cKO mice, the vertebral growth plates are 
substantially enlarged and disorganized at week 7 and 10, with osteophyte-like lateral outgrowths, and 
ectopic cartilage islands below the growth plate (arrows). By week 10, some growth plates had been 
completely resorbed (asterisks). Scale bar = 250 µm.  
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3.15D), and by week 10 some growth plates had been completely resorbed while other growth plates 
remained expanded (Figure 3.16). Analysis of the mTmG reporter allele indicated that 5 days of 
tamoxifen treatment had induced recombination in ~50% of chondrocytes (Figure 3.15F). Importantly, not 
all chondrocytes in the cartilage outgrowths and enchondroma-like lesions had evidence of Cre-mediated 
recombination, suggesting that the lesions contained mixtures of Ptpn11 mutant and non-mutant 
chondrocytes  (Figure 3.15G,H). Thus, our histological and lineage tracing results indicate that mosaic 
inactivation of Ptpn11 in growth plates affects mutant and wild-type chondrocytes; the latter most likely 
due to altered paracrine signaling.   
To determine whether mosaic Ptpn11 inactivation alters the normal organization of chondrocytes 
into distinct maturation zones we performed immunohistochemistry (IHC) for type 10 collagen (COLX), 
which is produced by early-hypertrophic chondrocytes [18]. As expected, in control mice, COLX was 
localized to the matrix surrounding only the lowest ~3 cells in each chondrocyte column (Figure 3.17A). In 
contrast, the distribution of COLX was altered in Ptpn11 cKO mice. Their growth plates had regions in 
which the height of the COLX-positive zone was expanded to >10 cells (Figure 3.17B). Furthermore, the 
organization of the COLX-positive cells was altered, with ectopic COLX-positive clusters in upper growth 
plate zones, ectopic COLX-negative clusters in lower growth plate zones, and COLX-positive 
chondrocytes in the lateral outgrowths that were arranged into columns oriented perpendicular to the 
main axis of the growth plate (Figure 3.17B). Both COLX-positive and COLX-negative chondroyctes were 
detected in the enchondroma-like lesions (Figure 3.17C). These data indicate that the organization of 
chondrocytes into distinct growth plate zones is disrupted, and that the lateral outgrowths and 
enchondroma-like lesions contain both mature and immature chondrocytes.  
To further characterize the process of chondrocyte maturation, we examined the distribution of 
phospho-ERK1/2, which is normally detected in the hypertrophic zone [50], and FRA1, a transcription 
factor encoded by Fosl1, which decreased in abundance following SHP2 depletion in pellet cultures 
(Figure 3.14B). FRA1 and p-ERK1/2 were detected in hypertrophic chondrocytes in Ctrl mice (Figure 
3.17A), but were distributed in a scattered, disorganized fashion in the hypertrophic zone of Ptpn11 cKO 
mice (Figure 3.17B). In addition, we observed minimal staining for the terminal differentiation marker 
osteopontin (SPP1) (Figure 3.17D,E) [18], suggesting that the hypertrophic zone was expanded due to an  
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Figure 3.17: Disordered maturation zones and delayed terminal differentiation in mouse 
vertebral growth plates following mosaic postnatal inactivation of Ptpn11. Immunohistochemistry 
performed on tissue sections from the vertebral growth plates of Ctrl mice (A,D) or the growth plates 
(B,E) or enchondroma-like lesions (C) in Ptpn11 cKO mice. A: Ctrl growth plate showing COLX, p-
ERK1/2 and FRA1 immunoreactivity in the hypertrophic zone. B: Ptpn11 cKO growth plate showing 
ectopic COLX-positive clusters at the top of the growth plate (a), ectopic COLX-negative clusters at 
the bottom of the growth plate (b), and disorganized, scattered p-ERK1/2 and FRA1 immunoreactivity 
in hypertrophic chondrocytes (c). C: Enchondroma-like lesions contain both COLX-positive and COLX-
negative chondrocytes. D: Ctrl growth plate showing SPP1 immunoreactivity at the bottom of the 
hypertrophic zone. E: In Ptpn11 cKO growth plates, expanded regions of SPP1-negative hypertrophic 
chondrocytes are observed (red arrows) and only a few scattered chondrocytes hypertrophic 
chondrocytes are SPP1-positive (black arrows). IHC tissue sections were counterstained with 
hematoxylin. Scale bars = 25 µm.  
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increase in the number of chondrocytes that had not yet reached the late-hypertrophic stage. In summary, 
the normal distribution pattern of stage-specific matrix components and signaling pathway components is 
altered in Ptpn11-cKO growth plates, and the observed delay in the terminal differentiation of hypertrophic 
chondrocytes is consistent with our pellet culture data.  
Disorganized chondrocyte maturation zones are also observed in excised human 
MC exostoses 
Finally, we determined whether chondrocyte maturation is altered in cartilage lesions from MC 
patients who carry mutations in PTPN11. We observed a variable and disorganized distribution of COLX 
in MC exostoses. In particular, we observed some regions of intense COLX immunoreactivity throughout 
the matrix (Figure 3.18A-C), while other regions had minimal and scattered COLX immunoreactivity 
(Figure 3.18D). We compared this to MHE exostoses, which have cartilage caps that display relatively 
normal growth plate architecture [1]. We found that MHE exostoses have a narrow zone of COLX 
immunoreactivity at the base of the cartilage cap, as previously reported [51] (Figure 3.18E). Thus, in 
contrast to MHE exostoses, lesions from MC patients display disorganized chondrocyte maturation 
zones.  
    
 
Figure 3.18: Disorganized distribution of COLX in exostoses from MC patients. 
Immunohistochemical staining of COLX in exostoses from MC patients (A-D) or an MHE patient (E). 
Note that the cartilage cap of an MHE exostosis shows a thin layer of COLX staining near the bone-
cartilage junction (E). In contrast, in MC exostoses, the distribution of COLX staining is variable and 
disorganized, with some exostoses showing staining directly below the outer fibrous layer (A,B) or 
within the center of the lesion (C), while other exostoses showing minimal staining (D). Scale bar = 
100 µm  
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3.6 Discussion 
 
Loss of PTPN11/SHP2 causes cartilage tumors in humans and mice [2,11,12].  However, the 
molecular mechanisms by which SHP2 depletion produces enchondromas and exostoses are 
incompletely understood.  We found that SHP2 depletion reduced ERK1/2 signaling and delayed 
chondrocyte terminal differentiation. Furthermore, we observed disorganized growth plate architecture in 
mice and humans that are mosaic for chondrocytes lacking SHP2. Finally, we found that cartilage lesions 
in mice contain both wild-type and SHP2-deficient cells.  
 Pellet cultures have been used to study chondrocyte biology at the molecular, biochemical, and 
histologic levels [16,17,52].  We applied massively parallel RNA-seq technology to comprehensively 
evaluate the transcriptome of wild-type, SHP2-depleted, and MEK1/2-inhibited pellet cultures.  In wild-
type cultures we confirmed previously reported changes in gene expression, and we identified new 
transcripts that likely distinguish proliferative from late-hypertrophic chondrocytes (Figure 3.1).  We also 
determined the effect of 4-hydroxytamoxifen (4-OHT) administration on wild-type transcriptomes, which is 
an important control experiment since 4-OHT is frequently administered to conditionally alter gene 
expression in vitro and in vivo (Figure 3.5).  When we depleted SHP2 in pellet cultures, we found that 
transcripts associated with pre-hypertrophic and early-hypertrophic chondrocytes increased and 
transcripts associated with late-hypertrophic chondrocytes decreased (Figure 3.9). SHP2 depletion also 
reduced ERK1/2 phosphorylation, which led us to determine whether the MEK1/2 inhibitor U0126 would 
have similar effects on the transcriptome of wild-type pellet cultures; it did (Figure 3.5; Figure 3.9).  Taken 
together, our data suggest that SHP2 depletion, acting in part via ERK1/2 signaling, delays the terminal 
differentiation of hypertrophic chondrocytes (Figure 3.19A).  We provided further support for this 
hypothesis in vivo by showing increased numbers of hypertrophic chondrocytes in growth plates of SHP2 
mutant mice (Figure 3.17) and in human MC lesions (Figure 3.18). Other studies have also observed 
accumulation of hypertrophic chondrocytes following Ptpn11 inactivation in mice [10,12,53].  
 In addition to regulating terminal differentiation, we found that mosaic inactivation of SHP2 
disrupted vertebral growth plate architecture (Figure 3.15; Figure 3.19B).  After we inactivated SHP2 in 
~50% of growth plate chondrocytes, we observed non-uniform rates of chondrocyte maturation and 
clusters of chondrocytes surrounded by bone, which resemble enchondromas seen in human MC 
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patients. In addition, we observed lateral-outgrowths with abnormal chondrocyte column orientation, 
which resemble vertebral osteophytes that have also been reported in MC patients [54]. We determined 
whether the mouse lesions solely contained SHP2 deficient cells by using a reporter allele (mTmG) to 
lineage trace cells that had undergone Cre-mediated inactivation of SHP2.  We observed that lesions 
contained both Cre-recombined and non-recombined cells (Figure 3.15).  These data imply that disturbed 
growth plate architecture is not only due to cell autonomous effects of SHP2 depletion, but also due to 
altered paracrine signaling between mutant and wild-type cells. 
Interestingly, in humans with MC, enchondromas are most often found in the appendicular 
skeleton [55], whereas in mice, mosaic postnatal inactivation of Ptpn11 in chondrocytes led to 
 
 
Figure 3.19: Model of the consequences of SHP2 depletion in pellet cultures, mouse vertebral 
growth plates and human MC exostoses. Schematic diagrams showing chondrocytes at different stages 
of maturation (PC = proliferative chondrocyte. HC = hypertrophic chondrocyte). A: In wild-type pellets, 
most chondrocytes are in the proliferative stage at w1, and transition to the late-hypertrophic stage by w3. 
Ptpn11 cKO or U0126-treated pellets have more pre-HC and early-HC transcripts and fewer late-HC 
transcripts compared to control pellets at w3. This suggests that SHP2 depletion or MEK1/2 inhibition 
delays the entry of chondrocytes into the late-hypertrophic stage, thus leading to an accumulation of 
chondrocytes in the pre-hypertrophic and early-hypertrophic stages. B: Mosaic postnatal inactivation of 
Ptpn11 in vertebral growth plates disrupts the normal organization of chondrocytes into distinct zones, 
leads to lateral outgrowths and enchondroma-like lesions.  The scarcity of chondrocytes in the late-
hypertrophic stage and the abundance of chondrocytes in the early-hypertrophic stage suggest that loss of 
SHP2 delays the transition from the early to late-hypertrophic stage, thereby delaying terminal 
differentiation. C: Hypertrophic chondrocytes are variably distributed in MC exostoses. This is in contrast 
to MHE exostoses, which have a cartilage cap that resembles a normal growth plate. 
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enchondroma-like lesions in the axial skeleton but not long bones [12,13] (Figure 3.15). Whether this 
difference is Col2a1-CreER-specific, due to differences in the timing of SHP2 loss between humans and 
mice, or reflective of differences in mechanical forces or signaling pathways in growth plates between 
mice and humans, remains to be determined.  
In pellet cultures SHP2 depletion reduced ERK1/2 phosphorylation (Figure 3.5), and nearly half of 
all transcripts affected by SHP2 depletion were similarly affected by MEK1/2 inhibition (Figure 3.11). 
These data suggest ERK1/2 is an important pathway downstream of SHP2 in growth plate chondrocytes.  
The striking overlap between the effects of SHP2 depletion and MEK1/2 inhibition on transcripts 
associated with chondrocyte maturation (Figure 3.9) is consistent with previous observations that 
inactivating Erk1 and Erk2 in primary chondrocytes increased the expression of an early-hypertrophic 
marker (Col10a1) and decreased the expression of a late-hypertrophic marker (Tnfsf11/RANKL) [14]. 
Similarly, inactivating Erk1 and Erk2 in vivo delayed cartilage resorption [14,15,50]. These results are 
consistent with our proposed role for SHP2 in promoting the transition from the early-hypertrophic to the 
late-hypertrophic stage via the ERK1/2 pathway.   
We do not know which receptor tyrosine kinases act upstream of SHP2 and MEK1/2 during 
chondrocyte terminal differentiation; however, EGFR1, FGFR1 and FGFR3 are likely candidates since 
inactivation of any one of these receptor leads to an expansion of the hypertrophic zone in mice [56–59]. 
Furthermore, transcripts encoding several transcription factors had altered abundance after SHP2 
depletion or MEK1/2 inhibition (Figure 3.14).  Under normal circumstances, these transcription factors 
likely regulate terminal differentiation in response to SHP2 and ERK1/2 signaling. Of particular interest 
are Hey1, Msx2, Dlx5 and Sox9, which have all been shown to delay the removal of hypertrophic 
chondrocytes in vivo (Figure 3.14) [22,37,38,40]. Since these four transcription factors are induced by 
BMP signaling [60–62], and the BMP pathway has been shown to inhibit terminal differentiation [63], it is 
possible that increased BMP signaling contributes to the delay in terminal differentiation following MEK1/2 
inhibition or SHP2 depletion. 
Our data, and those of other investigators, implicate aberrant IHH signaling in contributing to the 
growth plate abnormalities. IHH is a potent secreted regulator of chondrocyte proliferation and 
differentiation [64]. We observed significantly increased Ihh transcript abundance in SHP2-depleted and 
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MEK1/2-inhibited pellet cultures (Figure 3.9).  Similarly, it has previously been reported that knockdown of 
SHP2 in a chondrogenic cell line increases Ihh expression, and exostoses induced by SHP2 depletion 
have higher levels of Ihh expression than normal growth plates [11]. Also, an inhibitor of IHH signaling 
reduced the growth of cartilage tumors in mosaic SHP2 mutant mice [11].  However, we cannot preclude 
additional paracrine factors also contributing to tumor formation since transcripts for other secreted 
growth regulators (SOST, BMP7, BMP8A, WNT5B, WNT10B, and FGF21) exhibited increased 
abundance in SHP2-depleted pellet cultures. Thus, the pathogenic mechanism(s) that produce cartilage 
tumors in patients with MC may be complex.  
 Our data suggest that the exostoses in patients with MC develop via a fundamentally different 
mechanism than the exostoses in patients with MHE. In both disorders the lesions likely arise from 
perichondrial cells that have inappropriately differentiated into growth plate chondrocytes [11,12,65].  
However, the growth of an MC exostosis is highly disordered and there is little recognizable growth plate 
morphology (Figure 3.17).  In contrast, MHE lesions have well defined cartilage caps and well organized, 
but aberrantly directed, growth plates [1].  Therefore, EXT1 and EXT2 mutations likely predispose to 
misdirected growth by disorienting otherwise normally functioning chondrocytes, while SHP2 mutations 
cause misdirected and disorganized growth by creating dysfunctional chondrocytes that signal abnormally 
(Figure 3.19C). These differences in growth mechanism are consistent with the observation that MHE 
lesions do not regress but stop growing at puberty when growth plates normally close [1]. Exostoses in 
MC patients have been reported to regress or disappear over time [1], consistent with our observation 
that terminal differentiation is delayed rather than completely blocked.  Therefore, when SHP2 mutant 
chondrocytes finally terminally differentiate they will no longer drive abnormal growth.  In this regard, it will 
be interesting to determine whether restoration of SHP2 function will induce terminal differentiation of 
mutant chondrocytes and hasten regression of these lesions. 
 Whereas the mechanism of exostosis growth differs between MC and MHE, we do not yet know 
whether enchondroma formation that occurs in MC, Ollier disease, and Maffucci Syndrome have biologic 
overlap.  We found that mosaic inactivation of SHP2 disrupted the normal organization of maturation 
zones. This resulted in ectopic ossification within the growth plate, which led to displacement below the 
growth plate of chondrocytes containing hypertrophic and non-hypertrophic chondrocytes, and SHP2-
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deficient and wild-type chondrocytes (Figure 3.15). This suggests MC enchondromas are the result of 
disrupted growth plate architecture, rather than defective cartilage resorption or neoplastic growth alone. 
It is not yet known whether mutations in IDH1 or IDH2, which cause Ollier disease and Maffucci 
syndrome affect growth plate architecture in a similar manner to SHP2 depletion [7]. However, it has been 
shown that enchondromas in patients with IDH1 mutations also appear to contain both wild-type and 
IDH1-mutant chondrocytes [7]. Maffucci syndrome patients also develop vascular lesions, suggesting that 
in vasculature the consequence of SHP2 depletion and IDH1/IDH2 mutation are different.  
 The RNA-seq datasets we identified in chondrocyte pellet cultures should be useful to other 
investigators interested in endochondral growth and the ex vivo modeling of this process.  For 
investigators that use tamoxifen to induce Cre-mediated recombination of floxed alleles, the dataset of 
transcripts whose abundance changed following tamoxifen administration will also be helpful. In 
conclusion, by coupling ex vivo RNA-seq with in vivo conditional mouse models, we have added to our 
understanding of how cartilage tumors arise in patients with MC, as well as the pathways that are 
regulated by SHP2 during chondrocyte maturation.  
3.7 Methods 
 
Mouse Husbandry  
 The Boston Children’s Hospital Institutional Animal Care and Use Committee approved these 
studies. The Rosa26mTmG reporter allele [66] and the Tg(Col2a1-CreER) driver [67] were purchased from 
The Jackson Laboratory. The Ptpn11 floxed (Ptpn11fl/fl) and Tg(CMV-CreERT2) mice have been 
previously described [68,69]. For mosaic postnatal inactivation of Ptpn11 in chondrocytes, 1-week-old 
Tg(Col2a1-CreER);Rosa26mTmG/+;Ptpn11fl/fl mice were given daily intra-peritoneal injections of 50 mg/kg 
tamoxifen (Sigma) suspended in corn oil for 5 days.  Tg(Col2a1-CreER);Rosa26mTmG/+;Ptpn11fl/+ and 
Rosa26mTmG/+;Ptpn11fl/fl mice that were similarly treated with tamoxifen served as controls.  
Chondrocyte pellet culture  
 Chondrocytes were harvested from the rib cages of newborn mouse pups as previously 
described [70]. Pups were either wild-type (mixed 129/FVB background) or, for SHP2 depletion 
experiments, Tg(CMV-CreERT2);Ptpn11fl/– on a mixed 129/FVB background. Chondrocytes from 4 to 7 
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pups from the same litter and with the same genotype were pooled, which provided sufficient cells for all 
the experimental and control pellets of an individual experiment. Chondrocytes were re-suspended in 
DMEM/F12 with L-Glutamine (Invitrogen), supplemented with ascorbic acid (50 µg/ml), 1% Penicillin-
Streptomycin solution (Life Technologies) and 10% Fetal Bovine Serum (Omega Scientific). Five x 105 
cells were aliquoted into 0.5 mL eppendorf tubes, centrifuged at 500g for 5 min, and then cultured in 400 
µL of medium at 37°C and 5% CO2. Medium was changed every 1 to 2 days.  Stock solutions of 10 mM 
U0126 (Sigma) dissolved in DMSO, and 1 mM 4-OHT (Sigma) dissolved in 100% EtOH were aliquoted 
and stored at -20°C. For MEK1/2 inhibition experiments, starting at day 2 of culture, pellets were switched 
to medium containing 10 µM U0126 or 0.1% DMSO (vehicle control), which was changed daily, and 
pellets were harvested after 1 or 3 weeks. For SHP2 depletion or 4-OHT-treatment experiments, starting 
at day 1 pellets were placed in medium containing 1 µM 4-OHT or 0.1% EtOH (vehicle control), and either 
harvested after 1 week, or treated for an additional week, switched to untreated medium for 1 week, and 
then harvested (after 3 weeks total in culture). 
 RNA sequencing library construction and data analysis  
 Two pellet cultures were pooled prior to performing RNA extraction with the RNeasy mini kit 
(Qiagen) following the manufacturer’s recommendation. RNA extracts, which contained 200 to 1,000 ng 
RNA were used to prepare one barcoded cDNA library, using the TruSeq RNA Library Preparation Kit 
(Illumina).  Three different barcoded cDNA libraries were made for each genotype, treatment group, and 
time point.  Eight to 12 separate libraries were pooled and used to obtain 50-basepair paired-end reads 
per single lane of an Illumina HiSeq.  Reads were aligned to the mouse genome (mm9) using Tophat 
[71]. The number of reads mapping to the exons of each gene were calculated using the 
GenomicFeatures R package [72] and custom scripts (available on request). A trimmed mean method 
(excluding the 0.5% most and least abundant transcripts) was used to calculate the Pearson’s Correlation 
Coefficient between libraries [73].  Tests for differential gene expression was performed with edgeR [74] 
and p values were adjusted for multiple hypothesis testing. For identification of differentially expressed 
gene sets, only genes with an RPKM > 3, a fold change of at least 2, and an adjusted p value < 0.05 were 
included. A Chi-squared test was performed to determine whether the overlap between differentially 
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expressed transcripts at w1 and w3, and in Ptpn11 cKO pellets and U1026 treated pellets, was 
significant. 
Histology, fluorescence microscopy, and immunohistochemistry 
 Chondrocyte pellet cultures were fixed in 4% paraformaldehyde (PFA) for 1 hour at room 
temperature.  Mouse vertebrae and long bones were fixed in 4% PFA overnight at 4°C and then 
decalcified for 14 days in 0.5 M EDTA pH 8 (Apex BioResearch Products). All specimens were then either 
frozen in OCT embedding media (Tissue Tek) and stored at -80°C, or were stored in 70% EtOH at 4°C 
and then dehydrated in graded ethanol, cleared in xylene, and embedded in paraffin following standard 
methods. Paraffin-embedded exostoses were obtained from individuals with MC, who were previously 
described (Patients A-IV-8, A-IV-5 and B-IV-7 in Bowen et al (2011)). For histological analysis, 6 µm 
paraffin sections were stained with 0.1% Alcian Blue in 0.1 M HCl for 30 minutes and then counterstained 
with Nuclear Fast Red (Sigma) for 15 minutes. For fluorescence microscopy, frozen sections were 
mounted in DAPI-Fluoromount (SouthernBiotech). Immunohistochemistry was performed on 6 µm 
paraffin sections using the Vectastain Elite ABC kit (Vector Labs) following the manufacturer’s instructions 
and using the hybridization buffers, secondary antibodies and visualization reagents provided in the kit.  
To unmask antigens, tissue sections were first incubated in Citrate Buffer (10 mM citric acid, 0.05% 
Tween 20, pH 6.0) for 20 min at 90°C.  To detect the extracellular proteins Type 10 collagen (COLX), 
Indian Hedgehog (IHH) and Secreted phosphoprotein 1 (SPP1), sections were also treated with 1mg/ml 
Hyaluronidase (Sigma) for 1 hr at 37°C and Pepsin Solution (Diganostic Biosystems) for 15 min at 37°C.  
The following antibodies and dilutions were used: mouse anti-COLX (X53; Quartett) at 1:100, rabbit anti-
FRA1 (D80B4; Cell Signaling) at 1:400; rabbit anti-IHH (N-term; Abgent) at 1:100; rabbit anti-C3aR (H-
300; Santa Cruz) at 1:300; rabbit anti-SPP1 (from the laboratory of Dr. Dick Heinegard, Lund University) 
at 1:3,000; rabbit anti-ERK1/2 (137F5; Cell Signaling) at 1:400; and rabbit anti-phospho-SMAD1/5/8 (Cell 
Signaling Technology) at 1:400.  Primary antibodies were incubated with the tissue sections overnight at 
4°C.  
Quantitative reverse-transcriptase PCR (qRT-PCR) 
 Total RNA (500 ng) extracted from the pellet cultures was used to synthesize cDNA with the 
QuantiTect Reverse Transcription Kit (Qiagen) in a 20 µl reaction volume. qRT-PCR was performed using 
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SYBR Green JumpStart Taq ReadyMix (Sigma) and 1 µl of cDNA per reaction. Reactions were 
performed in triplicate. Changes in transcript abundance were calculated using the ddCt method [75] with 
β-actin (Actb) as the reference transcript. Actb was selected as a reference transcript because our RNA-
seq data indicated that its abundance was not significantly affected by SHP2 depletion, 4-OHT treatment 
or U0126 treatment. Gene-specific primer pairs are listed in Table 3.6.  
 
Table 3.6: Transcript-specific primers used for q-RT-PCR.  
 
Transcript Forward Primer Reverse Primer 
Col9a3 AGGTACACCTTGAGGCCCTT  TCCCACTGGGGAACTAGGAG  
Ihh TCAAGGACGAGGAGAACACG GAGTGATGGCCATCTTCATCC 
Phospho1 CTGTTGGTCTCCAGCTGTCA  GCAGAAGCACATCATCCACA  
Spp1 TGGCTATAGGATCTGGGTGC  TTGGCAGTGATTTGCTTTTG  
Adamts5 GTGTCACATGAATGATGCCC CGACCCTCAAGAACTTTTGC 
Hmga2 TCTCCTGAGCAGGCTTCTTC AAGGCAGCAAAAACAAGAGC 
Egr1 GAGTCGTTTGGCTGGGATAA  CCTTCAATCCTCAAGGGGAG  
Fosl1 CTCTTCCTCCTCTGGGCTG  TGGCCTATCCCCAGTACAGT  
Actb CAGCTTCTTTGCAGCTCCTT AGGAGTCCTTCTGACCCATTC 
 
 
Immunoblotting 
 Individual chondrocyte pellet cultures were homogenized in 60 µL of Pierce IP Lysis Buffer 
(Thermo Scientific) with freshly added Halt Protease and Phosphatase Inhibitor (Thermo Scientific). 
Twenty µL of lysate was added to 7.5 µL of NuPAGE LDS Sample Buffer and 3 µl NuPAGE Reducing 
Agent, heated to 70°C for 10 minutes, and loaded onto a 4–20% NuPAGE Bis-Tris Mini Gel (Life 
Technologies).  Following transfer to Invitrolon PVDF membranes using standard procedures, 
immunodetection was performed using the Western Breeze Chemiluminescent Immunodetection kit (Life 
Technologies). The following primary antibodies were used: mouse anti-SHP2 (M163; Abcam), rabbit 
anti-phospho-ERK1/2 (Thr202/Tyr204; D13.14.4E; Cell Signaling), rabbit anti-ERK1/2 (137F5; Cell 
Signaling), and rabbit anti-phospho-AKT (Ser473;D9E; Cell Signaling). All primary antibodies were diluted 
to 1:1000 and incubated overnight at 4°C.  
 
 
 
Chapter 3 
101 
3.8 Literature cited 
 
1.  Romeo S, Hogendoorn PCW, Dei Tos AP: Benign cartilaginous tumors of bone: from 
morphology to somatic and germ-line genetics. Adv Anat Pathol 2009, 16:307–315. 
2.  Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafé L, Superti-Furga A, Ikegawa S, Cormier-
Daire V, Bovée JV, Pansuriya TC, et al.: Loss-of-function mutations in PTPN11 cause 
metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 2011, 
7:e1002050. 
3.  Sobreira NLM, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, 
Smith JP, Maia JM, et al.: Whole-genome sequencing of a single proband together with linkage 
analysis identifies a Mendelian disease gene. PLoS Genet. 2010, 6:e1000991. 
4.  Grossmann KS, Rosário M, Birchmeier C, Birchmeier W: The tyrosine phosphatase Shp2 in 
development and cancer. Adv. Cancer Res. 2010, 106:53–89. 
5.  Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O’Donnell P, Grigoriadis 
A, Diss T, et al.: IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and 
central and periosteal chondromas but not in other mesenchymal tumours. The Journal of 
Pathology 2011, 224:334–343. 
6.  Amary MF, Damato S, Halai D, Eskandarpour M, Berisha F, Bonar F, McCarthy S, Fantin VR, Straley 
KS, Lobo S, et al.: Ollier disease and Maffucci syndrome are caused by somatic mosaic 
mutations of IDH1 and IDH2. Nature Genetics 2011, 43:1262–1265. 
7.  Pansuriya TC, van Eijk R, d’ Adamo P, van Ruler MAJH, Kuijjer ML, Oosting J, Cleton-Jansen A-M, 
van Oosterwijk JG, Verbeke SLJ, Meijer D, et al.: Somatic mosaic IDH1 and IDH2 mutations are 
associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci 
syndrome. Nature Genetics 2011, 43:1256–1261. 
8.  Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, 
Sangiorgi L, Wuyts W: Multiple osteochondromas: mutation update and description of the 
multiple osteochondromas mutation database (MOdb). Hum. Mutat. 2009, 30:1620–1627. 
9.  Yang W, Klaman LD, Chen B, Araki T, Harada H, Thomas SM, George EL, Neel BG: An 
Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival. Developmental 
Cell 2006, 10:317–327. 
10.  Bauler TJ, Kamiya N, Lapinski PE, Langewisch E, Mishina Y, Wilkinson JE, Feng G-S, King PD: 
Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of 
skeletal malformation in humans with SHP-2 mutations. Dis Model Mech 2011, 4:228–239. 
11.  Yang W, Wang J, Moore DC, Liang H, Dooner M, Wu Q, Terek R, Chen Q, Ehrlich MG, Quesenberry 
PJ, et al.: Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing 
hedgehog signalling. Nature 2013, 499:491–495. 
12.  Kim HKW, Feng G-S, Chen D, King PD, Kamiya N: Targeted disruption of Shp2 in chondrocytes 
leads to metachondromatosis with multiple cartilaginous protrusions. J. Bone Miner. Res. 
2013, doi:10.1002/jbmr.2062. 
13.  Kim HKW, Aruwajoye O, Sucato D, Richards BS, Feng G-S, Chen D, King P, Kamiya N: Induction 
of SHP2-deficiency in chondrocytes causes severe scoliosis and kyphosis in mice. Spine 
2013, doi:10.1097/BRS.0b013e3182a3d370. 
Chapter 3 
102 
14.  Matsushita T, Chan YY, Kawanami A, Balmes G, Landreth GE, Murakami S: Extracellular Signal-
Regulated Kinase 1 (ERK1) and ERK2 Play Essential Roles in Osteoblast Differentiation and in 
Supporting Osteoclastogenesis. Molecular and Cellular Biology 2009, 29:5843–5857. 
15.  Sebastian A, Matsushita T, Kawanami A, Mackem S, Landreth GE, Murakami S: Genetic 
inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the 
spinal canal. Journal of Orthopaedic Research 2011, 29:375–379. 
16.  Kato Y, Iwamoto M, Koike T, Suzuki F, Takano Y: Terminal differentiation and calcification in 
rabbit chondrocyte cultures grown in centrifuge tubes: regulation by transforming growth 
factor beta and serum factors. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:9552–9556. 
17.  Chen K-S, Tatarczuch L, Ahmed Y, Huang HH, Mirams M, Pagel CN, Mackie EJ: Identification of 
light and dark hypertrophic chondrocytes in mouse and rat chondrocyte pellet cultures. 
Tissue and Cell 2010, 42:121–128. 
18.  Nishimura R, Hata K, Ono K, Amano K, Takigawa Y, Wakabayashi M, Takashima R, Yoneda T: 
Regulation of endochondral ossification by transcription factors. Front. Biosci. 2012, 17:2657–
2666. 
19.  Oshlack A, Robinson MD, Young MD: From RNA-seq reads to differential expression results. 
Genome Biol. 2010, 11:220. 
20.  Zhang H: Profiling genes expressed in human fetal cartilage using 13,155 expressed sequence 
tags. Osteoarthritis and Cartilage 2003, 11:309–319. 
21.  Keene DR, Oxford JT, Morris NP: Ultrastructural localization of collagen types II, IX, and XI in 
the growth plate of human rib and fetal bovine epiphyseal cartilage: type XI collagen is 
restricted to thin fibrils. Journal of Histochemistry & Cytochemistry 1995, 43:967–979. 
22.  Hattori T, Muller C, Gebhard S, Bauer E, Pausch F, Schlund B, Bosl MR, Hess A, Surmann-Schmitt 
C, von der Mark H, et al.: SOX9 is a major negative regulator of cartilage vascularization, bone 
marrow formation and endochondral ossification. Development 2010, 137:901–911. 
23.  Naski MC, Colvin JS, Coffin JD, Ornitz DM: Repression of hedgehog signaling and BMP4 
expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 1998, 
125:4977–4988. 
24.  Shung C-Y, Ota S, Zhou Z-Q, Keene DR, Hurlin PJ: Disruption of a Sox9- -catenin circuit by 
mutant Fgfr3 in thanatophoric dysplasia type II. Human Molecular Genetics 2012, 21:4628–4644. 
25.  Iwamoto T, Nakamura T, Doyle A, Ishikawa M, de Vega S, Fukumoto S, Yamada Y: Pannexin 3 
Regulates Intracellular ATP/cAMP Levels and Promotes Chondrocyte Differentiation. Journal of 
Biological Chemistry 2010, 285:18948–18958. 
26.  Nishimura R, Wakabayashi M, Hata K, Matsubara T, Honma S, Wakisaka S, Kiyonari H, Shioi G, 
Yamaguchi A, Tsumaki N, et al.: Osterix Regulates Calcification and Degradation of 
Chondrogenic Matrices through Matrix Metalloproteinase 13 (MMP13) Expression in 
Association with Transcription Factor Runx2 during Endochondral Ossification. Journal of 
Biological Chemistry 2012, 287:33179–33190. 
27.  Houston B, Stewart AJ, Farquharson C: PHOSPHO1-A novel phosphatase specifically expressed 
at sites of mineralisation in bone and cartilage. Bone 2004, 34:629–637. 
Chapter 3 
103 
28.  Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: 
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of 
hypertrophic chondrocytes. Cell 1998, 93:411–422. 
29.  Hu H: Sequential roles of Hedgehog and Wnt signaling in osteoblast development. 
Development 2004, 132:49–60. 
30.  Brown AJ, Alicknavitch M, D’Souza SS, Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD, Farach-
Carson MC: Heparanase expression and activity influences chondrogenic and osteogenic 
processes during endochondral bone formation. Bone 2008, 43:689–699. 
31.  Makihira S: Thyroid Hormone Enhances Aggrecanase-2/ADAM-TS5 Expression and 
Proteoglycan Degradation in Growth Plate Cartilage. Endocrinology 2003, 144:2480–2488. 
32.  Little CB, Mittaz L, Belluoccio D, Rogerson FM, Campbell IK, Meeker CT, Bateman JF, Pritchard MA, 
Fosang AJ: ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in 
vitro or in vivo. Arthritis Rheum. 2005, 52:1461–1472. 
33.  Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, Tremante E, Sardella D, 
Bonucci E: Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in 
femur and tibia of the rat. J. Mol. Histol. 2005, 36:59–67. 
34.  Chen J, Shapiro HS, Sodek J: Developmental expression of bone sialoprotein mRNA in rat 
mineralized connective tissues. Journal of Bone and Mineral Research 2009, 7:987–997. 
35.  Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, Shelton JM, Richardson JA, Bassel-Duby 
R, Olson EN: MEF2C transcription factor controls chondrocyte hypertrophy and bone 
development. Dev. Cell 2007, 12:377–389. 
36.  Mikasa M, Rokutanda S, Komori H, Ito K, Tsang YS, Date Y, Yoshida CA, Komori T: Regulation of 
Tcf7 by Runx2 in chondrocyte maturation and proliferation. Journal of Bone and Mineral 
Metabolism 2010, 29:291–299. 
37.  Ferrari D, Kosher RA: Dlx5 Is a Positive Regulator of Chondrocyte Differentiation during 
Endochondral Ossification. Developmental Biology 2002, 252:257–270. 
38.  Amano K, Ichida F, Sugita A, Hata K, Wada M, Takigawa Y, Nakanishi M, Kogo M, Nishimura R, 
Yoneda T: Msx2 Stimulates Chondrocyte Maturation by Controlling Ihh Expression. Journal of 
Biological Chemistry 2008, 283:29513–29521. 
39.  Guo X, Zhao H: Foxp1/2/4, New Transcriptional Regulators for the Chondrocyte Hypertrophy 
and Osteoblast Differentiation during Skeletal Ossification. 2012. 
40.  Salie R, Kneissel M, Vukevic M, Zamurovic N, Kramer I, Evans G, Gerwin N, Mueller M, Kinzel B, 
Susa M: Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and 
chondrocyte hypertrophy in bone. Bone 2010, 46:680–694. 
41.  Kohn A, Dong Y, Mirando AJ, Jesse AM, Honjo T, Zuscik MJ, O’Keefe RJ, Hilton MJ: Cartilage-
specific RBPj -dependent and -independent Notch signals regulate cartilage and bone 
development. Development 2012, 139:1198–1212. 
42.  Dy P, Wang W, Bhattaram P, Wang Q, Wang L, Ballock RT, Lefebvre V: Sox9 Directs Hypertrophic 
Maturation and Blocks Osteoblast Differentiation of Growth Plate Chondrocytes. 
Developmental Cell 2012, 22:597–609. 
Chapter 3 
104 
43.  de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD: Early growth response 
gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J. Biol. Chem. 2005, 
280:35136–35147. 
44.  Liu Q-F, Yu H-W, Liu G-N: Egr-1 upregulates OPN through direct binding to its promoter and 
OPN upregulates Egr-1 via the ERK pathway. Mol. Cell. Biochem. 2009, 332:77–84. 
45.  Rockel JS, Bernier SM, Leask A: Egr-1 inhibits the expression of extracellular matrix genes in 
chondrocytes by TNFalpha-induced MEK/ERK signalling. Arthritis Res. Ther. 2009, 11:R8. 
46.  Zhang Y, Ross AC: Retinoic acid and the transcription factor MafB act together and 
differentially to regulate aggrecan and matrix metalloproteinase gene expression in neonatal 
chondrocytes. Journal of Cellular Biochemistry 2013, 114:471–479. 
47.  Ahmad R, Sylvester J, Zafarullah M: MyD88, IRAK1 and TRAF6 knockdown in human 
chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and 
promoter activity by impairing MAP kinase activation. Cell. Signal. 2007, 19:2549–2557. 
48.  Wu L, Tanimoto A, Murata Y, Fan J, Sasaguri Y, Watanabe T: Induction of human matrix 
metalloproteinase-12 gene transcriptional activity by GM-CSF requires the AP-1 binding site in 
human U937 monocytic cells. Biochem. Biophys. Res. Commun. 2001, 285:300–307. 
49.  Sharma P, Kumar S, Kundu GC: Transcriptional regulation of human osteopontin promoter by 
histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol. Cancer 2010, 9:178. 
50.  Miedlich SU, Zalutskaya A, Zhu ED, Demay MB: Phosphate-induced Apoptosis of Hypertrophic 
Chondrocytes Is Associated with a Decrease in Mitochondrial Membrane Potential and Is 
Dependent upon Erk1/2 Phosphorylation. Journal of Biological Chemistry 2010, 285:18270–
18275. 
51.  de Andrea CE, Wiweger MI, Bovée JVMG, Romeo S, Hogendoorn PCW: Peripheral 
chondrosarcoma progression is associated with increased type X collagen and 
vascularisation. Virchows Arch. 2012, 460:95–102. 
52.  Okubo Y, Reddi AH: Thyroxine downregulates Sox9 and promotes chondrocyte hypertrophy. 
Biochem. Biophys. Res. Commun. 2003, 306:186–190. 
53.  Lapinski PE, Meyer MF, Feng G-S, Kamiya N, King PD: Deletion of SHP-2 in mesenchymal stem 
cells causes growth retardation, limb and chest deformity and calvarial defects in mice. Dis 
Model Mech 2013, doi:10.1242/dmm.012849. 
54.  Herman TE, Chines A, McAlister WH, Gottesman GS, Eddy MC, Whyte MP: Metachondromatosis: 
report of a family with facial features mildly resembling trichorhinophalangeal 
syndromePediatr Radiol 1997 Nov;27(11):864. Pediatr Radiol 1997, 27:436–441. 
55.  Kennedy LA: Metachondromatosis. Radiology 1983, 148:117–118. 
56.  Jacob AL, Smith C, Partanen J, Ornitz DM: Fibroblast growth factor receptor 1 signaling in the 
osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev. 
Biol. 2006, 296:315–328. 
57.  Wang K, Yamamoto H, Chin JR, Werb Z, Vu TH: Epidermal growth factor receptor-deficient mice 
have delayed primary endochondral ossification because of defective osteoclast recruitment. 
J. Biol. Chem. 2004, 279:53848–53856. 
Chapter 3 
105 
58.  Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in 
mice lacking fibroblast growth factor receptor 3. Nat. Genet. 1996, 12:390–397. 
59.  Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P: Fibroblast growth factor receptor 3 is a 
negative regulator of bone growth. Cell 1996, 84:911–921. 
60.  Liu T, Gao Y, Sakamoto K, Minamizato T, Furukawa K, Tsukazaki T, Shibata Y, Bessho K, Komori T, 
Yamaguchi A: BMP-2 promotes differentiation of osteoblasts and chondroblasts inRunx2-
deficient cell lines. Journal of Cellular Physiology 2007, 211:728–735. 
61.  Pan Q, Yu Y, Chen Q, Li C, Wu H, Wan Y, Ma J, Sun F: Sox9, a key transcription factor of bone 
morphogenetic protein-2-induced chondrogenesis, is activated through BMP pathway and a 
CCAAT box in the proximal promoter. J. Cell. Physiol. 2008, 217:228–241. 
62.  Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH: BMP signals regulate Dlx5 during early 
avian skull development. Dev. Biol. 2003, 257:177–189. 
63.  Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP, Vortkamp A: BMP and 
Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. 
Development 2001, 128:4523–4534. 
64.  Lai LP, Mitchell J: Indian hedgehog: Its roles and regulation in endochondral bone 
development. Journal of Cellular Biochemistry 2005, 96:1163–1173. 
65.  Huegel J, Mundy C, Sgariglia F, Nygren P, Billings PC, Yamaguchi Y, Koyama E, Pacifici M: 
Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in 
developing long bones: A mechanism likely deranged in Hereditary Multiple Exostoses. Dev. 
Biol. 2013, doi:10.1016/j.ydbio.2013.02.008. 
66.  Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L: A global double-fluorescent Cre reporter 
mouse. Genesis 2007, 45:593–605. 
67.  Nakamura E, Nguyen M-T, Mackem S: Kinetics of tamoxifen-regulated Cre activity in mice using 
a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb 
skeleton. Dev. Dyn. 2006, 235:2603–2612. 
68.  Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, 
Philips MR, et al.: Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by 
Controlling Csk Recruitment. Molecular Cell 2004, 13:341–355. 
69.  Hayashi S, McMahon AP: Efficient recombination in diverse tissues by a tamoxifen-inducible 
form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. 
Biol. 2002, 244:305–318. 
70.  Gosset M, Berenbaum F, Thirion S, Jacques C: Primary culture and phenotyping of murine 
chondrocytes. Nature Protocols 2008, 3:1253–1260. 
71.  Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. 
Bioinformatics 2009, 25:1105–1111. 
72.  Carlson M, Pages H, Aboyoun S, Falcon S, Morgan M, Sarkar D, Lawrence M: GenomicFeatures: 
Tools for making and manipulating transcript centric annotations. R package   version 1.8.2. [date 
unknown]. 
Chapter 3 
106 
73.  Ayturk UM, Jacobsen CM, Christodoulou DC, Gorham J, Seidman JG, Seidman CE, Robling AG, 
Warman ML: An RNA-seq protocol to identify mRNA expression changes in mouse diaphyseal 
bone: Applications in mice with bone property altering               Lrp5               mutations. 
Journal of Bone and Mineral Research 2013, doi:10.1002/jbmr.1946. 
74.  Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics 2010, 26:139–140. 
75.  Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402–408. 
 
 
 
 
 
 
 
 
 
 
Chapter 4  
 
 
Efficient mapping and cloning of 
mutations in zebrafish by low-
coverage whole-genome sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 108 
4.1 Abstract 
 
 The generation and analysis of mutants in zebrafish has been instrumental in defining the 
genetic regulation of vertebrate development, physiology, and disease. However, identifying the 
genetic changes that underlie mutant phenotypes remains a significant bottleneck in the analysis 
of mutants. Whole-genome sequencing has recently emerged as a fast and efficient approach for 
identifying mutations in nonvertebrate model organisms. However, this approach has not been 
applied to zebrafish due to the complicating factors of having a large genome and lack of fully 
inbred lines. Here we provide a method for efficiently mapping and detecting mutations in 
zebrafish using these new parallel sequencing technologies. This method utilizes an extensive 
reference SNP database to define regions of homozygosity-by-descent by low coverage, whole-
genome sequencing of pooled DNA from only a limited number of mutant F2 fish. With this 
approach we mapped each of the five different zebrafish mutants we sequenced and identified 
likely causative nonsense mutations in two and candidate mutations in the remainder. 
Furthermore, we provide evidence that one of the identified mutations, a nonsense mutation in 
bmp1a, underlies the welded mutant phenotype. 
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4.4 Introduction 
 
 A major strength of the zebrafish (Danio rerio) model is the feasibility of performing large-scale 
genetic screens as a means to isolate mutants to study gene function. Such forward genetic screens 
have led to the identification of a large collection of mutants defective in a variety of biological processes. 
The standard approach for identifying the responsible mutation underlying a mutant phenotype is to 
perform bulked segregant analysis with simple sequence length polymorphisms (SSLPs) [1], followed by 
fine mapping using individual fish to define the region in which the mutation lies. Candidate genes within 
the mapped interval are then screened for the presence of mutations, typically by sequencing cDNA or 
genomic DNA. This approach is time and labor intensive, requiring large numbers of mutant fish and often 
years to successfully clone a mutant. To date this is a major limitation in zebrafish research, and large 
numbers of mutants have not yet been mapped or cloned.  
Whole-genome sequencing (WGS) has the potential to expedite the process of mutation 
detection in zebrafish. In Caenorhabditis elegans and Arabidopsis thaliana, multiple studies have shown 
that, by pooling from 10 to 500 recombinant progeny and sequencing to a relatively high depth, a linked 
region between 0.5 and 5 Mb in size as well as the responsible mutation can be identified [2–7]. Similarly, 
WGS of individual mutant mice [8] or human patients with genetic disorders [9] has led to the 
identification of causative mutations. However, in the case of mice and humans, prior knowledge of 
linkage was necessary to determine which of the many sequence variants identified in the genome were 
associated with the phenotype. 
Mapping mutants by performing WGS has not yet been applied to zebrafish. One prohibitive 
factor has been the high cost of sequencing an entire zebrafish genome (∼1.5 Gb, compared to 100 Mb 
for C. elegans and 120 Mb for A. thaliana). However, new sequencing platforms have increased the 
throughput of sequencing and reduced its cost, now making it practical to obtain low-coverage sequence 
data of an entire zebrafish genome. A second prohibitive factor for applying WGS for mutation detection 
in zebrafish is the high level of inter- and intrastrain variation [10–13] and the absence of a well-annotated 
catalog of natural variation; consequently, this makes it more difficult to determine whether a novel 
homozygous variant is a causative mutation or a low-frequency single-nucleotide polymorphism (SNP). 
This contrasts with the inbred organisms for which WGS has been successfully applied [2–7]. Here, we 
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describe the establishment of an extensive zebrafish SNP database. Using this database in combination 
with low-coverage (∼3×) WGS, we developed a rapid and inexpensive method to efficiently map, and 
frequently clone, recessive mutations in zebrafish. Furthermore, the methodology described here can be 
used to identify genetic loci in other model organisms with larger and highly polymorphic genomes that 
have annotated genomes, such as rats, mice, dogs, chickens, and other fish species. 
4.5 Results 
 
Sequencing libraries generated from pooled DNA 
 We performed WGS on five previously uncharacterized mutants isolated in an ENU mutagenesis 
screen for adult phenotypes (ZF-MODELS; Tübingen, Germany, 2004). These recessive mutants, 
generated in the Tü background, were outcrossed to a polymorphic mapping strain (WIK or TLF) (Figure 
4.1); progeny from F1 intercrosses were phenotyped and frozen for analysis. We pooled DNA from 20 
affected F2 fish from each mutant, mixing, when possible, individuals from several independent F1 
intercrosses. The F2 fish used often stemmed from either one or two parental (P0) crosses for a particular 
mutant, thus limiting the total genomic variation within a pool. Whole-genome sequencing was performed 
on genomic DNA libraries constructed from each mutant pool, resulting in between 60 and 83 million 100-
bp reads per library (Table 4.1). We obtained between 2.6× and 4.1× coverage of the genome per 
mutant, after excluding 2–9% of the reads that were potential PCR duplicates (reads with identical 5′-end 
coordinates) and ∼25% of reads that failed to map to unique locations in the reference genome (Zv9).  
We also sequenced the genomes of four routinely used wild-type strains to establish a database 
of existing SNP variation. This information enabled us to predict the parental origin of SNP alleles in our 
mutant pools. Tü and WIK strains are commonly used in laboratories around the world. To assess the 
diversity among parental strains, we generated WGS from lines maintained at Children’s Hospital Boston 
(TüB and WIKB) and the Max Planck Institute in Tübingen, Germany (TüG and WIKG). DNA libraries, 
constructed from pooled DNA from 20 fish for each of the TüB, WIKB, TüG, WIKG, TLF, and AB lines, 
were sequenced and 3.8× to 5.1× average genome coverage was obtained (Table 4.1). 
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Figure 4.1: Outline and predicted sensitivity of the approach. (1) The generation of fish used in 
mapping is accomplished by crossing identified mutants carrying a recessive ENU-induced mutation (*) 
within the Tü background, to a polymorphic mapping strain, (e.g., WIK).  Mutant carriers (Tü*/WIK) of the 
F1 generation are then intercrossed to generate F2 progeny.  These F2 fish are sorted based on the 
presence or absence of the mutant phenotype. (2) DNA is prepared from 20 F2 mutant progeny (Tü*/Tü*) 
and pooled in equal quantities. The diagram depicts the 40 chromosomes containing a phenotype-causing 
ENU-induced mutation (red asterisk) among the 20 mutant fish. The mutation is linked to genomic 
sequence originating from the Tü strain used for mutagenesis (grey fragments). Recombinants having 
sequence originating from the outcross strain (black fragments) can be observed at different distances 
from the causative mutation as a result of meiotic recombination during meiosis in the F1 generation. In a 
SNP located ~10 cM from the causative mutation, we expect by definition, 4 of the 40 mutation-containing 
chromosomes to show a mapping strain allele (G in WIK; black square) as a result of meiotic 
recombination.  (3) Physical fractionation of DNA from the 20 mutant fish produces DNA fragments, that 
contain the aforementioned SNP (boxed C for the Tü and G for the WIK alleles), (4) Whole genome 
sequencing of the fragmented DNA library is performed on a single lane of an  Illumina HiSeq platform 
resulting in ~3x genome coverage. (5) Probability for detecting a SNP as being homogenous or 
heterogeneous in pooled DNA from 20 mutant fish sequenced to 3x coverage. SNPs are classified as 
homogeneous if all 3 reads covering the SNP represent the same allele (probability = p3 + q3) and as 
heterogeneous if both alleles are represented (probability = 3p2q + 3pq2). In an unlinked region, where 
both alleles are equally represented (q = 0.5; p = 0.5), the probability of a SNP being detected as 
heterogeneous is 0.75. Likewise, in regions where 10% of the chromosomes are recombinant, as in our  
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(continued: Figure 4.1) example, statistically 4 out of 40 (q = 0.1) reads would show the mapping-strain 
allele (G), while 36 out of 40 (p = 0.9) would show the reference allele (C; Tü). Thus the probability of 
detecting the SNP in a heterogeneous state is 0.27. Therefore, the number of heterogeneous SNPs 
identified in such a region is expected to be ~64% lower than in an unlinked region (0.27/0.75 = 64%). 
Similarly, a ~90% reduction in heterogeneity is expected for regions containing 1 recombinant 
chromosome, while a ~25% reduction is expected for regions with 10 recombinant chromosomes. 
According to this analysis using low genome coverage, it would be of no added benefit to pool larger 
numbers of fish to increase the resolution of mapping. As the probability of detecting a single recombinant 
in, for example, 40 fish (80 chromosomes) would be lower than the level of detecting false positive 
heterogeneous SNPs and thus indistinguishable from noise. 
 
 
 
Table 4.1: Whole genome sequencing of pooled DNA from wild-type zebrafish strains 
Wild-type pool # readsa 
(millions) 
Genome 
coverage 
# SNPsb  
(per kb) 
% hetc 
TüB 97 5.1x 2.6 88 
TüG 81 4.1x 2.5 89 
WIKB 96 4.1x 2.9 64 
WIKG 81 4.0x 3.5 73 
AB 90 4.6x 3.3 79 
TLF 91 3.8x 2.9 56 
aNumber of 100 bp reads obtained by Illumina single end sequencing.  
bNumber of positions at which at least one read representing an alternate allele was 
observed. Only positions at the 7.6 million SNP sites identified in this study were considered. 
dPercentage of SNPs that were heterogeneous (i.e., both reference-genome and alternate 
alleles were represented)  
 
 
Establishment of a reference SNP database 
 With low-coverage sequencing of pooled DNA, it is challenging to distinguish true SNPs from 
sequencing errors as many variants are represented by only a single sequencing read. However, if the 
same variant is observed in more than one strain, it is more likely to be a real SNP than a sequencing 
error. Therefore, to enhance the accuracy of SNP detection we combined the WGS data from all wild-type 
strains and mutants, resulting in 50× genome coverage, and then selected only the variants that were 
present in at least three reads for inclusion in our SNP database (see Materials and Methods for filtering 
criteria). Although variants present in only one or two reads in the combined data could also represent 
real SNPs, many are likely to represent sequencing errors or alignment artifacts and therefore were not 
included in the database. In total, we identified a set of 7.6 million SNPs (http://www.fishyskeleton.com), 
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which is substantially greater than the 0.7 million zebrafish SNPs currently annotated in publically 
available databases. Of the SNPs in public databases, 85% were detected in at least one read in our 
sequence data, and 45% had been included in our SNP database since they met all filtering criteria (such 
as being present in at least three reads). Importantly, 7.3 million of the SNPs we identified were not 
annotated, thus vastly expanding our knowledge of genetic variation in zebrafish. Using the individual 
WGS data from pooled DNA for each mutant and wild-type strain, we were then able to classify each 
SNP within that sequence as being either heterogeneous (at least one read representing each SNP allele 
was observed) or homogeneous (all reads represented the same allele). In each pool, an average of ∼2 
heterogeneous and ∼3 homogeneous SNPs were observed per kilobase of genomic sequence (Table 
4.2). 
 
Table 4.2: Classifying SNPs identified by whole genome sequencing of pooled DNA from 
zebrafish mutants 
SNP genotypea 
 (average per kb)  
Parental origin of allelesb (average 
per kb) 
Hom 
Mutant pool Het  Non-ref Ref n/d 
Mapping strain 
allele 
Reference 
genome allele 
moto 1.6 0.9 1.8 1.3 0.6 0.6 
wdd 1.0 0.4 2.1 2.2 0.3 0.3 
hlw 1.7 0.4 2.4 1.0 0.4 0.8 
frnt 2.1 0.6 2.1 0.7 0.6 0.7 
sump 1.8 1.1 2.0 0.6 0.7 0.6 
aCalculated for the 7.6 million SNP sites identified in this study. SNPs were defined as 
heterogeneous (Het) for sites at which both a reference genome allele (Zv9) and an alternate allele 
were observed in the WGS of pooled DNA. SNPs were defined as homogeneous (Hom) for sites 
at which only the alternate allele (non-ref) or the reference genome allele (ref) were observed; 
sites that were covered by less than 2 sequencing reads were deemed uninformative (n/d).  
bCalculated for all SNP sites at which an alternate allele was present in the TLF or WIK mapping 
strain, but not in the Tü strain (0.7 million and 1.2 million sites respectively); Mapping strain allele = 
at least one read representing the alternate allele was observed in a mutant pool; Reference 
genome allele = all reads in a mutant pool represented the reference genome allele. Note that the 
reference genome is based on the Tü strain.   
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Identification of strain-specific diversity 
To allow us to predict the parental origin of alleles in mutant pools, which facilitates mapping 
based on homozygosity-by-descent, we identified alleles that differed between parental strains. In the 7.6 
million total SNPs identified, an alternate allele (with respect to the Zv9 reference genome, which is based 
on the Tü strain) was observed at 3–4 million sites in each wild-type line (Table 4.1). Consistent with 
previous reports noting a high degree of variation within each zebrafish strain [10–13], the vast majority of 
these sites were heterogeneous (i.e., had reads representing both the reference and the alternate alleles)  
(Table 4.1). Thus, to identify SNPs that differed between lines, we selected SNPs at which all reads 
represented the reference allele in one line, while the other line had at least one read representing an 
alternate allele. When only the SNPs with sequence coverage in all six lines (5.2 million) were 
considered, any two lines differed at ∼40% of loci (Figure 4.2A), which is in agreement with previous 
estimates of interstrain diversity [10]. The majority (72%) of SNPs were shared by at least three lines, 
while only 11% were unique to a single line (Figure 4.2B). For use in our mapping studies, we selected all 
sites at which alternate alleles were present in the strain used for outcrossing (TLF or WIK), but not in the 
strain used for mutagenesis (Tü). These alternate alleles were referred to as “mapping strain alleles” and 
consisted of 0.74 million and 1.2 million alleles for the TLF and WIK strains, respectively (Figure 4.2C-D). 
In each mutant pool, these sites were analyzed for the presence or absence of the mapping strain allele 
(Table 4.2). 
Mapping mutants using homozygosity-by-descent 
 We next mapped each mutant on the basis of homozygosity-by-descent. For each mutant pool, 
we scanned the WGS data for regions with two characteristics: having a reduced level of heterogeneity 
and a reduced level of SNPs originating from the outcrossed strain, relative to the genome-wide averages 
of these measures. To quantify these characteristics, we designed an algorithm that produced a “mapping 
score,” using sliding windows throughout the genome (Figure 4.3). Since we expected a characteristic 
footprint to span at least 10 cM on either side of the causative mutation (Figure 4.1), a window size of 20 
cM, tiled at 0.25-cM intervals, was utilized. We based the window size on genetic distance (centimorgans) 
rather than physical distance (megabases), to take local recombination rates into account. This makes 
the analysis more accurate in regions close to centromeres and telomeres. Once regions with high 
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Figure 4.2: Genetic variation in zebrafish strains detected in low coverage WGS data of pooled 
DNA from 20 fish. (a) Pairwise comparison of SNP genotypes between parental lines showing the 
percentages of SNPs that are polymorphic and thus could be used to predict the parental origin for 
mapping based on homozygosity-by-descent. SNPs were classified as polymorphic if only the reference 
genome allele was observed in one line, while at least one alternate allele was observed in the second 
line. (b) Graph showing the number of polymorphic SNPs (in millions) identified in each parental line, as 
well as the number of lines with which these SNPs are shared. For (a) and (b), only sites with sequence 
coverage in all lines were considered (5.2 million sites out of the 7.6 million total SNP sites). (c, d) Venn 
diagrams showing the SNPs that were classified as mapping strain SNPs. This includes 0.74 million 
SNPs found in TLF but not in either of the Tü lines, and 1.2 million SNPs found in either of the WIK lines 
but not in either of the Tü lines. For (c) the two Tü lines are shown separately, while in (d) the data from 
these two lines were combined. Interestingly, due to high levels of intra-strain variation, there is a high 
number of SNPs that are not shared between the two Tü lines (c), and a similar number of SNPs that are 
not shared between the two WIK lines (d).   
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mapping scores were identified for a particular mutant, we independently tested linkage to these regions 
by the use of SSLP or SNP markers on DNA pools as well as in individual progeny (Table 4.3). In each of 
the five mutants analyzed, we confirmed that the region with the highest mapping score was linked to the 
mutation (Figure 4.3). In some cases, other unlinked areas exhibited relatively high mapping scores. We 
postulate that these regions represent haplotype blocks that were, by chance, shared by the two parental 
fish used for the initial mapping cross. We asked whether these shared haplotype blocks could have been 
predicted on the basis of the WGS of the parental strains, but found that each block occurred in a region 
in which heterogeneous SNPs (and therefore more than one haplotype) were observed in each of the 
parental strains. Furthermore, these blocks occurred in different locations in each mutant analyzed. Thus, 
if multiple regions with a high mapping score are obtained, independent tests for linkage will be needed to 
distinguish shared haplotype blocks from the region linked to the causative mutation. The presence of 
multiple high mapping scores in the genome could also represent second-site modifiers of the phenotype. 
These regions could then be analyzed for sequence variants that alter the expressivity of the mutant 
phenotype. 
Our approach has two major differences from those previously used to map C. elegans and A. 
thaliana mutants [2–7]. First, our analysis is based on genetic rather than physical distance. Second, we 
combine the levels of homogeneity and strain-specific SNP signatures to map the locus. We find that this 
analytical method provides a robust and reliable means to correctly map the region linked to the mutation 
in zebrafish (Figure 4.4 and Figure 4.5). 
The genetic architecture of linked regions 
 We further refined the linked interval by identifying an area of homogeneity within the broader 
region defined by our mapping algorithm. Since 20 fish were pooled for each mutant, we expected the 
region of homogeneity to span, on average, 2.5 cM on either side of the causative mutation (one 
recombinant per 40 meioses). Because of the low resolution of the genetic map, we utilized 100-kb 
windows (rather than centimorgans) to facilitate fine mapping of the interval. Assuming random sampling 
of alleles with only ∼3× coverage, we expected and confirmed that linked regions containing two 
recombination events had an ∼81% reduction in heterogeneity compared to unlinked regions, while  
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Figure 4.3: Mapping zebrafish mutants based on homozygosity-by-descent. Individual graphs 
depicting the mapping scores along each chromosome for the five different mutants (moto, frnt, hlw, wdd, 
sump). The mapping score is calculated as the ratio of homogeneous to heterogeneous SNPs, multiplied 
by the ratio of reference alleles to mapping strain alleles in sliding windows. The size of the sliding 
windows is 20 cM with an overlap of 19.75 cM between adjacent windows. Physical distances were 
converted to genetic distances using markers from the MGH meiotic map that have been mapped onto 
the Zv9 reference genome. In each of the five mutants, the region with the highest mapping score in the 
genome (gray arrows) was subsequently confirmed as containing the linked interval using SSLP or SNP 
markers. 
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Table 4.3: SSLP and SNP marker linkage data 
   
Zebrafish 
mutant 
Chra Region of 
homogeneity (Mb)b 
Markerc  Positiond 
(Mb) 
Recombinants/meiosise 
moto 3 
 
19-36.6 z9964  34.3  2/90 
wdd 8 51.8-55 bmp1a  53.5 0/66 
hlw 8 
 
43-47 z25210  
z7130 
43 
45.6  
2/44 
1/46 
frnt 4 
 
15-27.8 z11538 
z20450 
23.1 
24.4 
3/44 
2/44 
sump 16 
 
41.8-51.2 z8819 
z15739  
z4670 
z6854 
41.3  
43.9  
50.8 
50.6 
2/56 
0/56 
1/40 
1/40 
aChromosome showing the highest mapping score.  
bInterval on the chromosome showing homogeneity.  
cMarker used to confirm linkage.  
dMarker position on the Chromosome in Mb.  
eRecombinants identified for each marker in the number of meiosis tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
120 
 
Figure 4.4:  Mapping by combining both the frequency of heterogeneous SNPs and the frequency 
of mapping strain SNPs helps to eliminate false positives. Graphs show the comparison between the 
ratio of homogeneous to heterogeneous SNPs (red lines) to the ratio of reference genome alleles to 
mapping strain alleles (gray bars), for the five mutants analyzed (moto, frnt, hlw, wdd, sump). Ratios were 
calculated for all 25 chromosomes using sliding windows of 20 cM in size, with an overlap of 19.75 cM 
between adjacent windows. Genetic distances were defined by the MGH meiotic map. The arrow 
indicates the linked region for each mutant. For three mutants (moto, frnt, wdd), both approaches 
independently predict the linked region as the region in the genome with the highest ratio. In the hlw and 
frnt mutants, other regions show the highest ratio of reference alleles to mapping strain alleles 
(arrowheads). These regions do not have a high ratio of homogeneous to heterogeneous SNPs. Similarly, 
for the sump mutant, region on Chr21 shows the highest ratio of homogeneous to heterogeneous SNPs, 
but this region does not have a high ratio of reference alleles to mapping strain alleles (arrowhead). 
Accordingly, these false positive regions would result in a lower mapping score in our combined analysis 
and thus would be ranked as less likely to be linked to the mutation. 
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Figure 4.5:  The sensitivity and specificity of mapping is affected by the size of the window used 
to calculate the mapping score. Graphs showing the genome-wide mapping scores using a sliding 
window of 15 Mb in size for all mutants (above), or a sliding window of 3 Mb in size for wdd (below), 
rather than the 20 cM windows used in our analysis. When 15 Mb sliding windows are used, in only three 
of the five mutants (moto, frnt, sump) the linked region is contained within the window with the highest 
mapping score in the genome (red arrows).  In hlw the linked region is contained within the peak with the 
third highest mapping score (red arrow). In wdd, the linked region is not detected by an increase in the 
mapping score (asterisk), because the linked interval on Chr8 spans only 4 Mb.  When a 3 Mb window 
was used for wdd, which should be small enough to detect the linked region, a mapping score peak 
appears at the linked interval (red arrow), but it is only the 5th highest peak. 
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regions containing one recombination event had a reduction in heterogeneity of ∼90% (Figure 4.6 and 
Figure 4.1). We found that regions without recombination events were almost, but not completely, 
homogeneous, likely due to false positive variants resulting from sequencing errors or alignment artifacts. 
Therefore, we defined a candidate region of homogeneity as having a reduction in heterogeneity >90%. 
This approach allowed us to narrow down the candidate interval in each mutant to a region between 4 
and 19 Mb in size (Table 4.4). 
Identifying candidate phenotype-causing mutations within linked intervals 
 One of the powerful aspects of WGS is that it provides a large amount of sequence information 
throughout the candidate interval, allowing for the exclusion of much of the sequence in the interval as 
harboring the causative mutation. Additionally, the sequence allows the potential to identify the causative 
change. In the five mutants analyzed, between 76% and 92% of the coding sequence within the 
candidate interval was covered by at least two sequencing reads (Table 4.4). We identified hundreds to 
thousands of homogeneous variants in each candidate interval, of which between 4 and 136 were 
predicted to be nonsynonymous. However, we could exclude most of these variants as being causative 
for the phenotype since we also observed them in the WGS from the other unaffected strains (Table 4.4). 
In two of the five mutants we identified the likely causative mutation as a nonsynonymous change 
covered by at least two reads; these particular changes are predicted to encode nonsense alleles. In the 
three other mutants, unique nonsynonymous changes covered by two or more reads were not detected, 
but between 7 and 22 nonsynonymous changes were present in sequences covered by one read (Table 
4.4). Further studies will be required to determine whether these single-read variants represent 
sequencing errors, normal variation, or phenotype-causing mutations. 
A benefit of having performed WGS is, apart from being able to map the mutation in all mutants 
analyzed and to identify candidate coding mutations, that >87% of the coding sequence within the interval 
could be excluded because it did not differ from the reference data set. A second benefit of having 
performed WGS is that homogeneous SNPs identified in the candidate interval can serve as markers to 
test for linkage in additional F2 fish, which will allow one to further refine the candidate interval. 
The nonsynonymous changes we identified in the welded (wddt31169) and the minamoto 
(motot31533) mutants exemplify the value of the WGS method. For the moto mutant, characterized by  
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Figure 4.6: Genetic architecture of SNP diversity at a linked interval. (A) Graph of the mapping score 
across chromosome 16 in the sump mutant. This chromosome contained the highest mapping score in 
the genome. (B) Graph depicting the percentage of SNPs that were classified as heterogeneous in non-
overlapping 100 kb windows along Chr16. The solid gray line indicates the genome wide average for 
SNPs classified as heterogeneous. Dotted gray lines indicate reductions in SNP heterogeneity of 90% 
(lower) and 81% (upper), respectively, as compared to the genome-wide average. The yellow bar 
demarcates the region with a reduction in heterogeneity of at least 30%, while the black bar demarcates 
the candidate region, defined by a reduction in heterogeneity of greater than 90%. Black arrows indicate 
the locations of SSLP markers used to confirmed linkage to this interval by individually genotyping the 20 
sump mutants that had been pooled for WGS. The fraction of recombination events per 40 meioses for 
each SSLP marker is indicated. (C) Graph showing the percentage of sites containing mapping strain 
alleles, in non-overlapping 100 kb windows along the chromosome. This percentage is only calculated for 
sites at which the strain used for mapping (WIK) showed an allele that was not observed in the strain 
used for mutagenesis (Tü). The gray line indicates the genome wide average of the percentage of sites 
containing mapping-strain alleles. Physical distances in Mb along Chr16 are indicated. The red vertical 
lines in the grey bar below the graphs indicate genetic distances, with lines spaced at ~1 cM intervals. 
The position of the centromere is indicated by black triangles.  
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Table 4.4: Characteristics of linked intervals identified by whole genome sequencing 
Zebrafish mutanta moto wdd hlw frnt sump 
Whole genome sequencing 
# reads (106) 61 81 60 79 83 
Genome coverage
 
2.6x 2.7x 2.8x 3.9x 4.1x 
Size of the linked intervalb 
 
Region of reduced heterogeneityc 
Physical size (Mb) 35 4 26 46 19 
Genetic size (cM) <25 <30 <25 <18 <18 
 
Region of homogeneityd 
Physical Size (Mb) 19 4 5 5 8 
Genetic size (cM) <14 <30 <4 <3 <11 
Coding sequence coverage in linked intervale 
≥1 read 93% 92% 87% 95% 88% 
≥ 2 reads 83% 77% 76% 92% 85% 
Homogeneous SNPs in linked intervalf 
Total 7640 225 1071 7783 9518 
Not in dbSNPg
 
5984 223 1023 6431 9110 
Noncoding 5663 207 997 6303 8687 
Synonymous 229 12 17 89 287 
Nonsynonymous 92 4 9 39 136 
 
Uniqueh      
   Noncoding 38 12 21 79 106 
   Synonymous 0 0 0 0 2 
   Nonsynonymous 
 
2 
(63)i
 1 
(119) 
0 
(22) 
0 
(4) 
0 
(7) 
 
aminamoto (motot31533), welded (wddt31169), hollow (hlwt3373), fruehrentner (frntt31786) and schrumpfkopf 
(sumpt3625). bIntervals identified by a high mapping score; linkage was confirmed by analysis of SSLP or 
SNP markers. cRegion with a reduction in heterogeneity of at least 30% compared to the genome-wide 
average. dDefined as a region with a greater than 90% reduction in heterogeneity compared to the 
genome wide average. eCoding sequence of RefSeq and Ensembl genes. fDetected homogeneous 
variants covered by at least 2 sequencing reads. gHomogeneous variants not present in the publicly 
available SNP database (dbSNP) downloaded from Ensemble. hHomogeneous variants not present in the 
reference strain database established in this study. iThe number of unique nonsynonymous mutations 
covered by only one sequencing read. 
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defective spermatogenesis, two nonsynonymous mutations (Table 4.4), covered by two and three reads 
respectively, were identified within the linked interval, one missense and one nonsense mutation. The 
nonsense mutation was confirmed to be homozygous in all 20 fish sequenced. This mutation lies within a 
novel gene (ENSDARG00000090664) that is conserved in vertebrates. Consistent with the observed 
spermatogenesis defects in the mutants, this gene is expressed in testes among vertebrates 
(http://www.ncbi.nlm.nih.gov/unigene) and thus is a strong candidate for causing the moto phenotype. For 
the wdd mutant, characterized by its adult craniofacial phenotype, only one nonsynonymous change, 
which was supported by eight reads, was detected in the linked interval (Table 4.4). This change creates 
a nonsense mutation (p.R227X) in the gene encoding Bone morphogenetic protein 1a (Bmp1a). PCR 
amplification and capillary dideoxy sequencing of the genomic region in individual F2 mutants and siblings 
confirmed the mutation and linkage to the mutant phenotype (0 recombinants in 66 meioses). It previously 
had been shown that morpholino-mediated reduction of Bmp1a function in zebrafish impairs larval 
development, leading to a wavy fin fold phenotype [14]. We detected a similar larval fin phenotype in wdd 
mutants and confirmed that this phenotype occurs in wild-type embryos injected with a morpholino 
targeting the translation initiation site of bmp1a (Figure 4.7). Thus we show that the nonsense mutation in 
bmp1a is the likely causative mutation underlying the wdd phenotype. With a causative mutation in hand, 
it is now possible to investigate the mechanistic basis of this skeletal phenotype. 
Minimum genome coverage needed for mapping 
 Our analysis showed that ∼3× genome coverage was sufficient to correctly map each mutant to a 
defined interval, to cover >87% of coding sequence within the candidate interval, and to identify a 
manageable number of variants as being potential causative mutations. To determine whether lower 
genome coverage would be sufficient for mapping and mutation detection, we applied the same mapping 
algorithm to randomly selected subsets of the total sequence reads obtained for each mutant. Utilizing 
only 5 million reads, which is equivalent to ∼0.2× genome coverage, we could still reliably identify the 
linked regions (Figure 4.8 and Figure 4.9). However, with 0.2× genome coverage, only 5% of coding 
sequence in the linked interval was covered by ≥2 reads, and 73% was not sequenced at all (Figure 4.8). 
Thus, using this method, it is feasible to map multiple mutants simultaneously by barcoding ∼14 mutant  
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Figure 4.7: Identification of a loss-of-function allele of Bmp1a that underlies the wdd mutant 
phenotype. (A) The mapping score plot for wdd is shown for Chr8, which contained the highest mapping 
score in the genome. In the graphs below, the genetic architecture of the linked region is shown. 
Annotation is similar to Figure 2. The location of the nonsense mutation within bmp1a that lies in the 
candidate interval is indicated (arrow). (B) Lateral-view of adult wild-type, and homozygous wdd mutant 
fish. Mutant fish are characterized by frontonasal shortening of the skull and deformed tailfins (red 
arrows). (C) Lateral- view of wild-type, wdd mutant, and bmp1a morpholino-injected larvae. Mutant and 
morphant larvae show a similar characteristic wavy appearance of their fin folds (red arrowheads) at 3 
days post fertilization (dpf), which is not observed in wild-type larvae. Insets show a higher magnification 
of the distal part of the finfold. 
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Figure 4.8: Mapping of mutants using only ~0.2x genome coverage. (A) Graph depicting the 
genome-wide mapping score plot for the moto mutant generated with a randomly selected subset (5 
million) of the total sequencing reads, which results in a genome coverage of 0.2x. (B) Graph depicting 
the percentage of SNPs that were classified as heterogeneous in non-overlapping 100 kb windows along 
Chr3. The arrow indicates the location of a SNP marker that was used to confirm linkage (0 recombinants 
in 40 meioses). While the overall number of detectable heterogeneous SNPs is reduced with a genome-
wide coverage of only 0.2x, the boundaries of the linked interval can be identified just as well as with 2.6x 
coverage. Black bar underlies the region of homogeneity (C) Graph depicting the loss in coverage of 
coding sequence that occurs as genome-wide coverage decreases.  
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Figure 4.9: Minimum coverage needed for efficient mapping of zebrafish mutants. Graphs depicting 
the genome-wide mapping scores calculated for each mutant in 20 cM sliding windows, using either only 
5 million (top) or 1 million (bottom) randomly selected Illumina sequencing reads. The actual map 
positions for each mutant are indicated (red arrows). When 5 million reads are used, the mapping score 
plots are not significantly different from those generated using all reads (>60 million) (Figure 1). The only 
exception is that, for sump, the linked region has only the 2nd highest mapping score. Even when only 1 
million reads are used, in three mutants (moto, frnt, hlw) the linked region has the highest mapping score 
in the genome. For two other mutants (wdd, sump), the relative heights of the false positive peaks are 
significantly increased.  
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DNA libraries and then sequencing a pool of these libraries on a single lane of an Illumina HiSeq 
apparatus. However, with this “bulk mapping” approach it would be unlikely to identify the causative 
mutations using the generated sequence alone. 
4.6 Discussion 
 
 We show that recessive zebrafish mutations can be efficiently mapped and cloned using low-
coverage WGS of only 20 pooled mutant progeny. While WGS has been used in other experimental 
models, such as C. elegans and A. thaliana [2–7], the size and polymorphic diversity of the zebrafish 
genome posed unique challenges. By constructing an extensive SNP database using WGS from six 
different wild-type lines, we increased the accuracy of mapping as well as the ability to distinguish 
phenotype-causing mutations from previously unannotated SNPs. This newly identified SNP database, 
containing millions of SNPs, is an order of magnitude larger than the SNPs previously annotated within 
publically available databases. This large database allowed us to identify strain-specific SNP signatures, 
which facilitated our detection of intervals that were homozygous-by-descent. 
An alternative strategy of mapping mutants using WGS would be to separately sequence pools of 
mutants and unaffected siblings, rather than using a comparison to wild-type strains. With the limited 
recombination rate within the 20 fish sequenced, both strategies would provide similar resolution of the 
mapping interval. Using a sequence data set representing ∼50× coverage, we increase the accuracy of 
identifying SNPs within the mapping interval without the need for low-coverage sequence data from 
siblings. Additionally, analysis of the siblings for each mutant would double the cost per mutant analyzed. 
We think that the strain-specific and reference SNP databases we created provide a more efficient means 
of analyzing sequence data from multiple mutants in parallel. This SNP data set can be utilized by a large 
number of researchers to facilitate mapping of mutants (data and scripts available at 
http://www.fishyskeleton.com).  
It is important to note that the detection of candidate mutations depends not only on the genome 
coverage obtained by WGS, but also on the quality and extent of the genome assembly that is used as a 
reference; in regions with poor genome assembly, lack of detection of a causative mutation will not be 
remedied by higher sequencing depth. Further improvements in assembly of the zebrafish genome, in the 
SNP database, and in massively parallel sequencing will enhance the sensitivity and specificity of our 
Chapter 4 
130 
mapping approach. At present, low-coverage WGS using pooled DNA samples provides a fast and 
efficient means for mapping and identifying recessive mutations in zebrafish, allowing for more timely 
determination of altered gene function and systematic analysis of genetic regulation of vertebrate 
development and physiology. 
4.7 Materials and methods 
 
Zebrafish husbandry and strains 
 Zebrafish were raised and maintained as described [15]. Mutants were identified in the 2004 ZF-
MODELS screen performed at the Max-Planck Institute for Developmental Biology (MPI-EB) in Tübingen, 
Germany. Mutant and wild-type strains were obtained from stocks at Children’s Hospital, Boston (TüB, 
WIKB, AB, and TLF) and at the MPI-EB (TüG and WIKG). The minamoto (motot31533), welded 
(wddt31169), hollow (hlwt3373), fruehrentner (frntt31786), and schrumpfkopf (sumpt3625) mutants were 
generated in the Tü background. For mapping, the majority of mutants were outcrossed to the WIK line, 
except for sump, which was crossed to TLF. F2 crosses were screened for the phenotype and identified 
mutants and siblings were frozen. 
Linkage analysis 
 Linkage was assessed by analysis of microsatellites (SSLPs) and SNP markers on genomic DNA 
from single fish using standard PCR amplification and, in the case of SNPs, analysis by dideoxy capillary 
sequencing. 
Morpholino injections 
 A morpholino directed against the translation initiation site of bmp1a (MO1) [14] was injected at a 
concentration of 0.3 mM into one-cell stage Tü embryos. The phenotype was assessed at 3 days 
postfertilization (dpf). 
Genomic DNA library construction and Illumina sequencing 
 For each mutant or parental strain, genomic DNA from 20 adult fish was pooled (150–250 ng 
from each fish—also easily obtainable from larvae), and 3–5 µg was sheared to an average size of 200 
bp, using Adaptive Focused Acoustics following the manufacturer’s protocol (Covaris). For three samples 
(wdd, sump, and frnt), the shearing step was omitted, since the genomic DNA appeared degraded, with 
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most fragments being <250 bp in size as assessed by electrophoresis on a 4% agarose gel. To construct 
DNA libraries, the DNA fragments were blunt-ended, 5′ phosphorylated, A-tailed, and ligated to adaptors 
as previously described [16] , with the exception that adaptors did not have a 3-bp barcode sequence, 
and the volume of AMPure XP beads used for purification was 1.4× rather than 3.0×. Phusion High-
Fidelity DNA polymerase (Finnzymes) was then used to amplify 12 µl (30%) of each library, in a total of 
four 50-µl PCR reactions, using the “postcapture” primers described in Bowen et al. (2011) [16]. Eight 
cycles of PCR were used for wdd and six cycles for all other samples. Each amplified library was 
sequenced on one lane of an Illumina HiSeq2000, using 100-bp single-end sequencing. Since the 
number of reads obtained for frnt, TüG, WIKG, and sump was lower than expected, one lane of GAII 100-
bp single-end sequencing was also performed for each of these samples. 
Illumina data analysis 
 Illumina sequence reads were aligned to the reference genome (version Zv9/danRer7), using 
Novoalign software (http://www.novocraft.com/main/index.php) with default settings and including 3′-
adaptor trimming. PCR duplicates were removed using the MarkDuplicates command in Picard 
(http://picard.sourceforge.net/). Multisample variant calling was performed for each chromosome on all 
samples simultaneously, using SAMtools and BCFtools. The SNPs were then filtered using the GATK 
VariantFiltrationWalker to exclude the following variants: (1) SNPs lying in low-complexity sequences or 
interspersed repeats, classified by RepeatMasker; (2) SNPs lying within 10 bp of an indel; (3) SNPs lying 
in a cluster of ≥3 SNPs per 10 bp; (3) SNPs with a quality score <30; (4) SNPs with a root-mean-square 
mapping quality of covering reads <40; and (5) SNPs with a total read depth <15 or >120. A perl script 
was used to exclude variants seen in <3 reads, variants not seen in both the forward and the reverse 
direction, variants with a tail bias <0.05, and variants that were not biallelic. Only the 7.6 million SNPs that 
passed these filtration steps were used for downstream analyses; of these, only a small percentage 
(0.25%, 18,978 SNPs) were found solely in one mutant and may represent ENU-induced variation. A perl 
script was written to classify the genotype of each mutant or reference strain at each of the 7.6 million 
“pass filter” SNP sites. Genotypes were classified as heterogeneous or homogeneous on the basis of the 
“BCFtools phred scaled genotype likelihood score.” Sites covered by <2 reads were considered 
uninformative. 
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To determine the physical size of the 20-cM windows used to calculate the mapping score, the 
MGH mapping panel was downloaded from ZFIN (http://zfin.org/zf_info/downloads.html#marker). A 
script was written to obtain the Zv9 genomic coordinate of each marker from Ensembl 
(http://useast.ensembl.org/index.html). A genomic coordinate could be obtained for 2100 of the 3845 
markers. Seventy markers mapped to more than one location and were excluded from the analysis. In 
addition, a BLAST search was performed to find the coordinates of some markers that did not have 
genomic coordinates listed in Ensembl. These markers were then used to approximate the genomic 
coordinate of sliding 20-cM windows throughout the genome, with a new window starting every 0.25 cM. 
 Annovar (http://www.openbioinformatics.org/annovar/) was used to classify variants as 
noncoding, synonymous, or nonsynonymous and to determine whether variants were listed in the 
publically available SNP database, downloaded from Ensembl 
(http://useast.ensembl.org/info/data/ftp/index.html). To identify variants present in only one read 
(which would not have been identified using SAMtools/BCFtools multisample variant calling), the 
SAMtools mpileup command was performed on all mutants and reference strains, for all coding exons, 
and a perl script was used to select variants unique to each mutant. All perl scripts, as well as aligned 
sequence files for each wild-type strain, are available online at http://www.fishyskeleton.com. 
 
4.8 Literature Cited 
 
1.  Geisler R, Rauch G-J, Geiger-Rudolph S, Albrecht A, van Bebber F, Berger A, Busch-Nentwich E, 
Dahm R, Dekens MPS, Dooley C, et al.: Large-scale mapping of mutations affecting zebrafish 
development. BMC Genomics 2007, 8:11. 
2.  Schneeberger K, Ossowski S, Lanz C, Juul T, Petersen AH, Nielsen KL, Jørgensen J-E, Weigel D, 
Andersen SU: SHOREmap: simultaneous mapping and mutation identification by deep 
sequencing. Nat. Methods 2009, 6:550–551. 
3.  Cuperus JT, Montgomery TA, Fahlgren N, Burke RT, Townsend T, Sullivan CM, Carrington JC: 
Identification of MIR390a precursor processing-defective mutants in Arabidopsis by direct 
genome sequencing. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:466–471. 
4.  Doitsidou M, Poole RJ, Sarin S, Bigelow H, Hobert O: C. elegans mutant identification with a one-
step whole-genome-sequencing and SNP mapping strategy. PLoS ONE 2010, 5:e15435. 
5.  Zuryn S, Le Gras S, Jamet K, Jarriault S: A strategy for direct mapping and identification of 
mutations by whole-genome sequencing. Genetics 2010, 186:427–430. 
Chapter 4 
133 
6.  Austin RS, Vidaurre D, Stamatiou G, Breit R, Provart NJ, Bonetta D, Zhang J, Fung P, Gong Y, Wang 
PW, et al.: Next-generation mapping of Arabidopsis genes. Plant J. 2011, 67:715–725. 
7.  Uchida N, Sakamoto T, Kurata T, Tasaka M: Identification of EMS-induced causal mutations in a 
non-reference Arabidopsis thaliana accession by whole genome sequencing. Plant Cell 
Physiol. 2011, 52:716–722. 
8.  Arnold CN, Xia Y, Lin P, Ross C, Schwander M, Smart NG, Müller U, Beutler B: Rapid identification 
of a disease allele in mouse through whole genome sequencing and bulk segregation 
analysis. Genetics 2011, 187:633–641. 
9.  Sobreira NLM, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, Ge D, Shianna KV, 
Smith JP, Maia JM, et al.: Whole-genome sequencing of a single proband together with linkage 
analysis identifies a Mendelian disease gene. PLoS Genet. 2010, 6:e1000991. 
10.  Stickney HL, Schmutz J, Woods IG, Holtzer CC, Dickson MC, Kelly PD, Myers RM, Talbot WS: 
Rapid mapping of zebrafish mutations with SNPs and oligonucleotide microarrays. Genome 
Res. 2002, 12:1929–1934. 
11.  Guryev V, Koudijs MJ, Berezikov E, Johnson SL, Plasterk RHA, van Eeden FJM, Cuppen E: Genetic 
variation in the zebrafish. Genome Res. 2006, 16:491–497. 
12.  Bradley KM, Elmore JB, Breyer JP, Yaspan BL, Jessen JR, Knapik EW, Smith JR: A major 
zebrafish polymorphism resource for genetic mapping. Genome Biol. 2007, 8:R55. 
13.  Coe TS, Hamilton PB, Griffiths AM, Hodgson DJ, Wahab MA, Tyler CR: Genetic variation in strains 
of zebrafish (Danio rerio) and the implications for ecotoxicology studies. Ecotoxicology 2009, 
18:144–150. 
14.  Jasuja R, Voss N, Ge G, Hoffman GG, Lyman-Gingerich J, Pelegri F, Greenspan DS: bmp1 and 
mini fin are functionally redundant in regulating formation of the zebrafish dorsoventral axis. 
Mech. Dev. 2006, 123:548–558. 
15.  Nusslein-Volhard C, Dahm R: Zebrafish: A Practical Approach. University Press; 2002. 
16.  Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafé L, Superti-Furga A, Ikegawa S, Cormier-
Daire V, Bovée JV, Pansuriya TC, et al.: Loss-of-function mutations in PTPN11 cause 
metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 2011, 
7:e1002050. 
 
Chapter 5  
 
 
Discussion and Future Directions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Chapter 5 
135 
5.1 Discussion and Future Directions 
 
 Next Generation Sequencing (NGS) technologies enable the parallel sequencing of millions of 
DNA fragments, making it feasible to sequence entire genomes, exomes and transcriptomes. In this 
thesis, I used NGS to further our understanding of skeletal development and disease in both humans and 
model organisms. I explored three applications of NGS: targeted re-sequencing (Chapter 2), RNA-seq 
(Chapter 3) and whole genome sequencing (WGS) (Chapter 4). Firstly, by performing targeted re-
sequencing of genes in an interval identified by genome-wide linkage analysis, I identified heterozygous 
loss-of-function mutations in PTPN11 as the genetic cause for the cartilage tumor syndrome, 
metachondromatosis (MC) (Chapter 2). Secondly, I performed RNA-seq on chondrocytes undergoing 
maturation in vitro, and found that loss of Ptpn11 delayed terminal differentiation and maintained the 
expression of genes associated with earlier maturation stages (Chapter 3). I confirmed this in vivo by 
showing that terminal differentiation was delayed in mouse vertebral growth plates following mosaic 
inactivation of Ptpn11 (Chapter 3). Furthermore, I found that mosaic inactivation of Ptpn11 disrupted the 
organization of maturation zones in mouse vertebral growth plates and led to enchondroma-like lesions 
that contained both wild-type and mutant chondrocytes, and that cartilage tumors from MC patients also 
showed disorganized maturation zones (Chapter 3). Thirdly, I developed a data analysis pipeline to map 
and clone zebrafish mutations based on low-coverage WGS data, and applied this to map mutations that 
affect skeletal development (Chapter 4). Altogether, my results provide insight into the regulation of 
skeletal development and cartilage tumor formation in humans and model organisms, and demonstrate 
the utility of applying NGS technologies to skeletal biology.   
Genetic basis of cartilage tumor syndromes 
 Patients with the rare, autosomal dominant cartilage tumor syndrome, metachondromatosis (MC), 
develop cartilage tumors on the surface of their bones (exostoses) and inside their bones 
(enchondromas) [1]. Other cartilage tumor syndromes are associated with either exostoses (MHE) or 
enchondromas (Ollier disease, Maffucci syndrome), but not both [2]. When the work in this thesis was 
initiated in 2009, the genetic and molecular mechanisms underlying cartilage tumor formation were poorly 
understood (Figure 5.1). While it was known that heterozygous loss-of-function mutations in EXT1 or 
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EXT2 cause MHE [3,4], the genetic cause(s) of MC, Ollier disease and Maffucci syndrome were not 
known. In particular, it was not known whether each cartilage tumor syndrome had its own unique genetic 
cause, or whether they were caused by mutations that affected the same genes or the same pathways. In 
this thesis, I identified heterozygous loss-of-function mutations in PTPN11 in 11 out of 17 MC individuals 
or families (Chapter 2), consistent with the independent identification of PTPN11 mutations in two MC 
families by Sobeira et al (2010) [5]. Concurrently, it was shown that somatic gain-of-function mutations in 
IDH1 or IDH2 cause Ollier Disease and Maffucci Syndrome [6,7]. Thus, although MC shares phenotypic 
features with other cartilage tumor syndromes, it has a unique genetic cause. Furthermore, as discussed 
 
 
Figure 5.1: Timeline of research on the genetic causes of cartilage tumor syndromes. Research 
involving multiple hereditary exostoses (blue), Ollier disease and Mafficci syndrome (green) and 
metachondromatosis (red) is shown.  
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in more detail below, loss of Ptpn11 in mice appears to have different effects on chondrocyte maturation 
than loss of Ext1/Ext2 or mutations in Idh1, suggesting that the cartilage lesions in MC patients arise due 
to unique underlying molecular and cellular mechanisms.  
 In MC patients who carry heterozygous PTPN11 mutations, cartilage lesions could arise due to 
haploinsufficiency for PTPN11 or due to somatic second-hit PTPN11 mutations. To test these 
hypotheses, I sequenced DNA extracted from the cartilage core of MC exostoses. I found evidence for 
loss-of-heterozygosity (LOH) for PTPN11 in two MC exostoses, thus supporting the two-hit hypothesis 
(Chapter 2). Furthermore, cartilage tumors do not form in Ptpn11+/– mice but can be induced by mosaic 
bi-allelic inactivation of Ptpn11 [8–10] (Chapter 3). Together, these data support the hypothesis that 
tumors in MC patients form when both PTPN11 alleles are lost.  As suggested by lineage tracing in mice, 
both Ptpn11-deficient chondrocytes and wild-type chondrocytes can be incorporated into lesions 
(Chapter 3). Exostoses from MHE patients and enchondromas from Ollier disease patients are also 
thought to contain both mutant and non-mutant chondrocytes [7,11]. Together, these data suggest that 
enchondromas and exostoses may arise in part due to altered paracrine signaling that affects neighboring 
wild-type cells, rather than simply due to the neoplastic growth of mutant cells themselves. The extent to 
which neighboring PTPN11-heterozygous cells can be incorporated into lesions in human MC patients 
remains to be determined. One approach that could be used to quantify the relative proportion of 
PTPN11-heterozygous cells compared to PTPN11-null cells within a lesion would be to use digital droplet 
PCR [12].  
  We failed to detect any mutations in PTPN11 or in 74 genes that act in the same signaling 
pathways as PTPN11 in 6 out of 17 MC patients (Chapter 2). This included five individuals who were the 
first in their families to be affected with MC and one individual with a family history of MC. For these 
patients, only DNA from white blood cells was sequenced, since lesional tissue was not available. It is 
possible that these individuals have mutations in a second gene or in regulatory regions of PTPN11 that 
were not detected by our sequencing approach. Alternatively, the 5 individuals with sporadic MC could 
carry somatic PTPN11 mutations that are present only in only a small percentage of their white blood 
cells and therefore escaped detection by our sequencing approaches. Indeed, in one of the 11 MC 
families in which a PTPN11 mutation was detected, the mutation was detected by sequencing blood DNA 
Chapter 5 
138 
from two affected children, but was not detected in blood DNA from the affected mother who was the first 
in the family to have MC (Chapter 2). This demonstrates that PTPN11 mutations in individuals with 
sporadic MC can be present at low enough levels in blood DNA to escape detection by Sanger 
sequencing or low coverage NGS. Furthermore, in individuals who are somatic mosaics, there may be 
negative selection against PTPN11-heterozygous cells in the blood, as suggested by mouse studies 
indicating that Ptpn11 heterozygous hematopoietic stem cells (HSCs) have reduced survival compared to 
wild-type HSCs [13].  Thus, to determine whether individuals with sporadic MC have mutations in 
PTPN11 in their peripheral blood, one could perform very high coverage NGS of PTPN11 to determine 
whether mutations are present in a small fraction of cells.  
 Malignant progression of enchondromas and exostoses has been observed in Ollier disease, 
Maffucci syndrome and MHE patients, and has been documented for one MC patient [14,15]. 
Interestingly, it was shown that chondrosarcomas arising from exostoses with EXT1/EXT2 mutations 
arise from cells with functional EXT1/EXT2, rather than the EXT1/EXT2-deficient cells [16]. Thus, bi-allelic 
loss of EXT1/EXT2 is sufficient to induce the formation of an exostosis, which creates a 
microenvironment that supports the malignant progression of cells with functional EXT1/EXT2. It will be of 
interest to determine whether this scenario is also the case for the chondrosarcoma that was reported to 
arise from an MC enchondroma [15]. Since PTPN11 can act as an oncogene [17], it is plausible that cells 
with functional PTPN11 would be more likely to become malignant than cells lacking PTPN11.  
Cellular mechanisms of enchondroma formation 
 Enchondromas have been suggested to arise either from growth plate chondrocytes or from 
progenitor cells in the marrow cavity that inappropriately differentiate into chondrocytes [18,19]. Previous 
mouse models of enchondroma formation (mutant PTHR1 or over-expression of Gli2) indicated that 
enchondromas in the long bones can arise from growth plate chondrocytes [20]. Inactivation of Ptpn11 in 
chondrocytes was found to induce multiple enchondromas in the ribs and vertebrae [9,21] (Chapter 3), 
but only rarely affected the long bones – I observed an enchondroma in the tibia in only 1 out of 7 mice 
examined (data not shown). It is not known whether long bone enchondromas would have formed more 
frequently if Ptpn11 had been inactivated at an earlier time point or in a greater percentage of 
chondrocytes, or if the mice had been analyzed beyond 12 weeks of age; nevertheless, these data 
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indicate that enchondromas can arise from growth plate chondrocytes.  
 I found that loss of Ptpn11 in vitro delayed the terminal differentiation of hypertrophic 
chondrocytes, and that mosaic postnatal inactivation of Ptpn11 in chondrocytes in vivo led to non-uniform 
rates of proliferation, maturation, terminal differentiation and ossification in vertebral growth plates 
(Chapter 3). Importantly, ossification centers formed within vertebral growth plates, thereby causing the 
chondrocytes below them to become displaced from the growth plate. These displaced chondrocytes 
formed enchondroma-like lesions and contained both immature and mature chondrocytes (as assessed 
by COLX immunohistochemistry), and both Ptpn11-deficient and wild-type chondrocytes (as assessed by 
analysis of a reporter allele which marks cells in which Cre recombinase has acted) (Chapter 3). 
Together, these data suggest that MC enchondromas may arise due to both disrupted growth plate 
organization and delayed terminal differentiation, rather than simply due to neoplastic growth or delayed 
cartilage resorption alone (Figure 5.2). 
 
 
Figure 5.2: Model for exostosis and enchondroma formation in MC patients. A: Inactivation of 
PTPN11 in perichondrial cells causes ectopic chondrogenesis. The resulting chondrocytes proliferate in 
a disorganized fashion to form an exostosis. Inactivation of PTPN11 in growth plate chondrocytes 
disrupts the architecture of the growth plate and delays terminal differentiation, thereby leading to 
enchondroma formation. Enchondromas and exostoses likely contain both PTPN11-deficient (red 
outline) and PTPN11+/– chondrocytes.    
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 The observation that vertebral enchondromas can arise from the growth plate does not rule out 
the possibility that enchondromas could also arise from progenitor cells in the marrow cavity. It would be 
of interest to inactivate Ptpn11 in mesenchymal stem cells (MSCs) in the marrow cavity and determine 
whether this leads to ectopic cartilage formation. This could be achieved by using the Nestin-CreER or 
Mx1-Cre drivers. The Nestin-CreER driver is expressed in nerve cells, but has recently been shown to 
also be expressed in a population of perivascular MSCs in the marrow cavity that can give rise to 
osteoblasts and chondrocytes [22]. The Mx1-Cre driver can be used to label a population of osteogenic 
stem cells in the marrow cavity that partially overlaps with the Nestin+ MSC population [23]. These Cre 
drivers could be used to determine whether inactivation of Ptpn11 in progenitor cells in the marrow cavity 
can cause them to differentiate into chondrocytes instead of osteoblasts. Alternatively, local 
administration of adenoviral Cre could be performed by injection into the marrow cavity.   
 Interestingly, an enchondroma in the proximal femur was observed when Ptpn11 was inactivated 
in the perichondrium using Ctsk-Cre [10]. This suggests that enchondromas could also arise from 
perichondrial cells that inappropriately undergo chondrogenesis and proliferate inwards towards the 
marrow cavity to form an enchondroma. However, since a fraction of Ctsk-Cre-positive cells were shown 
to migrate from the perichondrium into the growth plate and articular cartilage during normal development 
[10], it is also possible that the enchondroma observed in the Ctsk-Cre;Ptpn11fl/fl mouse arose from the 
growth plate. Further analysis of Ctsk-Cre;Ptpn11fl/fl mice should be performed to determine how 
frequently and in which locations enchondromas form, and earlier stages of the disease should be 
examined to determine whether the enchondromas arise from perichondrial cells or growth plate 
chondrocytes. 
 It is not yet known whether the mechanism of enchondroma formation in MC, Ollier disease and 
Maffucci syndrome patients is the same. Ollier disease and Maffucci syndrome are caused by somatic 
missense mutations in IDH1 or IDH2, the most common of which is the R132C mutation in IDH1 [6,7,24]. 
While these mutations have been shown to lead to increased DNA methylation [25], it is not yet know how 
they affect the growth plate and lead to enchondroma formation. An inducible IDH1(R132H) knock-in 
mouse has recently been generated [26]. Preliminary results indicate that expression of mutant IDH1 in 
chondrocytes induces enchondroma formation and reduces the height of the hypertrophic zone (Benjamin 
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Alman, personal communication, Nov 2012). It will be of interest to characterize the enchondromas in 
these mice and determine whether their location, frequency, and histology are similar to or different from 
enchondromas in Ptpn11 cKO mice. Interestingly a shorter hypertrophic zone was also observed in other 
mouse models of enchondroma formation (mutant PTHR1 or over-expression of Gli2) [20], in contrast to 
the expanded hypertrophic zone observed following Ptpn11 inactivation (Chapter 3). This suggests that 
mutations in Ptpn11 and IDH1/IDH2 have different effects on chondrocyte maturation.  
Molecular mechanisms of enchondroma formation 
 PTPN11 encodes a phosphatase, SHP2, involved in many signaling events [17]. The signaling 
pathways that contribute to the disruption in vertebral growth plate organization, delay in terminal 
differentiation and enchondroma formation that we observed following SHP2 depletion in vivo (Chapter 3) 
are not yet known. One likely candidate pathway for contributing to both the disrupted organization and 
delay in terminal differentiation is the ERK1/2 pathway. Inactivation of Ptpn11 in chondrocytes decreases 
phospho-ERK1/2 immunoreactivity [9,10,27] and inhibiting the ERK1/2 pathway in chondrocyte pellet 
cultures delays terminal differentiation in a similar manner to SHP2 depletion (Chapter 3). Furthermore, 
there is a striking overlap in the phenotypes of mice with an osteo-chondroprogenitor specific deletion of 
Ptpn11 or of Erk1 and Erk2 – in both cases the mice develop severe chondrodysplasia and an 
accumulation of hypertrophic chondrocytes [27,28]. Similarly, mice with a chondrocyte-specific deletion of 
Ptpn11 or of Erk1 and Erk2 both develop an expanded hypertrophic zone in the long bones and a severe 
 
 
Figure 5.3: Inactivation of Erk1 and Erk2 in chondrocytes leads to an accumulation of 
hypertrophic chondrocytes in the long bones and an expansion and disorganization of 
vertebral growth plates. Hemotoxylin, eosin and alcian blue staining of the E16.5 femur (A) and 
E18.5 spine (B) in Ctrl mice or mice lacking Erk1 and Erk2 in chondrocytes. Images adapted from 
Matsushita et al (2009). 
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expansion and disorganization of the vertebral growth plates [8,21,28] (Chapter 3) (Figure 5.3). Together, 
these studies indicate that ERK1/2 is a likely candidate for acting downstream of SHP2 in the growth 
plate. It will be of interest to determine whether inactivation of Erk1 and Erk2 is sufficient to induce 
enchondroma formation. The vertebral growth plates of mice lacking Erk1 and Erk2 were only studied at 
embryonic stages [28]; thus, an area of future research would be to inactivate Erk1 and Erk2 postnataly in 
chondrocytes and determine whether enchondromas arise.  
 SHP2 is thought to act downstream of most, if not all, receptor tyrosine kinases (RTKs) [17]. 
However, there are 58 known RTKs [29] and it is not yet known which of these receptors SHP2 
modulates specifically in chondrocytes. Our finding that loss of SHP2 delays terminal differentiation 
suggests that SHP2 acts downstream of EGFR, FGFR1 or FGFR3, since each one of these receptors 
has been suggested to promote terminal differentiation [30–32]. FGFR3 is a particularly strong candidate, 
since Fgfr3 knockout mice develop enchondroma-like lesions in some long bones [33] (Figure 5.4). 
Furthermore, Fgfr3 knockout mice have an increased rate of chondrocyte proliferation and develop 
expanded and disorganized vertebral growth plates [33,34] (Figure 5.4). The vertebral phenotype is 
similar to what is observed following Ptpn11 inactivation (Chapter 3). However, since the phenotype in 
Fgfr3 knockout mice is less severe than in Ptpn11 cKO mice, loss of signaling through FGFR3 cannot be 
solely responsible for the phenotypes that arise following SHP2 depletion in chondrocytes. Thus, the 
consequences of SHP2 depletion in chondrocytes are likely to be complex.  
 In the growth plate, a positive feedback loop exists between IHH and BMP signaling, whereas 
 
 
Figure 5.4: Inactivation of Fgfr3 leads to expanded and disorganized vertebral growth plates, and 
enchondroma-like lesions in the long bones. A-B: Sections of a vertebral growth plate from a P20 
wild-type mouse (A) or Fgfr3 knockout mouse (B). Image adapted from Deng et al (1996) C: Section of 
the distal femur of a 6.3 month-old Fgfr3 knockout mouse. Note the enchondroma-like lesions below the 
growth plate (arrows). Image adapted from Colvin et al (1996).  
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FGF signaling antagonizes IHH and BMP signaling [32,35]. Since SHP2 and ERK1/2 can act downstream 
of FGF growth factors [36], it would be expected that loss of SHP2 or ERK1/2 signaling would promote 
IHH and BMP signaling. Indeed, I found that Ihh was one of the transcripts with the most substantial 
increases in abundance after SHP2 depletion or ERK1/2 inhibition in pellet cultures (Chapter 3). 
Similarly, I also observed an increase in the abundance of transcripts encoding transcription factors 
known to both be induced by BMP signaling and to inhibit terminal differentiation (Hey1, Msx2, Dlx5, 
Sox9) [37–39][40–43] (Chapter 3). Together these results suggest that loss of SHP2 leads to a decrease 
in ERK1/2 signaling, which may increase IHH and BMP signaling. IHH and BMP both promote 
chondrocyte proliferation [44] and BMP signaling has been suggested to delay the terminal differentiation 
of hypertrophic chondrocytes [32]. Therefore, increased IHH and BMP signaling could be factors 
contributing to the expansion of the vertebral growth plates observed in Ptpn11 cKO mice (Chapter 3). 
Interestingly, overexpression of Ihh accelerates the differentiation of periarticular chondrocytes into 
proliferative chondrocytes [45]. Thus, it is possible that increased IHH levels in Ptpn11 cKO vertebral 
growth plates accelerates the maturation of resting zone chondrocytes, which would explain why some 
growth plates were found to be completely resorbed by week 10 (ie their resting zones had been 
depleted) (Chapter 3).  It would be of interest to determine whether the vertebral growth plate phenotype 
that results from Ptpn11 inactivation could be rescued by decreasing IHH or BMP signaling, for example 
by using mice that are heterozygous for loss-of-function mutations in IHH signaling components, Ihh or 
Smo, or BMP pathway components, Smad1, Smad5 and Smad8.   
 It is not known whether chondrocytes in the vertebral growth plates of Ptpn11 cKO mice are 
disorganized simply due to unequal rates of proliferation between Ptpn11-deficient and wild-type clusters 
of chondrocytes, or whether loss of Ptpn11 has a direct effect on chondrocyte polarity and columnar 
organization. In normal growth plates, chondrocyte orientation and polarity are tightly controlled [46]. The 
cell division plane of chondrocytes in the proliferative zone is always oriented such that daughter cells are 
displaced lateral to the axis of the column. Daughter cells then organize into columns through cell 
intercalation [46]. An area of future research would be to determine whether loss of Ptpn11 affects either 
the orientation of the cell division plane or the intercalation of chondrocytes to form columns, using the 
methods described in Ahrens et al (2009) [47]. 
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 In summary, many signaling pathways are likely to be affected by SHP2 depletion and contribute 
to enchondroma formation. It will be of interest to perform in situ hybridization or immunohistochemistry 
on Ptpn11 cKO growth plates to determine the activation status of pathways with known roles in the 
growth plate. In addition, further research into the signaling pathways regulating vertebral growth plates 
versus long bone growth plates may further our understanding of why loss of SHP2 has a more severe 
effect in the vertebrae than the long bones.    
Cellular mechanisms of exostosis formation 
 Exostoses have been hypothesized to arise either from perichondrial cells that inappropriately 
undergo chondrogenesis, or from chondrocytes that escape the normal boundaries of the growth plate 
[48]. Mouse data support a perichondrial origin for MC exostoses. Firstly, exostoses can be induced by 
inactivating Ptpn11 using Ctsk-Cre, which is expressed in the perichondrium and not in growth plate 
chondrocytes [10].  Secondly, when Ptpn11 is inactivated using Col2a1-CreERT2, which is expressed in 
chondrocytes and a few perichondrial cells, clusters of ectopic chondrocytes in the 
perichondrium/periostium are observed in the metacarpals after the growth plate has already closed [9]. 
These studies suggest that loss of Ptpn11 causes perichondrial cells to differentiate into chondrocytes, 
which then proliferate in a disorganized manner to form an exostosis (Figure 5.2). Interestingly, while 
exostoses formed on all long bones when Ptpn11 was inactivated using Ctsk-Cre [10], exostoses formed 
only on some bones (eg. metacarpals) and not others (eg. femur and tibia) when the Col2a1-CreERT2 
driver was used [9]. It is not known whether this is due to differences in efficiency of Col2a1-CreERT2 and 
Ctsk-Cre expression in the perichondrium in different bone types or due to differences in the timing of 
Ptpn11 inactivation. Further studies using a reporter allele could be performed to compare the 
perichondrial expression of Ctsk-Cre and Col2a1-CreERT2 in different bone types and at different time 
points.  
 It has been debated whether exostoses induced by loss of Ext1 originate from growth plate 
chondrocytes or perichondrial cells [11,49,50]. One hypothesis that is consistent with all published mouse 
data is that bi-allelic loss of Ext1 in either chondrocytes or perichondrial cells is sufficient to induce 
chondrogenesis in the perichondrium, and that once these ectopic chondrocytes start to proliferate, 
neighboring growth plate chondrocytes can be co-opted into the growing lesions.  Interestingly, 
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compound heterozygous Ext1+/–; Ext2+/– mice also develop exostoses [51], which suggests that a local 
reduction in the levels of extracellular heparan sulfate is sufficient to affect paracrine signaling in the 
perichondrium, thereby inducing ectopic chondrogenesis. Thus, it is likely that exostoses from both MC 
patients and MHE patients arise due to inappropriate chondrogenesis in the perichondrium. However, the 
way in which the ectopic clusters of chondrocytes expand to form an exostosis likely differs between MC 
and MHE. This statement is based on observations that MHE and MC lesions differ at the histological 
level. MHE exostoses have a cartilage cap that displays relatively normal growth plate architecture with a 
zone of hypertrophic (COLX-positive) chondrocytes at its base. In contrast, we found that MC exostoses 
have a cartilage core with a disorganized distribution of COLX-positive chondrocytes (Chapter 2 & 3). 
Similarly, when comparing the histology of exostoses in the radius and ulna in mice, exostoses arising 
due to Ext1 inactivation contain chondrocyte columns oriented perpendicular to the main axis of the 
growth plate [52], while exostoses arising due to Ptpn11 inactivation lack organization [9]. Furthermore, 
while postnatal inactivation of Ext1 in chondrocytes decreases the height of the hypertrophic zone [52], an 
expanded hypertrophic zone is observed following Ptpn11 inactivation (Chapter 3). Thus, although loss 
of Ptpn11 and loss of Ext1 each induces chondrogenesis in the perichondrium, the consequences on 
chondrocyte organization and maturation are different.  
Molecular mechanisms of exostosis formation 
 One pathway that may act downstream of SHP2 in perichondrial cells is the ERK1/2 pathway. 
Loss of SHP2 in the perichondrium reduces phospho-ERK1/2 immunoreactivity [10]. Furthermore, 
inactivating Erk1 and Erk2 in osteo-chondroprogenitor cells (Prx1-Cre) was found to induce ectopic 
chondrogenesis in the perichondrium; however, due to the severity of the skeletal defects, these mice 
were only examined at embryonic and early postnatal stages [28] (Figure 5.5). Therefore, it is not known 
whether the ectopic cartilage clusters would have progressed to exostoses had the mice survived until 
adulthood. An area of future research would be to inactivate Erk1 and Erk2 in perichondrial cells (Ctsk-
Cre [10]) or in a mosaic manner in osteo-chondroprogenitors (Prx1-CreER), and examine adult mice to 
determine whether exostoses develop. An alternate approach would be to constitutively activate the 
ERK1/2 pathway and determine whether this rescues exostosis formation in Ptpn11 cKO mice. This could 
be achieved using a constitutively active MEK1 transgene that is under the control of the Prx1 promoter 
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[28]. Together, these experiments will 
determine whether the reduction in ERK1/2 
signaling following loss of SHP2 is 
responsible for exostosis formation.  
 Other signaling pathways implicated 
in regulating the cell fate of perichondrial 
cells are the WNT, BMP and IHH pathways. 
Inactivation of beta-catenin in osteo-
chondroprogenitors (Prx1-Cre) induces 
ectopic cartilage formation in the 
perichondrium [53,54], and postnatal 
inactivation of beta-catenin in chondrocytes 
induces exostosis-like outgrowths [55]. In 
metatarsal organ cultures, activating BMP signaling while inhibiting HH signaling induces ectopic cartilage 
in the perichondrium [56]. Similarly, inactivating HH signaling by inactivation of Smoothened in 
perichondrial cells induces ectopic cartilage formation and prevents bone collar formation in long bones 
[57]. In contrast, it was also suggested that excessive IHH signaling in the perichondrium of 
synchondroses, caused by deletion of Kif3a in chondrocytes, drives ectopic cartilage formation [58]. In 
summary, inactivating WNT signaling or activating BMP signaling promotes ectopic chondrogenesis, 
while conflicting data exist on the role of HH signaling in promoting ectopic chondrogenesis. It will be of 
interest to determine whether loss of SHP2 in the perichondrium decreases WNT signaling or increases 
BMP signaling, and whether modulating either of these pathways can decrease the rate of exostosis 
formation in Ptpn11 cKO mice.  
Can metachondromatosis be treated? 
 The formation of exostoses and enchondromas in MC patients can lead to nerve or blood vessel 
compression, restricted motion of joints and deformity of the affected bones [59]. Exostoses can be 
surgically removed, but may re-grow after surgery. Therefore, it would be of great benefit to MC patients if 
a method to prevent lesion formation or promote lesion regression could be identified. It was found that 
 
 
Figure 5.5: Ectopic chondrogenesis in the 
perichondrium following inactivation of Erk1 and 
Erk2. Tissue sections of the femur and ulna of Ctrl 
mice or mice lacking Erk1 and Erk2 in osteo-
chondroprogenitor cells. Arrows indicate ectopic 
cartilage in the perichondrium. Images adapted from 
Matsushita et al (2009). 
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treating Ptpn11 cKO mice with an inhibitor of HH signaling reduced the severity of exostosis formation 
[10]. This is likely due to the role of IHH in promoting chondrocyte proliferation [44]. It will be of interest to 
determine whether inhibiting HH signaling can also reduce enchondroma formation or reduce the 
expansion of the vertebral growth plates observed after Ptpn11 inactivation. Also of importance will be to 
determine whether inhibiting HH signaling is only beneficial if treatment is started at a young age, or 
whether inhibiting HH signaling in adult mice could induce the regression of exostoses or enchondromas 
that have already formed. Finally, careful studies will be needed to determine whether inhibiting HH 
signaling in children would negatively effect skeletal development. In one study it was found that treating 
young mice with a HH inhibitor led to permanent skeletal defects [60]. In humans, inhibiting HH signaling 
is being used to treat cancer in adults, but has not yet been tested on children [61]. It could also be tested 
whether an inhibitor of HH signaling could be administered locally, by injection into the lesional tissue, 
rather than systemic administration.  
 Our observation that loss of Ptpn11 delays chondrocyte terminal differentiation (Chapter 3) raises 
the possibility that inducing terminal differentiation may promote the regression of lesions. An area of 
future research would be to induce exostoses and enchondromas in mice by inactivating Ptpn11, and 
then restoring Ptpn11 by using a reversible gene trap allele and determining whether this induces 
chondrocytes to terminally differentiation, thereby promoting lesion regression. Alternatively, activation of 
pathways known to promote terminal differentiation, such as the ERK1/2 pathway, may promote the 
regression of lesions.  
Developing more efficient methods for mapping zebrafish mutants 
 In chapter 4, I focused on the use of zebrafish as a model organism for studying the genetic 
regulation of skeletal development. The laboratory of Dr. Matthew Harris isolated a variety of recessive 
zebrafish mutants with adult phenotypes, including defects in the skeleton. Since the traditional method 
for mapping and cloning zebrafish mutations is time consuming and costly, I developed a method for 
mapping and cloning zebrafish mutations using low-coverage whole genome sequencing (WGS). Since 
the existing genetic variation in zebrafish was not well characterized, I first performed WGS on several 
wild-type laboratory strains and created an extensive database of common polymorphisms. I then 
incorporated this SNP database into a data analysis pipeline that I developed to map mutants based on 
Chapter 5 
148 
homozygosity-by-descent. For each mutant, I performed WGS on pooled DNA from ~20 mutant offspring 
from a mapping cross. I developed an algorithm to scan the genome in sliding windows, searching for 
regions of reduced diversity that were the expected genetic size (20 cM). Regions of reduced diversity 
smaller than 20 cM were excluded and may represent haplotype blocks that were shared in the parental 
strains. I showed that this method could be used to successfully map five different zebrafish mutants, 
which was confirmed with independent SSLP mapping data (Chapter 4).  
 Other investigators have also recently developed methods to use NGS to map zebrafish 
mutations [62–66]. All methods rely on the basic principle of sequencing pooled DNA, obtained from >20 
mutant offspring from an outcross, and performing homozygosity mapping using SNPs identified in the 
sequence data. However, some aspects of the experimental design and data analysis differ between 
these published methods (Figure 5.6). Here, I firstly discuss the two main differences between these 
published methods, and secondly provide suggestions for future work that may improve the accuracy and 
lower the cost of mapping. 
 The first key difference between published methods is the use of WGS [62–64] versus RNA-seq 
[65,66] (Figure 5.6). Each sequencing method has advantages and drawbacks. With RNA-seq, only the 
 
Figure 5.6. Comparison of published methods for mapping zebrafish mutations using Next 
Generation Sequencing.  
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transcriptome is sequenced, rather than the entire genome. Thus, greater fold coverage of the coding 
sequence can be obtained for a lower cost, thereby enabling more accurate variant detection. In addition, 
RNA-seq would be capable of identifying causal mutations that affected splicing or expression levels. 
However, a disadvantage of RNA-seq is that the coverage is not distributed evenly and will be biased 
towards genes that are highly expressed at the particular time-point or in the particular tissue type that 
was used for RNA extraction. This will lower the likelihood of identifying the causal mutation if it lies in a 
gene that is not abundantly expressed. Another disadvantage of RNA-seq is that there will be far fewer 
polymorphisms available for mapping, since the majority of polymorphisms lie in non-coding regions of 
the genome. Thus, mapping may be difficult if the causative mutation lies in a gene desert, or in a region 
of low diversity due to shared haplotype blocks between the parental strains.   
 The second difference between published methods is the use of genetic distances (cM) versus 
physical distances (bp) (Figure 5.6). In each of the published methods for mapping zebrafish mutations, 
the data analysis pipeline involves subdividing the genome into bins, and searching for the bin with the 
lowest level of heterogeneity. Using a large bin size allows one to eliminate false positive regions that 
have reduced heterogeneity due to short haplotype blocks that were shared by the parental strains. What 
differs between methods is whether these bins are defined based on a physical distance [62], genetic 
distance [63,65] (this thesis), or number of SNPs [64,66]. We believe that defining the bin size based on 
genetic distance is most accurate. Recombination rates are not equal throughout the genome, with high 
rates of recombination in telomeres and low rates of recombination in centromeres. If a causative 
mutation lay close to the telomere, the sequence linked to the mutation would span a relatively small 
physical distance, and therefore this region of reduced heterogeneity might escape detection if the bin 
size was based on physical distance. Nevertheless, despite the differences between published methods, 
each method was shown to be capable of mapping at least one zebrafish mutant. Therefore, any one of 
these methods is likely to be a good starting point for investigators who wish to perform mapping based 
on NGS.  
  The drawback of NGS is that data analysis can be complicated and often requires a significant 
time investment. Therefore, for NGS to be widely adopted by zebrafish labs, an automated and easy-to-
use data analysis pipeline needs to be made available. Four such pipelines have recently been 
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developed: SNPtrack [63], RNAmapper [66],  MMAPPR [65], and MegaMapper [63]. These pipelines 
provide an excellent starting point for labs that do not have expertise in analyzing NGS data. However, 
these pipelines could be improved by incorporating a more extensive database of known common 
polymorphisms. This would increase the accuracy of mapping when dealing with low coverage sequence 
data. In regions of low coverage, if a variant is observed in only one or two sequencing reads, it is difficult 
to know whether it represents a sequencing error or a true polymorphism. Noise from sequencing errors 
can be significantly reduced by excluding all variants that do not occur at sites of known common 
polymorphisms. Therefore, the more comprehensive the list of common polymorphisms, the more  
accurate this method of mapping is likely to be. We compiled a database of 7.6 million common 
polymorphisms that we identified in our WGS data from several wild-type strains (Chapter 4). This 
database could now be improved by incorporating additional WGS data from other zebrafish wild-type 
strains and mutants that have subsequently been sequenced [62–66].  Not only will this allow for more 
accurate mapping, but, once the linked interval has been identified, it will help narrow down the list of 
potential causal mutations (since variants that are known common polymorphisms can be excluded as 
being causal).  
 Future improvements in the quality of the zebrafish genome assembly will also make mapping 
more accurate. As noted by Leshchiner et al (2012), accurate mapping can be compromised by 
incorrectly placed scaffolds in the genome assembly [62]. Furthermore, some scaffolds exist in the Zv9 
version of the zebrafish genome that have not yet been placed on a chromosome. Mapping a mutation 
that lies on one of these unassigned scaffolds is not likely to be successful. The accuracy of mapping is 
likely to be improved when the next version of the genome (Zv10) is released in 2014 
(http://www.sanger.ac.uk). Future improvements in the annotation of the zebrafish genome will also be 
beneficial, since if a causal mutation lay in an unannotated gene, it is likely that it would be overlooked.    
 It will also be of interest to determine whether the cost of mapping could be reduced by 
multiplexing samples and performing targeted sequencing of the exome instead of WGS or RNA-seq. 
Since the exome is two orders of magnitude smaller than the genome, sufficient coverage could be 
obtained even if multiple samples were sequenced per lane. Targeted sequencing of the exome may be a 
more robust method than RNA-seq, since one is likely to obtain more even coverage across all exons. 
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This is in contrast to RNA-seq, which provides extremely high coverage for abundant transcripts, but low 
or no coverage for low abundance transcripts. Agilent has only recently developed a zebrafish exome 
capture array (www.agilent.com). Using this capture array, Ryan et al (2013) showed that zebrafish 
mutants can be mapped by obtaining high coverage of the exome [67]. Thus, an area of future research 
would be to sequence multiple libraries per lane to obtain low coverage of the exome, and determine 
whether this is sufficient for mapping.    
 Finally, it will also be of interest to develop tools for using NGS to map mutations in other model 
organisms. Whole genome or exome sequencing has been used to identify mutations in mice, but studies 
normally rely on prior linkage data, obtained using SNP arrays, to determine which of the many mutations 
identified is the causative mutation [68,69]. Leshchiner et al (2012) demonstrated that the WGS approach 
they developed to map zebrafish mutations could also be used to map a mouse ENU-induced mutation 
[62]. It will be of interest to determine whether these methods can also be applied to map traits in other 
organisms with large and polymorphic genomes, such as chickens, pigs, rabbits and other fish species.   
5.2 Conclusions 
  
 In the first component of this thesis, I showed that PTPN11/SHP2 acts as a suppressor of benign 
cartilage tumors and regulates the proliferation, maturation and organization of growth plate 
chondrocytes, which may be mediated in part by the ERK1/2 pathway. The work in this thesis 
demonstrates that the cartilage tumors in MC patients may form due to different genetic, cellular and 
molecular mechanisms to the cartilage tumors in MHE, Ollier disease and Maffucci Syndrome. 
Furthermore, while gain-of-function mutations in PTPN11 are known to promote childhood leukemia and 
developmental defects associated with Noonan Syndrome, the work in this thesis is the first to associate 
loss of PTPN11 with a human disorder. Future studies may reveal why different tissue types have 
different sensitivities to either gain or loss of SHP2 activity.  
 In the second component of this thesis, I demonstrate that low-coverage whole genome 
sequencing can be used to map zebrafish mutations based on homozygosity-by-descent. The data 
analysis pipelines I developed, together with computational tools developed by other investigators, are 
likely to expedite the process of mapping mutations in zebrafish. This will increase the utility of zebrafish 
as a model organism to study the genetic regulation of skeletal development. Now that mapping using 
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NGS has been shown to be possible, future work will be needed to firstly more fully characterize the 
existing genetic variation in laboratory zebrafish strains, secondly determine to what extent the cost of 
mapping can be reduced by multiplexing samples, and thirdly develop robust and easy-to-use software 
for investigators without expertise in the analysis of NGS data.  
 Finally, the novel NGS approaches I developed have been utilized to address additional 
questions related to skeletal development in disease that were beyond the scope of this thesis. For 
example, we used the array that I designed to target genes acting in the same pathway as PTPN11 to 
identify mutations in PIK3CA as the genetic cause for the overgrowth syndrome, CLOVES [70], and I 
applied the WGS mapping pipeline I developed to a craniofacial trait that differs between the DBA/1J and 
DBA/2J mouse strains [71]. As sequencing technologies continue to improve, with longer read lengths, 
higher accuracy and greater throughput, approaches using NGS will continue to expedite the process of 
mutation identification, mapping and gene expression profiling in humans and model organisms.   
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